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There are two general classes of resistance to anticancer drugs: those that impair 
delivery of anticancer drugs to tumour cells, and those that arise in the cancer cell 
itself due to genetic and epigenetic alterations that affect drug sensivity. Impaired 
drug delivery can result from poor absorption of administered drugs, increased drug 
metabolism or increased excretion, resulting in lower levels of drug in the blood and 
reducing drug concentration into the tumour mass 1, 2. Cancer cells become resistant 
to anticancer drugs by several mechanisms. One way is to pump drugs out of cells by 
increasing the activity of efflux pumps, such as ATP-dependent transporters 3. 
Alternatively, resistance can also be mediated by reduced drug uptake. Water-soluble 
drugs are used to bring into the cell by  endocytosis or through transporters and 
carriers, these mechanisms can be alterated in resistant tumor 4, 5.  
In cases in which drug accumulation is unchanged, activation of detoxifying proteins 
can promote drug resistance. The activation of detoxifying systems, such as 
cytochrome P450mixed-function oxidases, can be induced after exposure to any drug 
6
. Cells can also activate mechanisms that repair drug induced DNA damage. Finally, 
resistance can result from defective apoptotic pathways. This might occur as a result 
of malignant transformation; for example, in cancer with mutant or non-functional 
p53. Alternatively, cells might acquire changes in apoptotic pathway during exposure 
to chemotherapy or changes in cell cycle machinery, which activate checkpoints and 
prevent initiation of apoptosis. 
An important principle in multidrug resistance is that cancer cells are genetically 
heterogeneous, although the process that results in uncontrolled cell growth in cancer 
favours clonal expansion, tumor cells that are exposed to chemotherapeutic agents 
will be selected for their ability to survive and grow in presence of cytotoxic drugs. 
These cancer cells are likely to be genetically heterogeneous because of the mutator 
phenotype. So, in any population of cancer cells that is exposed to chemotherapy, 
more than one mechanism of multidrug resistance can be present. This phenomenon 
has been called Multifactorial Multidrug Resistance. 
 
 
 
CHARACTERIZATION OF THE HUMAN ABC GENE FAMILY 
 
The ATP-binding cassette (ABC) genes represent the largest family of transporter 
genes and many of these genes are implicated in disease processes and/or drug 
resistance 7-10. The prototype ABC protein binds ATP and uses this energy to 
transport molecules across cell membranes. While hydrophobic compounds are the 
most common substrates, ABC transporters are able of transporting metal ions, 
peptides and sugars. 
ABC genes are abundant in the genomes of bacteria and archaebacteria where their 
principal role is in the import of essential molecules 11, 12. The yeast genome contains 
29 ABC genes, and most of these transporters function to move compounds out of the 
cell or into intacellular organelles 8, 10.  
ABC genes are dispersed widely in eukaryotic genomes and are highly conserved 
between species, indicating that most of these genes have existed since the beginning 
of eukaryotic evolution. There are  25 ABC genes in E. coli, 29 in S. cerevisiae, 56 in 
C. Elegans , 56 in Drosophila, 51 in Mouse and 48 in Homo Sapiens 3. 
Human ABC genes are localized on 16 different autosomes and 2 genes reside on the 
X chromosome. Analysis of amino acid sequence alignments of the ATP-binding 
domains has allowed the ABC genes to be classified into subfamilies. There are seven 
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ABC genes subfamilies in the human genome. For the most part these subfamilies 
contain genes that also display considerable identity in the trans-membrane (TM) 
domains and have identical gene organization, and similar intron localization. Five of 
these subfamilies are also found in the yeast genome, indicating that these groups 
were established early in the evolution of eukaryotes, and have been retained. 
However, the function of ABC genes corresponds poorly to subfamily organization, 
and often genes in different subfamilies share more similarity in substrate recognition 
than do genes in the same subfamily 3. 
 
 
Table I. List of human ABC genes, Chromosomal location and Features. 
 
ATP-BINDING CASSETTE TRANSPORTERS- PROTEIN STRUCTURE 
The ABC genes encode large membrane proteins, they are very difficult to express 
and purify in quantities sufficient for crystal structure determination. A small number 
of bacterial NBDs have been crystallized and provide some structural information of 
the whole protein 13. In addition, the structure of a few bacterial ABC transporters has 
been solved 14-16. Eukaryotic ABC transporters have been even more refractory to 
structural analysis than bacterial ABC transporters and the first three-dimensional 
structure for an intact eukaryotic ABC transporter (P-gp) suggests significant 
differences with the structures of two prokaryotic ABC transporters in the packing of 
the transmembrane α-helices within this protein family 17. 
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ABC transporters  bind and hydrolyze ATP and use the energy from ATP hydrolysis 
to pump compounds across the membrane or to flip molecules from the inner to the 
outer leaflet of the membrane 9, 18, 19. Genes are classified into the ABC superfamily 
based on the sequence identity of the ATP-binding domain(s),also known as 
nucleotide-binding folds (NBFs) 3, 19. NBFs contain residues that are found in other 
ATP-binding proteins (the Walker A and B motifs), separated by 90–120 amino acids 
and an additional element, the signature or C motif, located just in front of the Walker 
B site 20. ATP residues are bound by residues from both NBFs. This provides a 
mechanism where the binding of ATP can induce a substantial structural change in 
the molecule, sufficient to force the transported compound across the membrane 17. 
These proteins also possess two transmembrane (TM) domains composed of 6–11 
membrane-spanning α-helices. The transmembrane helices are often at considerable 
angles to the bilayer or even parallel to the membrane. The functional transporter can 
either be a single protein with two NBFs and two TM domains (a full transporter) or 
be a dimer consisting of two half transporters. In vertebrates the ABCA and ABCC 
subfamilies are composed exclusively of full transporters, the ABCD, ABCG and 
ABCF subfamily of half transporters and the ABCB subfamily contains both half and 
full transporters (Fig. 1). The ABCE and ABCF subfamilies consist of proteins with 
two NBFs and no TM domains. These proteins are not transporters but they are 
clearly evolutionarily related based on analysis of their NBFs 21.  
                    
                    
 
Figure 1. The structure of three categories of ABC transporter 
 
ROLE OF THE NBDs 
 
The overall sequence identity among ABC proteins is low, especially in the TMDs. 
The presence of more conserved NBDs is consistent with the notion that the varied 
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functions of the proteins (e.g. ion channels, lipid transporters, peptide transporters) 
depend on the divergent TMDs; the common feature of nucleotide binding and 
hydrolysis, however, require the structurally conserved NBDs. Many ABC proteins 
from lower organisms contain two identical NBDs, and NBD1 and NBD2 of many 
other ABC proteins, including P-glycoprotein, have very similar sequences and 
functional properties. In contrast, the two NBDs of other ABC proteins have very 
different functional roles. Proteins of this kind include those of the MRP subfamily 
(ABCC) 22. 
Both NBDs are required for proper function of mammalian ABC proteins, and a 
mandatory positive catalytic cooperativity between the NBDs occurs in P-
glycoprotein 23-26. In this protein, hydrolysis occurs at only one NBD per hydrolysis 
cycle, NBD1 and NBD2 are equivalent, and ATP binds randomly to either NBD. 
Although there are some asymmetries between the two NBDs of P-glycoprotein, both 
behave fairly similarly from a functional point of view 22-26. The current working 
hypothesis for CFTR channel gating also proposes cooperativity between NBD1 and 
NBD2. The simplest interpretation of single-channel analysis studies using nucleotide 
analogs and mutations at NBD1 and/or NBD2 is that the main effects of ATP 
hydrolysis by NBD1 and NBD2 are to “open” and “close” the channel, respectively22, 
24
. However, recent data point towards a more complex picture that involves a more 
stable nucleotide interaction and a slower rate of hydrolysis at NBD1, compared with 
NBD2. The NBDs of SUR also have distinct functions 22. It has been proposed that 
SUR ATPase activity resides at NBD2, while NBD1 binds, but does not significantly 
hydrolyze ATP22. 
The structure of the NBDs is conserved among ABC proteins, independently of the 
degree of primary-sequence homology. The structure of HisP, the ATP-binding 
subunit of a histidine permease in Salmonella thyphimurium, is shown in Fig. 2A 27, 28 
and represents a model for NBDs structure of ABC proteins. Each NBD is formed by 
two arms. One (Arm I in Fig. 2A) contains the basic core domain, homologous to the 
F1-ATPase (red α−helices and β−sheets), with the conserved motifs A and B (see 
Fig. 2B). An antiparallel β-sheet subdomain that interacts with the sugar and base 
moieties of the nucleotide is also contained in this arm (ABCβ, yellow β-sheets). The 
basic aspects of binding of the α and β nucleotide phosphates and Mg2+ are 
conserved between ABC proteins and the F1-ATPase. They share a “Rossman fold” 
consisting of a central core of β-sheets surrounded by α-helices28. Motifs A and B are 
more than 90 amino acids apart in the primary sequence of ABC proteins (Fig. 2B), 
but are close to each other in the 3-D structure. Motif A (also called P-loop) is a 
pyrophosphate-binding site that binds the β and γ phosphates of nucleotide 
triphosphates. It is located between a β-sheet and an α-helix (red β1 and α1 in Fig. 
2B). Most hydrogen bonds are formed between the main-chain nitrogens and the 
phosphates. Therefore, the residue side chains can vary, consistent with the poor 
conservation of the primary sequence of the central region of motif A (Gly-X4-Gly-
Lys-Thr/Ser). The conserved Lys contributes most of the binding energy of the 
pyrophosphate/motif A interaction. Motif B is in a highly hydrophobic β-sheet that 
ends in an acidic residue that interacts with Mg2+. The acidic residue is not the 
catalytic carboxylate, but it is necessary for completion of the hydrolytic cycle22. The 
other arm of the NBDs (Arm II in Fig. 2A) contains a structurally conserved α-helical 
subdomain (ABCα, green α-helices, Fig. 2). This subdomain contains 3 α-helices and 
motif C (signature sequence), the most conserved sequence among ABC proteins. It 
is likely that this subdomain participates in nucleotide binding and also interacts with 
the TMDs. In the hinge region between the arms, the so-called Gly (approximately 
equivalent to the γ-phosphate linker labelled in Fig. 2B, purple loop in Fig. 2A and 
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His loops interact through conserved Gly and His residues with Mg2+ and are 
involved in the presentation of the hydrolytic water. The molecular mechanism of 
nucleotide hydrolysis by ABC proteins involves approximation of ATP and Mg2+ 
and base activation of the attacking water. The activating base is likely a nucleophilic 
side chain that donates an electron pair to a water molecule, increasing its 
nucleophilicity. This "activated" water then attacks the bond between the β- and γ-
phosphates22. 
 
 
                                 
                       
 
 
Figure 2.  Structure of the nucleotide-binding domains. a). Structure of the ATP-binding subunit of the 
Salmonella thyphimurium histidine permease, HisP. Model NBD structure where α-helices and β-
sheets are shown as cylinders and flat arrows, respectively. b). Primary and secondary structure of 
HisP. Cylinders and arrows depict α-helices and β-sheets, respectively. The conserved motifs A, B and 
C are underlined, and the -phosphate linker (Gly loop) is marked by a purple dot line. See text for 
details and color labelling of the subdomains. 
 
 
Proper function of ABC proteins requires two “normal” NBDs 24-26. Nucleotide 
binding to the NBD monomers elicits conformational changes via an induced-fit 
mechanism 29, which do not seem to be responsible for the power stroke that couples 
substrate transport and ATP hydrolysis 29. Recent evidence suggests that the two 
NBDs interact physically, and it has been proposed that this interaction provides the 
power stroke during the transport cycle. The characteristics of the interaction between 
NBDs in functional ABC proteins with the complete core domain structure (P-
glycoprotein and MRP1) are unknown. However, cysteine crosslinking experiments 
on P-glycoprotein suggest a Rad50CD-like NBD arrangement, at least at some stages 
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during the ATP binding/hydrolysis cycle. In apparent contrast with the Rad50CD-like 
model and most of the available data, recent mutagenesis studies of SUR suggest that 
motif C is not directly involved in ATP binding. Therefore, additional experiments 
using functional ABC proteins are needed to resolve the important issue of the nature 
of the physical interactions of the NBDs during the transport cycle in functional 
proteins 22. 
 
 
MOLECULAR MECHANISM OF TRANSPORT 
 
The idea that there is a hydrophobic drug-binding pocket in multidrug-resistance 
proteins, where hydrophobic substrates bind to the protein without specific 
interactions can be ruled out based on large differences in affinity for similar 
compounds (the proteins are poly-specific rather than non-specific). Extensive studies 
on P-glycoprotein have provided only limited information on the substrates 
requirements 22. Hydrophobicity due to the presence of planar aromatic groups is 
important. A basic nitrogen atom is frequently encountered in good substrates, and a 
tertiary amine seems associated with high-affinity interaction with P-glycoprotein. 
Hydrogen bonds play major roles in the protein-drug interaction, with relevant 
electron donor groups in the drugs that are spatially separated by 2.5 or 4.6 Å. 
Mutations in P-glycoprotein and MRP1 helix residues that can form hydrogen bonds 
support their role in the drug-protein interaction 22. 
Dimerization of the NBDs of ABC proteins can explain the cooperativity between the 
NBDs and also provide a general mechanism of coupling between ATP hydrolysis 
and substrate transport. A speculative model for the catalytic cycle of P-glycoprotein 
can be presented based on recent biochemical/biophysical and structural data on ABC 
proteins and NBDs, as well as biochemical and structural studies on P-glycoprotein. 
The drug can access a high-affinity hydrophobic drug-binding site from the inner 
leaflet of the membrane or the cytosol, and its binding to the protein produces a 
conformational change in the NBDs that increases their affinity for ATP 22. Binding 
of one ATP to each NBD monomer occurs by interaction with the core and 
antiparallel subdomains, producing a rotation in the a-helical subdomain that is 
coupled to the interaction of the γ-phosphate of ATP with the conserved Gly in the γ-
phosphate linker (see Fig. 2). ATP binding causes NBD dimerization because of the 
interaction of the bound ATP with motif C of the other monomer, sandwiching two 
ATP molecules between the NBDs. Hydrolysis of one ATP produces a 
conformational change in the TMDs that involves movement of the helices that form 
the drug-binding pocket 30, 31, with a decrease in drug-binding affinity. The 
conformational change increases the exposure of the drug to a more hydrophilic 
environment in the chamber (reducing binding affinity), from where it diffuses to the 
extracellular solution or is expelled by peristaltic forces exerted by the TMDs. ATP 
hydrolysis also produces a major decrease in ATP-binding affinity at the other NBD 
22, 23
, which may result in the release of the non-hydrolyzed ATP. The electrostatic 
repulsion between the ADP bound to motif A of one monomer and the phosphate 
bound to motif C of the other monomer destabilizes the dimer state. Phosphate is 
rapidly released after hydrolysis and ADP is release afterwards (it is the rate limiting 
step of the hydrolysis cycle) 23. The drug-binding site, however, remains in a low 
drug-binding-affinity state and hydrolysis of another ATP is required for resetting the 
transporter for a new drug transport cycle 22, 23. Some interesting aspects of the 
proposed P-glycoprotein catalytic cycle are that hydrolysis occurs at one NBD at any 
given time, the NBDs are recruited randomly for each hydrolysis cycle, and transport 
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of one drug is coupled to hydrolysis of two ATP molecules 23. If the P-glycoprotein 
catalytic cycle does include hydrolysis of 2 ATPs per cycle, as supported by the data 
and the model proposed by Ambudkar and co-workers 23, it is possible that two NBD 
association/dissociation events occur per transport cycle, one coupled to drug 
transport and the other to resetting of the transporter for a new cycle (Fig. 3). The 
power stroke for substrate transport can be the formation or the dissociation of the 
dimers. Since the NBDs and TMDs are tightly associated, association/dissociation of 
the NBDs may control the “gate” of the translocation pathway formed by intracellular 
loops. Tightening of helix packing on the cytoplasmic side could be the key step for 
substrate efflux (e.g. in P-glycoprotein) and the opposite could be true for substrate 
influx (Btu). Alternatively, the gate of the chamber on the cytoplasmic side may 
always be closed and the dimerization of the NBDs could produce conformational 
changes in the TMDs that reduce drug-binding affinity and also allow for substrate 
movement from (for efflux) or to (from influx) the inner leaflet of the membrane. 
Independently of the molecular mechanism, it seems that for P-glycoprotein the 
power stroke for transport is ATP binding, as opposed to hydrolysis, because the 
major conformational and functional changes seem to occur at this step. It is possible 
that this is the case for ABC efflux pumps, while hydrolysis provides the power 
stroke for the ABC importers by opening the gate of the translocation pathway 22. 
 
                               
                                   
                    
 
Figure 3. A proposed scheme for the catalytic cycle of P-gp. The ellipses represent the substrate-
binding sites: the ‘ON’ (high affinity) and the ‘OFF’ (low affinity) site. The hexagon depicts the ‘ON’ 
site with reduced affinity for the drug. The green circles represent the ATP sites, and the empty square 
portrays the ATP site with reduced affinity for nucleotide. Step I: substrate binds to the high-affinity 
‘ON’ site of P-gp, and ATP binds to either of the two ATP sites. Step II: ATP is hydrolysed and the 
drug is moved to the lower-affinity ‘OFF’ site. Step III: Pi is released and the drug extruded from P-gp 
at this step. Step IV: the ADP and Vi dissociate from the complex, the ATP sites revert to the ‘high-
affinity’ state, but affinity for drug substrate continues to be low. Step V: following disassociation of 
the ADP in step IV, an additional molecule of ATP binds to the alternate ATP site. Step VI: ATP is 
hydrolysed. Step VII: Pi is released. Step VIII: the disassociation of ADP allows the conformation of 
P-gp to be restored to its original state (step I), to initiate the next cycle. The ADP release at steps IV 
and VIII (underlined) appears to be rate limiting in the catalytic cycle. ATP hydrolysis is shown as 
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being initiated in the C-terminal ATP site; our data suggest that the site of initiation of ATP hydrolysis 
may be random, but the two sites operate alternately. 
 
 
 
OVERVIEW OF HUMAN ABC GENE SUBFAMILIES AND 
THEIR PHYSIOLOGICAL FUNCTIONS 
 
ABCA SUBFAMILY 
 
This subfamily is composed of 12 full transporters  that are split into two subgroups 
32
. The first group (ABCA1–A4, A7, A12, A13) includes seven genes that map to six 
different chromosomes. The second group of ABCA genes (ABCA5–A6, A8–A10) is 
organized into a head-to-tail cluster on chromosome 17q24. This gene cluster is also 
found in the mouse genome.  
The expression pattern of the chromosome 17 genes is restricted with ABCA5 and 
ABCA10 expressed in skeletal muscle, ABCA9 in the heart, ABCA8 in the ovary, and 
ABCA6 in the liver. No diseases map to the corresponding region of the mouse and 
human genomes, and the functions are as yet uncharacterized. The ABCA subfamily 
genes are dispersed in the genome, except for the cluster on chromosome 17. An 
alignment of the sequences and phylogenetic analysis demonstrates that the members 
of the chromosome 17 gene cluster form a distinct subgroup. This is consistent with 
the genes that have arisen by gene duplication. Analysis of the splice sites of the 
genes shows that the chromosome 17 gene cluster members each have 38 introns, 
whereas the other ABCA genes have 50 –51 introns. The location of the introns and 
the size of the exons are highly correlated among the chromosome 17 genes, again 
supporting a recent duplication. The mouse genome also has a cluster of ABCA 
subfamily genes related to the cluster on chromosome 17. In contrast, there are no 
such genes in the Drosophila or C. elegans genomes, suggesting that these genes 
arose after the separation of vertebrates from insects and worms 32. 
ABCA1 controls the extrusion of membrane phospholipids and cholesterol toward 
specific plasmatic acceptors, the apolipoproteins. It has been proposed that the 
ABCA-dependent step involves the flux of membrane phospholipids (PL), mostly 
phosphatidylcoline (PC), toward the lipid-poor nascent apolipoprotein particle, which 
now can accept cholesterol. The ABCA1-dependent homeostatic control of the lipid 
content of the membrane dramatically influences the plasticity and fluidity of the 
membrane itself and, as a result, affects the lateral mobility of membrane proteins 
and/or their association with membrane domains of special lipid composition. The 
proposed activity of ABCA1 as a facilitator of the engulfment of apoptotic bodies fits 
with this view. Indeed, mutations in ced-7, a putative ABCA1 ortholog, in C. elegans 
hampers optimal phagocytosis by precluding the redistribution of phagocyte receptors 
around the apoptotic particle. The ABCA4 gene was found to be highly expressed in 
rod photoreceptors, and maps to the region of chromosome 1p21 containing the gene 
for the Stargardt disease, a recessive childhood retinal degeneration syndrome. 
Retinol (vitamin A) derivatives produced in the photoreceptor outer segment disks 
must be transported to the cytoplasm to be further metabolized and transported out of 
the cell. ABCA4 is believed to mediate this transport by flipping outwardly modified 
phosphatidyethanolamine (PE). Abca4-/- mice display increased all trans-
retinaldehyde following light exposure, elevated PE in the rod outer segments (ROS), 
and accumulation of these compounds. Retinoids stimulate the ATP hydrolysis of the 
ABCA4 protein in vitro, consistent with a role for these compounds as substrates.  It 
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is of interest in the context of lipid transport to note that photoreceptors represent an 
exquisite example of membrane dynamics and lipid composition. Indeed, disk 
membranes are located in the interior of the ROS and arise from evaginations of the 
ROS plasma membrane. Nascent disks are progressively organized as a discontinuous 
stacked array of flattened membranous sacs and displaced toward the apical tip as 
additional new disks are formed. The transition from the base to the tip takes 
approximately 10 days, and maintains the ROS at constant length. The lipid 
composition of disk and plasma membranes is dramatically different and suggests a 
tremendous sorting of lipid constituents at the base of the ROS upon disk biogenesis. 
During the apical displacement of the disk, their cholesterol content decreases 5-fold, 
whereas fatty acid and PL composition is virtually unchanged. The loss of cholesterol 
is thought to take place by its exchange out of the PE-rich disk membrane into the 
PC-rich plasma membrane; the relative PE/PC ratio being instrumental to favor the 
movement of cholesterol toward the plasma membrane during the disk life span. The 
proposed PE flippase activity of ABCA-4 may thus fit well along a delicate sorting 
pathway of the lipid species across the ROS compartments 32. 
The ABCA2 gene is highly expressed in oligodendrocytes in the brain; the ABCA7 
gene highly expressed in the spleen and thymus. The function of these genes, as well 
as ABCA12 and ACBA13, is not known, although it is tempting to speculate that 
they similarly participate in cellular lipid homeostasis in specialized environments. 
This is supported by the recent findings that both ABCA2 and ABCA7 share with 
ABCA1 a sterol dependent upregulation 32. 
 
 
ABCB SUBFAMILY [MULTIDRUG RESISTANCE (MDR)/TAP)] 
 
The ABCB subfamily is composed of four full transporters and seven half 
transporters, and this is the only human subfamily to have both types of transporters. 
The ABCB1 (MDR/PGY1) gene was discovered as a protein overexpressed in certain 
drug-resistant tumor cell lines. Cells that overexpress this protein display MDR and 
are resistant to or transport a wide variety of hydrophobic compounds including 
colchicine, doxorubicin, adriamycin, vinblastine, digoxin, saquinivir, and paclitaxel. 
ABCB1 is expressed primarily in the liver and blood brain barrier, and is thought to 
be involved in protecting cells from toxic agents. The gene is duplicated in mice. 
Animals lacking both genes unfortunately display a very limited phenotype and are 
still viable and fertile. However, they have been very useful models to identify and 
characterize other drug resistance genes. Secretion of cholesterol, phospholipids (PL), 
and other compounds into the bile is critical for normal bile function including the 
excretion of cholesterol and other sterols and the absorption of fat-soluble vitamins. 
The ABCB4 and B11 proteins are both located in the liver and participate in the 
secretion of phophatidylcholine (PC) and bile salts, respectively. Mutations in 
ABCB4 and ABCB11 are responsible for several forms of progressive familial 
intrahepatic cholestasis (PFIC). Defects in ABCB4 are responsible for PFIC3, and are 
associated with intrahepatic cholestasis of pregnancy. Mutations in the ABCB11 gene 
are found in patients with PFIC2. The process of antigen recognition by the class I 
histocompatibility genes involves the digestion of cellular and foreign proteins into 
short peptides and their transport into the ER where they form complexes with class I 
proteins and are expressed on the cell surface. The ABCB2 and B3 (TAP) genes are 
half transporters that form a heterodimer to transport these peptides into the ER. Rare 
families with defects in these genes display profound immune suppression, as they 
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lack this essential portion of the immune recognition process. Altered alleles in the 
TAP genes in the rat are associated with restricted ability to present certain peptides. 
The remaining ABCB subfamily half transporters are expressed in the lysosome 
(ABCB9) or the mitochondria (ABCB6, B7, B8, and B10). One of the mitochondrial 
genes (ABCB7) is located on the X-chromosome and mutations in this gene are 
responsible for X-linked sideroblastic anemia and ataxia (XLSA/A) phenotype. The 
human ABCB9 gene can complement the yeast ortholog of ABCB7, Atm1. This gene 
plays a role in mitochondrial iron homeostasis and in the biogenesis of cytosolic Fe/S 
proteins 32. 
 
 
ABCC SUBFAMILY [CYSTIC FIBROSIS TM CONDUCTANCE 
REGULATOR (CFTR)/MULTIDRUG RESISTANT PROTEIN (MRP)] 
 
The ABCC subfamily contains 12 full transporters that perform functions in ion 
transport, toxin secretion, and signal transduction. The MRPs studied thus far, 
MRP1–5, are all organic anion pumps, but they differ in substrate specificity, tissue 
distribution, and intracellular location, MRPs come in two structural types, one with 
17 transmembrane segments (MRP1, 2, 3, 6), and one with 12 (MRP4, 5, 7, 8). Cystic 
fibrosis (CF) is an inherited multisystemic disorder characterized by anormalities in 
exocrine gland function consequent to loss of function of the CFTR transporter 
(ABCC7). The CFTR protein is unique among ABC proteins in that it is a cAMP-
regulated chloride ion channel 33.  
The ABCC8 gene was identified as the locus for familial persistent hyperinsulinemic 
hypoglycemia of infancy, an autosomal recessive disorder characterized by 
unregulated insulin secretion. Subsequent work demonstrated that the ABCC8 gene is 
a high affinity receptor for the drug sulfonylurea. Sulfonylureas are widely used to 
increase insulin secretion in patients with non-insulin-dependent diabetes. These 
drugs bind to the ABCC8 and the closely related ABCC9 protein, and inhibit the 
KIR6 potassium channel 32. The remaining ABCC genes are nine MRP-related genes. 
ABCC1 (MRP1) was identified as a multidrug resistance gene and demonstrated to 
transport glutathione conjugates of many toxic compounds. MRP1 is a prototype GS-
X pump and a remarkably versatile one. It transports a variety of drugs conjugated to 
GSH, to sulfate or to glucuronate, as well as anionic drugs and dyes, but also 
neutral/basic amphipathic drugs and even oxyanions. The oxyanions arsenite and 
antimonite and the neutral/basic drugs are co-transported with GSH. Notwithstanding 
this enormous range of substrates transported, MRP1 is not indiscriminate 34. Similar 
to ABCB1, ABCC1 transports and confers resistance to a wide variety of toxic 
substrates, but is not essential for growth or development. ABCC1 can also transport 
leukotriene C4, a potent chemotactic factor controlling dendritic cell migration from 
peripheral tissues to lymph nodes 32. In the brain, MRP1 has an important function in 
the “cleansing” of toxic compounds from cerebrospinal fluid (CSF). These cells 
normally contain high levels of MRP1 in their basolateral membrane; an absence of 
MRP1 causes etoposide levels to increase ten-fold in the CSF after intravenous 
administration of the drug. Obviously, the body needs a basolateral transporter to 
protect sperm or CSF. P-gp in the apical membrane would pump drug into the cavity 
rather than protect its content.  
MRP2 and MRP1 have about the same size and putative membrane topology, and 
they both transport a similar large range of organic anions. However, the tissue 
distribution of MRP2 is much more restricted than that of MRP1, and MRP2 is 
located in the apical membrane of  epithelial cells, whereas MRP1 is basolateral. 
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MRP2 has an important function in the biliary excretion of endogenous metabolites, 
such as glucuronosyl-bilirubin, as well as many exogenous compounds. MRP2 is 
expressed not only in the liver but also in the kidney and the intestine of rats and 
humans. There is considerable species difference in the level of expression in these 
two organs compared to the liver. The most extreme example is in rabbits, in which 
expression in kidney and intestine is higher than in the liver. Intestinal MRP2 
excretes organic anions into the gut and plays a role in reducing the oral availability 
of  food-derived carcinogens. Mutations in the MRP2 gene cause the Dubin-Johnson 
syndrome. These patients suffer from an inherited conjugated hyperbilirubinemia, 
which indicates that bilirubin can enter the hepatocytes and is conjugated with 
glucuronate, but is not secreted into bile. Because of the similarity in the substrates 
transported by MRP1 and 2, one would expect cells transfected with the MRP2 gene 
constructs to become resistant to the same range of anticancer drugs as MRP1 
transfectants. It has been technically difficult to verify this prediction because MRP2 
is not routed efficiently to the plasma membrane in most transfected cells. Whether 
MRP2 contributes to anticancer drug resistance in patients remains to be seen. MRP2 
has been detected in renal, lung, gastric, colorectal, and hepatocellular carcinomas, 
but no correlation between MRP2 and clinical resistance has emerged 32.  
MRP3 is an organic anion transporter, basolateral like MRP1 35, and prominently 
present in liver, gut, and kidney like MRP2. The strong upregulation of MRP3 in the 
liver under some cholestatic conditions and the ability of MRP3 to transport some 
bile salts 36 have led to speculations that MRP3 might play a role in the enterohepatic 
recycling of bile salts and in the removal of toxic organic anions from the hepatocyte 
under cholestatic conditions 35. MRP3 differs from MRP1 and 2 in that it appears 
unable to transport GSH 35. This may explain why cells transfected with MRP3 gene 
constructs are not resistant to most of the anticancer drugs that are probably 
cotransported with GSH by MRP1/2. The only exceptions are the 
epipodophyllotoxins etoposide and teniposide 34, 35. MRP3-mediated resistance 
against these drugs does not require intracellular GSH, and etoposide appears to be 
transported by MRP3 in unmodified form. MRP3 is present in cancer cell lines from 
many tissues 37, but initial studies on MRP3 in a panel of drug-resistant cancer cell 
lines did not turn up any association between MRP3 levels and resistance 37. MRP3 
levels are high in the adrenal cortex 38. Given the high affinity of MRP3 for estradiol-
17β-glucuronide, it is therefore possible that MRP3 contributes to the transport of 
endogenous steroid conjugates 34. Glucoronide and sulphate conjugates of bile salts 
are substrates of both MRP1 and MRP3, but MRP3 also mediates transfer of 
monovalent bile salts including glycocholate 39. Glucoronide conjugates 
(e.g.,E217βG) seem to be preferentially transported by MRP3 compared with GSH 
conjugates such as 2,4-dinitrophenyl S-glutathione (DNP-SG) and leukotriene C4 
(LTC4) 39, 40.  
MRP4 and MRP5 are both organic anion pumps, but they have the interesting ability 
to transport cyclic nucleotides and nucleotide analogs, a class of organic anions 
apparently not transported by MRP1–3 or 6. The transport of nucleotide analogs by 
MRP4 and 5 can result in resistance to clinically used base, nucleoside, and 
nucleotide analogs, at least in transfected cells that highly overproduce MRP4 or 5. 
The rate of cyclic nucleotide transport by these transporters is low and the 
physiological role of this transport remains to be defined. 
Initial studies on MRP5 showed that this protein is an organic anion pump, able to 
transport acidic organic dyes, S-(2,4-dinitrophenyl)glutathione, GS-DNP, and GSH, 
and inhibited by sulfinpyrazone. However, substantial drug resistance in MRP5-
transfected cells was found only for 6-mercaptopurine (6MP) and thioguanine (TG), 
Introduction 
 
 12 
two purine bases that are definitely not acidic 34. This paradoxical result was 
rationalized when Schuetz et al. 41 discovered that a cell line selected for resistance 
against PMEA, an adenine nucleotide analog, highly overexpressed the MRP4 gene. 
This suggested that MRP4 and 5 are nucleotide transporters and that the resistance of 
MRP5 cells to thiopurines was a result of conversion of the bases into the 
corresponding nucleotides and extrusion of the nucleotides from the cell by MRP5. 
Whereas MRP4 appears to prefer methylated thioIMP, MRP5 prefers the 
unmethylated thionucleotides. There is no indication that MRP5 can transport 
nucleoside di- or triphosphate analogs. 
Cells with high concentrations of MRP4 are highly resistant to PMEA and AZT and 
much less resistant to other nucleoside analogs used in antiviral therapy, such as 
lamivudine, ddC, and d4T 41. MRP4, but not MRP5, confers resistance to short-term 
incubation with high concentrations of MTX. Like MRP4, MRP5 can transport 
nucleotide analogs with a normal pyrimidine ring 34. The list of substrates transported 
by MRP4 and 5 was substantially broadened by vesicular transport studies. 
Jedlitschky et al. 42 discovered that MRP5 can transport cyclic GMP and AMP 
(cGMP and cAMP), and Hopper et al. 43 recently found this for MRP4 as well. The 
affinity for cGMP is higher than for cAMP. There is no indication that MRP4 or 5 
can use standard 5’- or 3’-mononucleotides as substrate. Estradiol-17β-glucuronide is 
transported relatively well by MRP4. Interestingly, the cGMP transport by MRP5 is 
efficiently inhibited by the inhibitors of cGMP phosphodiesterase, sildenafil (Viagra), 
trequinsin, and zaprinast. The tissue distribution of MRP4 and MRP5 is still not well 
known. Recent studies suggest that MRP4 is more widely expressed than initially 
thought, with the highest levels in kidney and prostate. Analysis of tissue RNA 
suggests that MRP5 is ubiquitously expressed. The highest levels are found in skeletal 
muscle and brain. All attempts to generate antibodies that allow the localization of 
MRP5 in tissues with anti-MRP5 antibodies have failed thus far. This is presumably 
because the expression levels are too low, as these antibodies readily detect MRP5 in 
transfected cells. On Western blots MRP5 can be detected in human and murine 
erythrocytes, which might explain the observed cGMP transport in these cells, 
although this needs verification using red cells from Mrp5 (-/-) mice. The 
physiological functions and possible role in drug resistance of MRP4 and 5 remain to 
be defined. Obviously, the discovery that these pumps can transport cyclic 
nucleotides, notably cGMP, has raised the question of whether MRP4/5 can affect the 
signal transduction role of cGMP by removing it from the cell, which would 
supplement the degradation by phosphodiesterases. There is also evidence for an 
extracellular signaling role for cGMP in kidney and several other tissues, and 
MRP4/5 might be involved. Any role that MRP4/5 may have in drug resistance is 
also under investigation. As nucleobase and nucleoside analogs are used extensively 
in anticancer and antiviral therapies, there is potential for MRP4/5 to mediate 
resistance to these compounds. 6MP and methotrexate are both used in the treatment 
of childhood leukemias and MRP4 is the only drug transporter known thus far that 
can transport both drugs 34. Expression of multidrug transporter MRP4/ABCC4 is a 
marker of poor prognosis in neuroblastoma and is also able to confer significant 
resistance in vitro to the topoisomerase I poison irinotecan and its active metabolite 
SN-38. This drug is approved for treatment of colon and lung cancers and shows 
promising activity against a number of other cancers including cervical, ovarian 
carcinomas, and also neuroblastoma 44. No human disease has been associated with 
alterations in MRP5, and the Mrp5 knock out mouse, has no obvious phenotype. It is 
possible, however, that the overlapping substrate specificities of MRP5 and MRP4 
(and possibly MRP8 and 9) may hide the physiological function of MRP5.  
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Human MRP6 is mainly expressed in liver and kidney, like Mrp6 (MLP-1), its rat 
homolog, but low RNA levels have also been detected in other tissues.  The substrate 
specificity of MRP6 is still a mystery. Madon et al. 45 tested a series of typical MRP 
substrates in vesicular transport studies and found transport only of BQ-123, an 
anionic cyclopentapeptide and an antagonist for the endothelin A receptor. 
Endothelin-1 itself was transported by MRP2, but not by MRP6. These results 
suggest that MRP6 could be a highly selective pump for organic anions. 
Amplification of the 3’ part of the MRP6 gene was found in leukemia cells selected 
for anthracycline (epirubicin) resistance 34. The anthracycline resistance was initially 
thought to be due to a new resistance determinant, called the anthracycline resistance 
gene, ARA. Subsequent work has shown, however, that the epirubicin resistance of 
cell lines with ARA gene amplification can be explained by co-amplification of the 
MRP1 gene together with the 3’ half of the adjacent MRP6 gene 34. There is no 
indication that the MRP6 gene is ever associated with anticancer drug resistance. 
How defects in MRP6 cause pseudoxanthoma elasticum, a heritable disorder 
characterized by calcification of elastic fibers in skin, arteries, and retina, is unclear. 
Why the loss of a highly specialized pump located in the basolateral membrane of 
liver and kidney cells would lead to such a generalized connective tissue disease is 
hard to explain. Speculations include indirect effects on Ca2+ metabolism or elastic 
fiber assembly through excretion of cytokine-like organic anionic peptides 34. 
 
 
ABCD SUBFAMILY [ADRENOLEUKODYSTROPHY (ALD)] 
 
This subfamily contains 4 genes that encode half transporters expressed exclusively 
in the peroxisome. ABCD1– 4, which are also called ALDP, ALDR, PMP70, and 
PMP69, respectively. Interaction between these proteins was demonstrated by co-
immunoprecipitation and yeast two-hybrid assays 34. One of the genes, ABCD1, is 
responsible for the X-linked form of ALD, a disorder characterized by 
neurodegeneration and adrenal deficiency, typically initiating in late childhood. The 
presentation of ALD is highly variable with adrenomyeloneuropathy, childhood 
ALD, and adult onset forms. However, there is no correlation between the phenotype 
of ALD and the genotype at the ABCD1 locus. Cells from ALD patients are 
characterized by an accumulation of unbranched saturated fatty acids, but the exact 
role of ABCD1 in this process has yet to be elucidated. The functions of the other 
ABCD family genes have also not been worked out, but the marked sequence 
similarity (especially for ALDP-ABCD2) suggest that they may exert related 
functions in fatty acid metabolism. The in vitro demonstration of homo- or 
heterodimerization of the product of ABCD1 with either ALDRP or PMP70 suggest 
that different peroxisomal half transporter heterodimer combinations are involved in 
the import of specific fatty acids or other substrates. ABCD genes are under complex 
regulation at the transcriptional level, and being very tightly linked to cell lipid 
metabolism, it is not surprising that they share with the ABCA and ABCG subclasses 
the sensitivity to the peroxisome proliferator-activated receptor and retinoid X 
receptor family of nuclear receptors 32. 
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ABCE [OLIGOADENYLATE BINDING PROTEIN (OABP) AND ABCF 
(GCN20)-NONMEMBRANE ABC PROTEINS] SUBFAMILIES 
 
The ABCE and ABCF subfamilies are composed of genes that have ATP-binding 
domains that are closely related to those of the other ABC transporters, but these 
genes do not encode any TM domains. The ABCE subfamily contains a single 
member, the OABP, ABCE1. This protein recognizes oligoadenylate produced in 
response to certain viral infections 32. The ABCE1 gene is the most conserved 
member of the ABC gene family and is one of the most conserved genes in vertebrate 
and archaeal genomes 46. This fact alone suggests that the gene plays an essential role 
in biology that is common between archae and eukaryotes. In addition, null mutations 
in the gene are homozygous lethal in every organism that has been examined. ABCE1 
is essential in Xenopus and that suppression of translation or splicing with 
morpholino oligonucleotides results in the cessation of growth of the embryo during 
gastrulation, a period when the germ layers of the embryo are formed and the body 
plan of the mature organism is established. 
ABCE1 mRNA was detectable by reverse transcription-PCR in oocytes, and growth 
cessation presumably occurs at the point at which most of the maternal protein has 
degraded. The ABCE1 protein was originally identified due to an interaction with and 
inhibition of RNase L, a nuclease induced by interferon 47. However, RNase L is not 
found outside of vertebrates, indicating that 
ABCE1 has alternate functions. The identification of the role of the RLI/ABCE1 
protein in ribosome biogenesis and in assembly of the pre-initiation complex of the 
ribosome in S. cerevisiae provides a function that is both essential and universal to 
eukaryotes 48. Therefore this is likely to be the original role of ABCE1 and the protein 
has adapted interaction with RNase L as a secondary function. The mammalian 
ribosome is substantially different from the yeast ribosome. For example the initiation 
complex compnent eIF3 has 14 subunits in mammals and only 6 in yeast. Therefore 
the importance of ABCE1 in mammalian protein initiation required experimental 
evidence. 
The important role of ABCE1 in protein synthesis is extended by the data showing 
that the protein is essential in in vitro and in vivo translation of mammalian proteins. 
Antisera to ABCE1 block in vitro translation of mRNA in rabbit reticulocyte lysates 
but not of poly(U) molecules that can be translated independent of initiation factors. 
As in yeast, ABCE1 interacts with the eukaryotic initiation factors eIF5 and eIF2 
components of the pre-initiation complex. Inhibition of ABCE1 in human cells results 
in dramatic inhibition of growth, reduction in the amount of large polysomes, and 
incorporation of labeled amino acids into newly synthesized protein. This is 
consistent with the results in yeast and supports a critical role for ABCE1 in the 
initiation of translation. The inhibition of ABCE1 could have therapeutic 
applications. Because the protein is essential to most or all eukaryotes, specific 
inhibitors could be used in the treatment of pathogens. For example, inhibitors 
specific to plasmodia, fungi, and/or protozoan parasites could be used to inhibit such 
organisms as they infect human or other animals. We have shown here that ABCE1 
inhibitors efficiently suppress the growth of human tumor cells. It is known that 
tumor cells have a high capacity for protein translation, and proteins involved in 
translation such as S6 kinase, mTOR, and 4E-BP1 are molecular targets for cancer 
therapy. It is possible that cancer cells are more sensitive to inhibition of protein 
translation through ABCE1 than are normal cells. Last, ABCE1 is required for the 
assembly of HIV-1 and other lentiviruses. Drugs that interfere with the HIV/ABCE1 
interaction could be used as antiretroviral agents. The ABCE1 protein is unusual in 
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containing a Fe-S cluster binding site. It has long been known that Fe-S clusters are 
assembled in the mitochondria, and this process is essential to the cell. ABCE1 
clearly represents one essential Fe-S containing protein 46.  
The ABCF genes each have a pair of NBF, and the best characterized member is the 
S. cerevisiae GCN20 gene. GCN20 is involved in the activation of the eIF-2 alpha 
kinase. A human homolog, ABCF1 is part of the ribosome complex and may play a 
similar role 32. 
 
 
ABCG (WHITE) SUBFAMILY 
 
The human ABCG subfamily contains six half transporters that have an NBF at the 
N-terminus and a TM domain at the C-terminus: the reverse of the orientation of all 
other ABC genes. The Drosophila White locus was the first gene located by genetic 
mapping. The white protein forms a heterodimer with either of two other ABCG-
related proteins, brown and scarlet, to transport guanine and tryptophan in the eye 
cells of the fly. These molecules are precursors of the fly eye pigments. Surprisingly, 
there are only 5 ABCG genes in the human genome, whereas there are 15 in the 
Drosophila genome and 10 in yeast. Evolutionary analysis of the yeast genes shows 
that nearly all of them diverged a long time ago. This is also evident in analysis of the 
position of the introns that shows that they are not conserved among the genes 32. The 
only exception is the ABCG1 and ABCG4 genes. This pair is closely related both in 
amino acid sequence and in having nearly identical intron location. ABCG1 is highly 
expressed in macrophages and is induced by cholesterol. ABCG4 is highly expressed 
in the brain. It will be interesting to see if these genes have related functions. The 
ABCG5 and ABCG8 genes are located head-to-head on the human chromosome 2p15-
p16, separated by a region of 200 bp. The genes are both mutated in families with 
sitosterolemia, a disorder characterized by defective transport of plant and fish sterols 
and cholesterol. Sitosterolemia patients display deficient sterol secretion from the 
intestine and the liver. This genetic evidence indicates that the two half transporters 
form a functional heterodimer. This is supported by the finding that the two genes are 
coordinately regulated by cholesterol. Perplexingly, the ABCG5 gene is principally 
mutated in Asians; the ABCG8 gene in Caucasians. This suggests that the proteins 
may form both hetero- and homodimers to transport the wide range of dietary sterols 
(compesterol, stigmasterol, avenosterol, sitosterol, cholesterol) encountered in the 
diet. The mammalian ABCG1 gene is also induced by cholesterol and is involved in 
cholesterol transport regulation. The analysis of cell lines selected for high level 
resistance to mitoxantrone that do not overexpress ABCB1 or ABCC1 were 
instrumental in the identification of the ABCG2 (ABCP, MXR1, BCRP) gene as a 
multidrug transporter. ABCG2 can use anthracycline anticancer drugs, as well as 
topotecan, mitoxantrone, or doxorubicin as substrates. The ABCG2 gene is either 
amplified or rearranged by chromosomal translocations in resistant cell lines. 
Transfection of ABCG2 into cells confers resistance, consistent with its functioning as 
a homodimer. ABCG2 can also transport several dyes (rhodamine and Hoechst 
33,462), and the gene is highly expressed in a subpopulation of hematopoetic stem 
cells (side population) but not in mature blood cells. The normal function of ABCG2 
is not known; however, it is highly expressed in placental trophoblast cells, 
suggesting that it may pump toxic metabolites from the fetal to the maternal blood 
supply. The Abcg3 gene is so far only found in the mouse and other rodent genomes. 
The gene is expressed in the spleen and thymus and has an ATP-binding domain that 
is missing several conserved residues in the Walker A and Signal domains 32. 
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ABC GENES AND HUMAN GENETIC DISEASE 
 
Many ABC genes were originally discovered during the positional cloning of human 
genetic disease genes. To date, 14 ABC genes have been linked to disorders 
displaying Mendelian inheritance. As expected from the diverse functional roles of 
ABC genes, the genetic deficiencies that they cause also vary widely. Because ABC 
genes typically encode structural proteins, all of the disorders are recessive, and are 
attributable to a severe reduction or lack of function of the protein. Heterozygous 
variants in ABC gene mutations, however, are being implicated in the susceptibility 
to specific complex disorders 3. 
 
 
CYSTIC FIBROSIS AND CFTR (ABCC7) 
 
Cystic fibrosis is the most common fatal childhood disease in Caucasian populations, 
reaching frequencies ranging from 1: 900 to 1:2500. This corresponds to a carrier 
frequency of 1:15–1:25. The disease is much less common in African and Asian 
populations, where carrier frequencies of 1:100 to 1:200 have been estimated. The 
disease frequency correlates with the frequency of the major allele of the CF gene, a 
deletion of three base pairs (∆F508). At least two other populations, however, have 
high frequency CF alleles. The W1282X allele is found on 51% of the alleles in the 
Ashkenazi Jewish population and the 1677delTA allele has been found at a high 
frequency in Georgians and is also present at elevated level in Turkish and Bulgarian 
populations. This has led several groups to hypothesize that these alleles arose 
through selection of an advantageous phenotype in the heterozygotes. It is through 
CFTR that some bacterial toxins such as cholera and E. coli cause increased fluid 
flow in the intestine and result in diarrhea. Therefore, several researchers have 
proposed that the CF mutations have been selected for in response to these diseases. 
This hypothesis is supported by studies showing that CF homozygotes fail to secrete 
chloride ions in response to a variety of stimulants, and a study in mice in which 
heterozygous null animals showed reduced intestinal fluid secretion in response to 
cholera toxin. CFTR is also the receptor for Salmonella typhimurium and implication 
in the innate immunity to Pseudomonas aeruginosa. Patients with two severe CFTR 
alleles like ∆F508 typically display severe diseases with inadequate secretion of 
pancreatic enzymes leading to nutritional deficiencies, bacterial infections of the lung, 
and obstruction of the vas deferens, leading to male infertility. Patients with at least 
one partially functional allele display enough residual pancreatic function to avoid the 
major nutritional and intestinal deficiencies and subjects with very mild alleles 
display only congenital absence of the vas deferens, a genetic cause of male 
infertility, with none of the other symptoms of CF. Recently, heterozygotes of CF 
mutations have been found to have an increased frequency of pancreatitis and 
bronchiectasis. Therefore, there is a spectrum of severity in the phe-notypes caused 
by this gene that is inversely related to the level of CFTR activity. Clearly, other 
modifying genes and the environment also affect disease severity, particularly the 
pulmonary phenotypes 3. 
 
 
ADRENOLEUKODYSTROPHY/ABCD1 
 
Adrenoleukodystrophy (ALD) is an X-linked recessive disorder characterized by 
neurodegenerative phenotypes with onset typically in late childhood. Adrenal 
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deficiency commonly occurs and the presentation of ALD is highly variable. AMN, 
childhood ALD and adult onset forms are recognized, but there is no apparent 
correlation to ABCD1 alleles. ALD patients have an accumulation of unbranched, 
saturated fatty acids with a chain length of 24–30 carbons, in the cholesterol esters of 
the brain and in adrenal cortex. The ALD protein is located in the peroxisome, where 
it is believed to be involved in the transport of very long chain fatty acids 3. 
 
 
FAMILIAL PERSISTENT HYPERINSULINEMIC HYPOGLICEMIA OF 
INFANCY /ABCC8 
 
The ABCC8 gene is a high-affinity receptor for the drug sulfonylurea. Sulfonylureas 
are a class of drugs widely used to increase insulin secretion in patients with non-
insulin-dependent diabetes. These drugs bind to the ABCC8 protein and inhibit an 
associated potassium channel KIR6.2 (KCNJ11). Familial persistent 
hyperinsulinemic hypoglycaemia of infancy is an autosomal recessive disorder in 
which subjects display unregulated insulin secretion. The disease was mapped to 
11p15-p14 by linkage analysis, and mutations in the ABCC8 gene are found in PHHI 
families. Multiple studies have reported association of the E23K variant of Kir6.2 
with risk of type 2 diabetes. However, this variant has a very strong allelic association 
with the A1369S variant in the ABCC8 gene. Thus the association cannot be ascribed 
to either gene and may be a compound effect of both variants 21. 
 
 
BILE  SALT  TRANSPORT DISORDER 
 
Several ABC transporters are specifically expressed in the liver, have a role in the 
secretion of components of the bile, and are responsible for several forms of 
progressive familial intrahepatic cholestasis (PFIC). PFICs are a heterogeneous group 
of autosomal recessive liver disorders, characterized by early onset of cholestasis that 
leads to liver cirrhosis and failure before adulthood. The ABCB4 (PGY3) gene 
transports phosphatidylcholine across the canalicular membrane of hepatocytes. 
Mutations in this gene cause PFIC3  and are associated with intrahepatic cholestasis 
of pregnancy. The rat Abcc2/Mrp2 gene was found to have a frame-shift mutation in 
the strain defective in canalicular multispecific organic anion transport, the TR- rat. 
The TR- rat is an animal model of Dubin-Johnson syndrome and mutations in ABCC2 
have been identified in Dubin- Johnson syndrome patients. The ABCC2 protein is 
expressed on the canalicular side of the hepatocyte and mediates organic anion 
transport. The ABCB11/BSEP gene was originally identified based on homology to 
ABCB1.  ABCB11 is highly expressed on the liver canalicular membrane and has 
been shown to be the major bile salt export pump. Mutations in ABCB11 are found in 
patients with PFIC2 3. 
 
 
RETINAL DEGENERATION/ABCA4 
 
The ABCA4/ABCR gene is expressed exclusively in photoreceptors where it 
transports retinol (vitamin A) derivatives from the photoreceptor outer segment disks 
into the cytoplasm 49. The chromophore of a visual pigment rhodopsin, retinal, or 
conjugates with phospholipids are the likely substrates for ABCA4, as they stimulate 
the ATP hydrolysis of the protein. Mice lacking Abca4 show increased all-trans-
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retinaldehyde (all-trans-RAL) following light exposure, elevated 
phosphatidylethanolamine (PE) in outer segments, accumulation of the protonated 
Schiff base complex of all-trans-RAL and PE (N-retinylidene-PE), and striking 
deposition of a major lipofuscin fluorophore (A2-E) in retinal pigment epithelium 
(RPE). These data suggest that ABCR is an outwardly directed flippase for N-
retinylidene-PE. Mutations in the ABCA4 gene have been associated with multiple 
eye disorders 50. A complete loss of ABCA4 function leads to retinitis pigmentosa, 
whereas patients with at least one missense allele have Startgardt disease (STGD). 
STGD is characterized by juvenile to early adult onset macular dystrophy with loss of 
central vision. ABCA4 mutation carriers are also increased in frequency in age-related 
macular degeneration (AMD) patients. AMD patients display a variety of phenotypic 
features, including the loss of central vision after the age of 60. The causes of this 
complex trait are poorly understood, but a combination of genetic and environmental 
factors have a role. The abnormal accumulation of retinoids, caused by ABCA4 
deficiency has been postulated to be one mechanism by which this process could be 
initiated. Defects in ABCA4 lead to an accumulation of retinal derivatives in the 
retinal pigment epithelium behind the retina 3. 
 
 
MITOCHONDRIAL IRON HOMEOSTASIS/ABCB7 
 
Several half transporters of the MDR/TAP subfamily have been localized to the inner 
membrane of the mitochondria. The yeast ortholog of ABCB7, Atm1, has been 
implicated in mitochondrial iron homeostasis, as a transporter in the biogenesis of 
cytosolic Fe/S proteins. Two distinct missense mutations in ABCB7 are associated 
with the X-linked sideroblastic anemia and ataxia (XLSA/A) phenotype. Three more 
half transporters from this subfamily, ABCB6, ABCB8 and ABCB10 have also been 
localized to mitochondria 3. 
 
 
STEROL TRANSPORT DEFICIENCIES 
 
Tangier disease is characterized by deficient efflux of lipids from peripheral cells, 
such as macrophages, and a very low level of HDL. The disease is caused by 
alterations in the ABCA1 gene, implicating this protein in the pathway of removal of 
cholesterol and phospholipids onto HDL. Patients with hypolipidemia have also been 
described that are heterozygous for ABCA1 mutations, suggesting that ABCA1 
variations may have a role in regulating the level of HDLs in the blood. 
Subsequently, the sterol-dependent regulation of ABCA1 expression was shown. 
Current models for ABCA1 function place it at the plasma membrane where it 
mediates the transfer of phospholipid and cholesterol onto lipid-poor apolipoproteins 
to form nascent HDL particles. The ABCA1-mediated efflux of cholesterol is 
regulated by nuclear hormone receptors, such as oxysterol receptors (LXRs) and the 
bile acid receptor (FXR), as heterodimers with retinoid X receptors (RXRs). ABCA1 
also plays a role in the engulfment of apoptotic bodies. Furthermore, the ced-7 gene, 
an ABCA1 ortholog in C. elegans, plays a role in phagocytosis by precluding the 
redistribution of phagocyte receptors around the apoptotic particle. Recently, two 
half-transporter genes, ABCG5 and ABCG8 were characterized, located head-to-head 
on the human chromosome 2p15-p16, and regulated by the same promoter. These 
genes are both mutated in families with sitosterolemia, a disorder characterized by 
defective transport of plant and fish sterols and cholesterol. Most likely, the two half-
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transporters form a functional heterodimer. The ABCG1 gene is also regulated by 
cholesterol and ABCG4 is highly expressed in the liver, suggesting that these two 
genes may also be involved in cholesterol transport 3. 
 
 
LAMELLAR ICHTYOSIS TYPE 2 (LI2)/ABCA12 
 
Lamellar ichthyosis type 2 is a genetically heterogeneous skin disorder characterized 
by large, dark, pigmented scales. The disease was mapped to chromosome 2q33–35, 
the region where ABCA12 is located. Mutations in ABCA12 were identified in several 
LI2 families. It is likely that ABCA12 plays a role in lipid secretion or membrane 
organization in the developing skin. The ABCA12 gene is also expressed in the 
stomach, indicating that it may play a role in mucous secretion 21. 
 
 
SURFACTANT DEFICIENCY/ABCA3 
 
Respiratory distress syndrome is an important cause of neonatal mortality and 
morbidity and is often caused by a deficiency in lung surfactants. Surfactant forms a 
lipid rich monolayer that coats the pulmonary airways and is essential for the inflation 
of the lung. Surfactant is produced and secreted by alveolar type II cells and consists 
of lipids, cholesterol, and specialized proteins. The ABCA3 gene is expressed in 
alveolar type II cells, and the protein is localized to lamellar bodies. Mutations in the 
ABCA3 gene are an important cause of this disease, and patients display abnormal 
surfactant, elevated surface tension, and abnormal lamellar bodies. Although typically 
fatal, mild cases have been identified and associated with missense mutations in the 
ABCA3 gene 21. 
 
 
IVERMECTIN SENSITIVITY/ABCB1 
 
Ivermectin is a highly useful drug that is effective against a variety of invertebrates, 
including helminthes, Onchocerca volvulus (the worm causing river blindness), and 
mites (including those causing scabies). Ivermectin is in wide use in both veterinary 
and human medicine. Collie dogs frequently display sensitivity to the drug, as do 
mice that are Abcb1a -/-. It was found that collies have a 4bp deletion in the gene and 
that at least nine other breeds carry this mutation. ABCB1 is a drug transporter that is 
expressed in many tissues, but plays a particularly important role in the blood–brain 
barrier. ABCB1 mutant collies are also sensitive to a number of other drugs, 
including doramectin, loperamide, and several anticancer drugs 21. 
 
 
IMMUNE DEFICIENCY/TAP1 AND TAP2 
 
The TAP1/ABCB2 and TAP2/ABCB3 genes are half transporters that form the pump 
in the endoplasmic reticulum that complexes peptides with HLA class I molecules for 
antigen presentation on the cell surface. Rare mutations in each of these genes have 
been identified in patients with immune deficiency. An allele of the TAP2/ABCB3 
gene (M577V) has been identified that is present at 5% in the general population and 
is associated with the presence of autoantibodies in patients with Sjogren syndrome. 
This allele is also associated with the altered presentation of peptides on HLA class I 
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molecules. Tumor cells can potentially evade the immune system by failing to present 
class I antigens, and mutations in TAP genes have been found in cancer cell lines that 
are class I negative 21. 
 
 
PSEUDOXANTHOMA ELASTICUM/ABCC6 
 
Pseudoxanthoma elasticum is an autosoma recessive disease characterized by skin 
laxity and vision impairment characterized by angioid streaks and occlusion of blood 
vessels. Calcification of elastic fibers is a diagnostic feature. PXE is caused by 
mutations in the ABCC6 gene. Interestingly, there is considerable variation in the 
presentation of PXE even within affected individuals in the same family, suggesting 
that the clinical manifestations of PXE are biochemically removed from the function. 
ABCC6 is expressed predominantly in the liver and kidney and is proposed to 
transport a critical metabolite into or out of the blood. Mutation carriers of ABCC6 
variants have been associated with an increased risk of cardiovascular disease 21. 
 
 
DILATED CARDIOMYOPATHY/ABCC9 
 
Individuals with dilated cardiomyopathy present with heart failure and rhythm 
disturbances. ABCC9 displays low affinity binding to sulfonylurea and is a major 
regulator of ATP dependent potassium channels in muscle. ABCC9 mutations have 
been identified in two patients with dilated cardiomyopathy and these variants have 
been shown to disrupt catalytic K(ATP) channel gating 21. 
 
 
 
MULTIDRUG RESISTANCE 
 
Cells exposed to toxic compounds can develop resistance by a number of 
mechanisms including decreased uptake, increased detoxification, alteration of target 
proteins, or increased excretion. Several of these pathways can lead to multidrug 
resistance (MDR), in which the cell is resistant to several drugs in addition to the 
initial compound. This is a particular limitation to cancer chemotherapy and the MDR 
cell often displays other properties, such as genome instability and loss of checkpoint 
control, which complicate further therapy. ABC genes have an important role in 
MDR and several of them are associated with drug transport (Table 2). 
The best characterized ABC drug pump is the ABCB1 gene, formerly known as 
MDR1 or PGY1. ABCB1 was the first human ABC transporter cloned and 
characterized through its ability to confer a multidrug resistance phenotype to cancer 
cells that had developed resistance to chemotherapy drugs 
51
. P-gp efficiently removes cytotoxic drugs and many commonly used 
pharmaceuticals from the lipid bilayer. Its broad substrate specificity presumably 
reflects a large, polymorphous drug-binding domain or domains within the 
transmembrane segments. ABCB1 has been demonstrated to be a promiscuous 
transporter of hydrophobic substrates, hydrophobic drugs including drugs including 
colchicine, VP16, adriamycin and vinblastine as well as lipids, steroids, xenobiotics, 
and peptides 52. The gene is thought to have an important role in removing toxic 
metabolites from cells, but is also expressed in cells at the blood–brain barrier and 
presumably has a role in transporting compounds into the brain that cannot be 
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delivered by diffusion. ABCB1 also affects the pharmacology of the drugs that are 
substrates and a common polymorphism in the gene affects digoxin uptake 3. Because 
P-gp binds many different hydrophobic compounds, it has been easy to find potent P-
gp inhibitors. Two inhibitors that are used in the laboratory and in clinical trials that 
attempted to reverse drug resistance are the calcium channel blocker verapamil and 
the immunosuppressant cyclosporin A. As not all multidrug-resistant cells express P-
gp, a search for other efflux pumps was initiated, leading to the discovery of the 
multidrug-resistance-associated protein 1 (MRP1, or ABCC1) 53. 
 
                   
 
 
. 
Table 2. Tissue localization and possible functions of ABC transporters 
 
MRP1 is similar to P-gp in structure, with the exception of an aminoterminal 
extension that contains five-membranespanning domains attached to a P-gp-like core. 
MRP1 recognizes neutral and anionic hydrophobic natural products, and transports 
glutathione and other conjugates of these drugs, or, in some cases — such as for 
vincristine — co-transports unconjugated glutathione 54, 55. The discovery of MRP1 
stimulated a genomic search for homologues, leading to the discovery of eight 
additional members of the ABCC subfamily of transporters, of which six have been 
studied in some detail. Like MRP1, some of these MRPs have the five 
transmembrane amino-terminal extension (ABCC2, ABCC3 and ABCC6, also named 
MRP2, 3, and 6), whereas others do not. Many MRP family members transport drugs 
in model systems and therefore have the potential to confer drug resistance 56. Some 
anticancer drugs, such as mitoxantrone, are poor substrates for MDR1 and MRP1. 
Selection for mitoxantrone resistance results in multidrug-resistant cells that produce 
a more distant member of the ABC transporter family, ABCG2 — also known as 
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MXR (mitoxantrone-resistance gene), BCRP (breast cancer resistance protein) or 
ABC-P (ABC transporter in placenta). This transporter is thought to be a homodimer 
of two half-transporters, each containing an ATP-binding domain at the amino-
terminal end of the molecule and six transmembrane segments 57. 
The first two original ABCG2 genes that were cloned from resistant cells encoded 
proteins with either a threonine or glycine substituted for arginine at amino acid 482, 
giving them much broader substrate specificity, including the ability to transport 
doxorubicin. This finding, together with many well-documented mutations in P-GP, 
shows that even single amino-acid substitutions can change substrate specificity. 
Other ABC family members have been associated with drug resistance. For example, 
the bile salt export protein (BSEP, also known as ABCB11), first reported as the 
‘sister of P-gp’ (SPGP), is expressed at high levels in liver cells, and in transfection 
experiments it confers low level resistance to paclitaxel 58. MDR3 (sometimes called 
MDR2), a phosphatidylcholine flippase that is closely related to P-gp, normally 
transports phospholipids into bile, but can transport paclitaxel and vinblastine, albeit 
inefficiently unless it is mutated 57. Finally, ABCA2 is overexpressed in estramustine-
resistant cells 59. Estramustine is a nitrogen mustard derivative of oestradiol, so 
ABCA2 — which is expressed intracellularly in endosomal/lysosomal vesicles — 
might participate in steroid transport. Although the lung resistance protein (LRP) is 
not an ABC transporter, it is frequently included in discussions of drug resistance, as 
it is expressed at high levels in drug-resistant cell lines and some tumours 57. LRP is a 
major vault protein found in the cytoplasm and on the nuclear membrane. Vaults are 
large ribonucleoprotein particles that are present in all eukaryotic cells. Their shape is 
reminiscent of the nucleopore central plug, and the major vault proteins account for 
70% of their mass. Although their role in normal physiology is not yet established, 
vaults might confer drug resistance by redistributing drugs away from intracellular 
targets 57. 
 
 
ABC TRANSPORTERS IN HUMAN CANCERS  
 
Although it seems likely that cancer cells use several different types of ABC 
transporter to gain drug resistance, most clinical studies have focused on P-gp. Early 
studies showed that P-gp was highly expressed in colon, kidney, adrenocortical and 
hepatocellular cancers. Initially, there was hope that increases in P-gp expression 
alone could explain cancer drug resistance. However, the failure of these cancers to 
respond to drugs that are not P-gp substrates indicated that other factors are involved, 
and attention turned to cancers that acquire resistance following chemotherapy. In 
seeking to define the role of P-gp in drug resistance, researchers have assumed that P-
gp expression is highest in tumours that are dependent on expression for survival, that 
expression impairs response to chemotherapy, and that expression levels increase as 
tumours become drug resistant. On the basis of these assumptions, clinical trials 
aimed at increasing chemotherapy sensitivity in drug-resistant tumours, through 
inhibition of P-gp, have been implemented. So, does P-GP expression confer drug 
resistance in human cancer? Most studies that correlate P-GP expression with clinical 
outcome have been small, retrospective, single-institution studies with insufficient 
power to draw reliable conclusions. One problem with designing a study that provides 
statistically valid results is that methods for detecting P-gp expression are imperfect. 
This is primarily due to the lack of specificity 
of many commonly used anti-P-gp antibodies. To complicate matters, researchers 
also use different methods to quantify expression, to control for tumour 
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heterogeneity, and to account for the presence of normal tissue in tumour biopsies. 
Despite efforts to bring uniformity to P-gp quantification, it is still difficult to discern 
valid from invalid data. 
Expression of MRP1 has also been analysed in clinical samples. Antibodies against 
MRP1 seem to be more specific than those that recognize P-gp, and MRP1 is highly 
expressed in leukaemias, oesophageal carcinoma and non-small-cell lung cancers. 
Conclusions about expression levels of other ABC transporters in human tissue await 
more extensive analysis 57. 
         
LEUKEMIA  
 
The most uniform associations between MDR1/P-gp expression and drug resistance 
have been reported in acute myelogenous leukaemia (AML). P-gp expression has 
been reported in leukaemic cells from about one-third of patients with AML at the 
time of diagnosis, and more than 50% of patients at relapse; higher levels occur in 
certain subtypes, including secondary leukaemias. P-gp expression is correlated with 
a reduced complete remission rate, and a higher incidence of refractory disease — a 
surprising finding, as treatment regimens include not only the P-gp substrate 
daunorubicin, but also AraC, which is not a P-gp substrate 57. Recent studies report 
that P-GP expression is associated with a poorer prognosis, although the magnitude 
of the effects on response and survival is probably not as great as initially thought. 
These clinical results are supported by ex vivo studies of leukaemic cells, which have 
shown that P-GP expression reduces the intracellular accumulation of daunorubicin. 
In addition, administration of a P-gp inhibitor increases daunorubicin accumulation in 
leukaemic cells 57. MRP1 and LRP expression have also been evaluated in leukaemia. 
Increased MRP1 expression has been reported in chronic lymphocytic and 
prolymphocytic leukaemia cells. Expression levels are less frequently elevated in 
AML cells (10–34%) 60, 61, and these studies lead to different conclusions about 
whether MRP1 confers a poor prognosis. So far, the largest trial in untreated patients 
found no correlation between MRP1 or LRP expression and prognosis, but observed a 
correlation between PGP expression and prognosis 57. Finally, low expression levels 
of BCRP/MXR have been observed in AML cells 62. Taken together, the clinical data 
support a role for PGP in drug resistance in AML patients, and for MRP1 expression 
in chronic lymphocytic and prolymphocytic leukaemias. Additional studies are 
needed to confirm and extend these findings 57. 
 
 
BREAST CANCER  
 
Detection of transporters in solid tumour samples has been more difficult. A 1997 
meta-analysis of 31 reports from 1989–1996 found that 41% of breast tumours 
expressed P-GP. P-GP expression increased after therapy and was associated with a 
greater likelihood of treatment failure. However, there was considerable interstudy 
variability, preventing a solid conclusion about the role of P-GP in breast cancer. 
Recent imaging studies using 99mTc (technetium)-sestamibi (Cardiolite), a transport 
substrate recognized by P-GP, indicate that its activity is increased in breast 
carcinomas 63. Whether the MRP1 expression levels associated with breast cancer are 
enough to confer drug resistance is not yet resolved. As MRP1 is expressed 
ubiquitously, it is not surprising that using reverse transcriptase polymerase chain 
reaction (RT—PCR), MRP1 mRNA can be detected in all breast cancer samples at 
levels comparable to that in normal tissues. One immunohistochemical analysis of a 
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series of resected invasive primary breast carcinomas reported a correlation between 
relapse-free survival and MRP1 expression 57. 
 
 
NEUROBLASTOMA 
 
NB is the second most common solid cancer in young children accounting for 9% of 
all childhood cancers 64. It is characterised by a heterogeneous clinical behaviour that 
ranges from spontaneous regression in 10% of all cases to rapid and largely treatment 
resistant progression with fatal outcome. At present, patient risk classification 
includes N-MYC gene amplification, 1p chromosomal deletion, tumour stage, and age 
of the child at diagnosis 65, 66. Amplification or overexpression of the N-MYC 
oncogene is present in about 25–30% of primary untreated NBs, which is associated 
with advanced stage disease, rapid progression and unfavourable prognosis 67. 
Moreover, this patient subgroup often demonstrates a multiple drug resistant (MDR) 
phenotype that develops from exposure to chemotherapeutic agents and increases 
with intensity of the therapy accommodated. NB treatment includes induction 
chemotherapy, maintenance of high dose chemotherapy, radiotherapy, tumour 
surgery and consolidation therapy. Chemotherapeutic protocols combine alkylating 
agents with microtubule active drugs, topoisomerase inhibitors and antibiotics. Anti-
neoplastic drugs are effectively used in the treatment of NB patients. Following initial 
treatment with cytotoxic drugs, NB tumours are highly chemoresponsive, displaying 
significant partial or complete remission in about 80% of tumours, even those with 
unfavourable prognostic outcome 68. Although many high-risk NBs initially respond 
to the first cycles of intensive chemotherapy, they frequently become refractory to 
treatment as the disease progresses. N-MYC clearly contributes to the drug-resistant 
phenotype of NB, as amplification of this oncogene is strongly associated with rapid 
tumor progression and poor prognosis 69, 70. The role of MDR1 gene in mediating 
multidrug resistance in neuroblastoma is still unclear. Chan and associates 71 
demonstrated that P-GP expression in neuroblastoma independently predicted for 
poor outcome, but other studies of MDR1 expression in this malignancy have failed 
to confirm these results 72. Controversy regarding the contribution of MDR1 to the 
chemoresistant phenotype was heightened by a study, which reported that P-GP 
expression in neuroblastoma was restricted to the normal infiltrating stroma cells 73. 
In neuroblastoma cell lines, induced to differentiate by exposure with retinoic acid , 
MDR1 expression increases in parallel with other markers of neuronal differentiation 
74
 and this increased expression was not associated with the expected decrease in 
accumulation of cytotoxic drugs. As result of these disparate data, the contribution of 
the MDR1 gene to either drug resistance or to patient outcome in neuroblastoma 
remains ill-defined. MDR1 gene expression failed to predict for outcome in this 
tumour, but MRP1 gene expression is a powerful prognostic indicator for children 
with neuroblastoma 72. High MRP1 expression but low MDR1 expression was 
observed in tumours with N-MYC amplification and the expression of these two genes 
was not correlated in this subset of tumours 73. High levels of MRP1 expression were 
strongly associated with reductions in both survival and event-free survival. Altough 
MRP1 is a direct target of N-Myc 75, a multivariate analysis demonstrates that N-MYC 
amplification had no prognostic value when MRP1 expression was included as a 
prognostic factor, may be N-Myc governs the transcription of critical genes, such as 
MRP1, conferring multidrug resistance 72. Although available evidence strongly 
suggests that MRP1 is critically associated with the drug-resistant behavior of 
primary NB 72, this drug efflux pump does not appear to mediate resistance to either 
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alkylating agents or platinum compounds 57. Members of both these classes of 
compounds, such as cisplatin and cyclophosphamide, are commonly used in the 
treatment of NB. Thus, despite the high levels of MRP1 observed in many aggressive 
NBs at diagnosis, the use of these non-MRP1 substrate drugs may explain why the 
majority of NB do initially respond to chemotherapy. Nevertheless, over half of these 
previously responsive tumors will eventually relapse with chemoresistant disease, 
suggesting the development of additional drug-resistance mechanisms 75. Also MRP4 
is expressed in primary neuroblastoma and also its overexpression is significantly 
associated with N-MYC amplification and MRP1 expression. The drug resistance 
phenotype of MRP4 has to date been thought to encompass primarily nucleoside 
analogues (including antiretroviral agents) and methotrexate. MRP4 is also able to 
confer significant resistance in vitro to the topoisomerase I poison irinotecan and its 
active metabolite SN-38. This drug is approved for treatment of colon and lung 
cancers and shows promising activity against a number of other cancers including 
cervical, ovarian carcinomas, and also neuroblastoma. Like MRP1, also high MRP4 
expression correlate with poor clinical outcome in neuroblastoma 44. 
 
 
OTHER SOLID TUMOURS 
 
Variability in expression is also a problem for other solid tumours. In ovarian cancer 
samples, 16–47% were found to express P-GP, as measured by 
immunohistochemistry. Critical analysis of these data reveals that P-GP is expressed 
by only about 20% of ovarian cancers when samples were taken at diagnosis. This 
makes it difficult to demonstrate a correlation between expression and outcomes, 
such as disease- free survival, particularly given the importance of cisplatin in 
therapy. In lung cancer samples, MDR1 mRNA expression was reported to be 
increased in 15–50% of tumours. The incidence of MRP1 expression is much higher 
(about 80%) in small-cell lung cancer (SCLC) samples. MRP1 expression was 
detected in 100% of non-small cell lung cancers (NSCLC),with higher levels noted in 
30% of the samples — this might not be surprising, given its ubiquitous expression in 
normal lung tissue. Immunohistochemical studies confirmed the predominantly 
plasma-membrane localization pattern of MRP1. Given the low levels of MDR1 
expression and the nearly ubiquitous expression of MRP1, lung cancer should be an 
excellent model in which to evaluate the role of MRP1-specific inhibitors. Sarcomas 
represent another malignancy in which P-gp expression seems to be important for 
drug resistance. Immunohistochemical studies of both soft-tissue sarcomas and 
osteosarcomas revealed a strong association between P-gp expression, relapse-free 
survival and overall survival. Other methodologies, however, have been used to 
substantiate and refute these findings, and there has been no consensus regarding the 
effect of P-gp on survival in sarcomas 57. 
 
 
DEVELOPMENT OF DRUG RESISTANCE ABC-MEDIATED 
 
Three mechanisms have been proposed to understand how an alterated expression of 
ABC transporters can result in drug resistance in human tumours (Fig. 4). According 
to intrinsic resistance model, tumor cells are intrinsically resistant due to high 
constitutive expression of ABC transporters. This high expression may be a reflection 
of the expression levels in the tissue of origin (for example, colon) or a result of a 
change in the expression of a tumor suppressor gene (e.g. p53) during progression to 
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the malignant state that influences ABC genes transcription. In this scenario, 
chemotherapy has little effect on the intrinsically resistant tumor. Acquired resistance 
model is the result of inherent genomic instability, thus an initially sensitive tumor 
acquires a subpopulation of mutant cells that constitutively express high levels of 
ABC transporters. In this scenario, chemotherapy eradicates drug-sensitive cells, but 
the resistant subset of cells survives treatment and may ultimately replicate.  
 
     
                                
 
Figure 4.  Models of drug resistance in tumour cells. Three proposed mechanisms (intrinsic, acquired 
and inducible) by which overexpression of MDR1 can result in drug resistant in human tumours.  
 
 
Finally, the inducible resistance  model propose that a subset of tumor cells within a 
drug-sensitive population are able to rapidly (and transiently?) induce ABC genes 
expression in response to stress stimuli. Upon exposure to chemotherapy, sensitive 
cells are killed, but the inducible subset increases the expression of  ABC genes, 
permitting survival and repopulation. Whether/how long ABC transporters levels 
remain elevated in surviving tumor cells in the clinical setting has not yet been 
investigated 76. 
 
 
 
ROLE OF TUMOUR STEM CELLS IN THE DEVELOPMENT OF 
DRUG RESISTANCE 
 
The discovery of cancer stem cells in solid tumours has changed our view of 
carcinogenesis and chemotherapy. One of the unique features of the bone marrow 
stem cells that are required for normal haematopoiesis is their capacity for self-
renewal. In the haematopoietic system, there are three different population of 
multipotent progenitors-stem cells with high capacity for long-term renewal, stem 
cells with high capacity for short-term renewal, and multipotent progenitors that 
cannot renew but differentiate into the varied lineages in the bone marrow 77. The 
multipotent progenitors and their derived lineages undergo rapid cell division, 
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allowing them to populate the marrow. The factors that determine the self-renewing 
capacity of a cell, and how cancer cells acquire this ability , are not yet understood. 
Pluripotent stem cells that possess both self-renewal capabilities and the ability to 
generate an organ-specific, differentiated repertoire of cells exist in organs other than 
the haematopoietic system and these can be studied to gain better insight into the 
stem-cell biology of a tumour. The concept of organ stem cells is difficult when one 
considers the many different cell types and functions of an organ, but emerging 
evidence indicates such pluripotent stem cells exist. In the normal mammary gland, 
for example, three cell lineages have been described — myoepithelial cells that form 
a basal cell layer, ductal epithelial cells, and milk-producing alveolar cells. Although 
transplantation studies in mice have demonstrated that most mammary cells have a 
limited capacity for self-renewal, clonal populations that can recapitulate the entire 
functional repertoire of the gland have been identified. In an elegant study, human 
mammary epithelial cells derived from reduction mammoplasties were used to 
generate non-adherent spheroids (designated mammospheres) in cell culture and 
demonstrate the presence of the three mammary cell lineages. More importantly, the 
cells in the mammospheres were clonally derived, providing evidence for a single 
pluripotent stem cell 78. These same approaches are being used to isolate and 
characterize breast cancer stem cells. In the haematopoietic system as well as in other 
normal tissues, the normal stem cell must be both self-renewing and pluripotent. 
Although stem cells can self-renew, they are generally quiescent, spending most of 
their time in G0. Because stem cells can repair their DNA as they self-renew, they 
have the potential to accumulate mutations acquired after exposure to carcinogens. If 
tumours arise from stem cells, the accumulation of these mutations might be what we 
have come to recognize as the ‘multistep process of carcinogenesis’. So do cancer 
stem cells arise from normal stem cells, or do they arise from differentiated cells that 
acquire self-renewal capacity, or both? Does the innate resistance of normal stem 
cells to radiation and toxins contribute to the failure of some cancer therapies? How 
can we exploit our knowledge of stem-cell biology to specifically target these cells 
and improve therapy? 
 
 
CANCER STEM CELLS 
 
Cells with stem-cell qualities have been identified in malignancies of haematopoietic 
origin and in some solid tumours. The existence of such a population would imply 
that the stem cell represents the cell of origin for the tumour, as illustrated in Fig. 5 79. 
One can predict that such cancer stem cells represent only a small fraction of a 
tumour, as they possess the capability to regenerate a tumour, and most cancer cells 
lack this regenerative capability. Studies of acute myelogenous leukaemia have 
shown that only 0.1–1% of all cells have leukaemia-initiating activity 80. These 
leukaemia-initiating cells have many markers and properties of normal 
haematopoietic stem cells 81, 82. So it is believed that leukaemia arises from a stem 
cell that becomes transformed and gives rise to a large population of clones that 
proliferate but cannot self-renew or fully differentiate. Similar populations of self 
renewing cells, such as those that carry the chromosomal translocation 
t(9;22)(q34;q11), which forms the BCR–ABL fusion gene, have also been identified in 
patients with chronic lymphocytic leukaemia and chronic myelogenous leukaemia 
(CML) 83. Evidence for the existence of a pluripotent cell in solid tumours includes 
clinical observations with human teratocarcinomas, an experiment of nature in which 
differentiated tissues such as muscle and bone can appear in the tumour mass, and 
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from the observation that mouse teratocarcinoma cells can produce a normal mouse. 
Instead of haematopoietic markers, stem cells identified from solid tumours usually 
express organ-specific markers. In eight of nine human breast cancer samples, for 
example, a tumorigenic stem-cell population was found that expressed the unique cell 
surface marker profile CD44+CD24–/low Lin– 78 This population was enriched 50- to 
100-fold with cells able to form tumours in mice. The resulting tumours possess the 
phenotypic heterogeneity found in the original tumour population, including both 
tumorigenic and non-tumorigenic cells. In another study, overexpression of the WNT 
family of genes, important regulators of normal cell development, led to expansion of 
the mammary-stem-cell pool and cancer susceptibility. Finally, stem cells with a 
capacity to self-renew and undergo pluripotential differentiation have been isolated 
from human central-nervous-system tumours 84, 85. These cells were reported to 
express CD133, a cell surface antigen known originally as a marker of 
haematopoietic stem cells and later observed as a marker of stem cells in other normal 
tissues 79.                              
          
 
 
Figure 5. Normal stem cells give rise to multipotent progenitor cells, committedprogenitors and 
mature, differentiated cells. Mutations in a stem cell give rise to a stem cell with aberrant proliferation 
and result in a pre-malignant lesion. Additional mutations lead to the acquisition of further increased 
proliferation, decreased apoptosis, evasion of the immune system, and further expansion of the stem-
cell compartment that is typical of malignant tumours. 
 
 
The exact origin of pluripotent stem cells in tumours might vary. They could arise 
from the malignant transformation of a normal stem cell that has accumulated 
oncogenic insults over time. Alternatively, the original tumour cell could be a more 
differentiated cell that develops the capacity for continual self-renewal, thus acquiring 
the properties of a stem cell. Distinguishing between these two might be difficult. 
Evidence that cells other than stem cells can acquire the ability to undergo self-
renewal has been recently provided in studies examining the progression of CML 83. 
The chronic phase of the disease occurs when a stem cell acquires the expression of 
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the BCR–ABL fusion protein, leading to increased proliferation of cells within the 
granulocyte–macrophage progenitor pool and their downstream progeny. It is 
hypothesized that progression to blast crisis follows additional genetic or epigenetic 
events that confer progenitor cells with the capacity to self-renew, making them 
indistinguishable from a leukaemic stem cell. Further proof is needed to confirm that 
progression to blast crisis occurs at the level of the progenitor pool, but the proposal 
that the stem-cell compartment is not rigidly defined is attractive and suggests a 
degree of plasticity in cancer. Cancer stem cells (with either inherent or acquired 
capabilities for self-renewal) give rise to cells that lack long-term self-renewal 
capability but retain a finite ability to divide. In normal physiology, this would be 
called ‘differentiation’, as the cell acquires traits specific to its place in the tissue. But 
in cancer, cells lack the ability to undergo differentiation into phenotypically mature 
cells. A limited amount of differentiation often does occur, giving rise to the well-
known histopathological and molecular distinctions between tumours. In fact, the 
further along this pathway the cancer cell travels, the more differentiated and the 
more like its normal counterpart it becomes, accordingly demonstrating a slower 
growth rate. Where the so-called ‘de-differentiated’ tumours fit along this continuum 
is uncertain, but it is possible that self-renewal might be a property that represents a 
higher order of differentiation. Therefore, the cancer stem cell shares many properties 
of the normal stem cell. It is generally accepted that normal stem cells show 
properties that provide for a long lifespan such as relative quiescence, resistance to 
drugs and toxins through the expression of several ATP binding cassette (ABC) 
transporters, an active DNA repair capacity, and a resistance to apoptosis. It follows 
that cancer stem cells might also possess these resistance mechanisms. The paradigm 
that drug resistance originates in the stem-cell phenotype might stimulate new 
strategies for the development of anticancer therapies 79. 
 
 
DRUG TRANSPORTERS IN STEM CELLS 
 
Stem cells have many properties that separate them from mature, differentiated cells. 
In addition to their ability to self-renew and differentiate, they are quiescent, dividing 
infrequently. They also require specific environments comprising other cells, stroma 
and growth factors for their survival. One particularly intriguing property of stem 
cells is that they express high levels of specific ABC drug transporters. For example, 
haematopoietic stem cells express high levels of ABCG2, but the gene is turned off in 
most committed progenitor and mature blood cells 86. The two ABC transporter-
encoding genes that have been studied most extensively in stem cells are ABCB1, 
which encodes P-glycoprotein 57, and ABCG286, 87. Along with ABCC1, they represent 
the three principal multidrug-resistance genes that have been identified in tumour 
cells. These genes, members of the ABC-transporter superfamily, are promiscuous 
transporters of both hydrophobic and hydrophilic compounds 3, 57.These transporters 
also have important roles in normal physiology in the transport of drugs across the 
placenta and the intestine (more accurately, the retention of drugs in the intestinal 
lumen), and are important components of the blood–brain and blood–testis barriers. 
By using the energy of ATP hydrolysis, these transporters actively efflux drugs from 
cells, serving to protect them from cytotoxic agents. Mice deficient in either Abcg2, 
Abcb1 or Abcc1 are viable, fertile and have normal stem-cell compartments. This 
indicates that none of these genes are required for stem-cell growth or maintenance. 
However, these knockout mice are more sensitive to the effects of drugs such as 
vinblastine, ivermectin, topotecan and mitoxantrone, consistent with a role for these 
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ABC transporters in protecting cells from toxins. The drug-transporting property of 
stem cells conferred by these ABC transporters is an important marker in the isolation 
and analysis of haematopoietic stem cells. Most cells accumulate the fluorescent dyes 
Hoechst 33342 and rhodamine 123, but stem cells do not, as these compounds are 
effluxed by ABCG2 and ABCB1, respectively. Because they don’t accumulate these 
fluorescent dyes, stem cells can be sorted by collecting cells that contain only a low 
level of Hoechst 33342 fluorescence 79. These cells are referred to as ‘dull cells’ or 
‘side population’ (SP) cells. The term side population was coined because during 
flow-cytometry analysis, SP cells are visualized as a negatively stained ‘side 
population’ to one side of the majority of cells on a density dot plot. A large fraction 
of haematopoietic stem cells are found in the SP fraction and when isolated from 
mice and transplanted into irradiated mice, small numbers of these SP cells can 
reconstitute the bone marrow, demonstrating that these cells are pluripotent. SP cells 
can be isolated from many tissues including the brain, breast, lung, heart, pancreas, 
testes, skin and liver, and these cells might represent lineage-specific stem cells 
88
.Hoechst-33342 staining of bone marrow from ABCG2-null mice fails to detect SP 
cells. However, the lack of staining for SP cells occurs not because these cells are 
absent, but because the lack of ABCG2 expression allows these cells to accumulate 
Hoechst dye and become fluorescent 79.  
 
 
SP CELLS IN TUMOURS AND CELL LINES 
 
Once it was recognized that stem cells were predominantly found in the SP fraction, it 
became possible to sort and purify stem cells from virtually any population of cells or 
tissue. SP cells were identified in 15 of 23 neuroblastoma samples and in 
neuroblastoma, breast cancer, lung cancer and glioblastoma cell lines 89. Furthermore, 
analysis of several cell lines that had been maintained in culture for long periods of 
time demonstrated a small population of SP cells. In the rat glioma C6 cell line, a 
population of SP cells was separated from a population of non-SP cells. Through the 
use of growth factors, investigators maintained these cells in culture, and showed that 
only the SP cells gave rise to both populations and produced cells with both neuronal 
and glial markers that were tumorigenic in mice 90. This latter study provided strong 
evidence that in this cell line the SP population reflected a population with a capacity 
for self-renewal and limited maturation. However, this isolation approach is imperfect 
as the SP compartment is composed of stem and non-stem cells, and some stem cells 
are not in the SP fraction. For example, non-stem-cell tumour cells often express 
ABCG2 and ABCB1. These genes are highly expressed in drug-resistant cells, and 
histopathological studies have reported increased expression of the ABCB1 
transporter in more differentiated tumours 79. In addition, in a range of cell lines, 
differentiating agents induce expression of ABCB1, inhibit cell growth, and increase 
the expression of markers of maturation 74. Additional limitations exist in using 
cancer cell lines cultured in vitro to study stem-cell biology and drug resistance. 
Although SP cells and cells with stem-cell properties have been reported in cultured 
cell lines, it is difficult to reconcile the hypothesis that only a small fraction of cells in 
culture possess stem-cell characteristics with the rapid doubling time of cells in 
culture. Current paradigms envision a small stem-cell compartment possessing cells 
with the capacity for perpetual self-renewal existing alongside a much larger 
proliferative compartment with cells that have a finite ability to proliferate before 
presumably arresting and/or undergoing apoptosis. These paradigms can explain the 
low cloning efficiency of most cell lines, their inefficiency at colony formation in soft 
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agar, and their limited tumorigenicity. However, none of these models can explain 
how the stem cells remain a constant fraction of the total population, if indeed they 
do. Any proposal will require stem cells to divide slowly, and must recognize that in a 
cell line derived from a solid tumour the number of cells undergoing apoptosis is 
relatively small. One possibility is that there is an interchange of cells between a 
proliferative compartment and the stem-cell pool. That such an interchange might 
occur is not improbable, as the cell line almost certainly originated from a stem cell 
with a proliferative advantage 21.  
 
 
ABC TRANSPORTERS AND NEURAL STEM CELLS 
 
The anatomical location and lineage specificities of NSCs were only established 
when they were finally identified in the subependymal region and in the hippocampal 
dentate gyrus (DG), where they divide to generate progenitors that migrate along the 
rostral migratory stream to differentiate in the olfactory bulb or to integrate into the 
surrounding hippocampal neural circuitry, respectively 91. Similar to HSCs, these 
nestin+ NSCs may be defined operationally as cells that can continuously self-renew 
and have the potential to generate intermediate and mature cells of both glial and 
neural lineages 92. Furthermore, NSCs have also been reported to differentiate into 
hematopoietic cells 93. Tumor-tropic NSCs have also been observed in peripheral 
malignancies apart from those primary brain malignancies. Reactive astrocytosis 
induced by inflammatory cytokines released by microglia in response to a 
pathological process is characterized by an increase in glial fibrillary acidic protein 
(GFAP), showing that GFAP is a marker in the differentiation of NSCs into 
astrocytes. In the brain, the proteins MRP1, MRP4 and MRP5 (ABCC family) were 
clearly localized, by confocal laser scanning microscopy, to the luminal side of brain 
capillary endothelial cells 94. The MRP4 and MRP5 proteins were also detected in 
astrocytes of the subcortical white matter 94 . Notably, MRP5 protein was present in 
pyramidal neurons 94. Another study has revealed that MRP1 and MRP5 are more 
abundant in various brain cells than the other family members though MRP3 and 
MRP4 could also be detected in astrocytes. MRP proteins may thus contribute to the 
resistance of the brain to several cytotoxic and antiviral drugs 91. A recent real-time 
reverse transcription-polymerase chain reaction (RT-PCR) assay has been used to 
investigate the specific expression pattern of the ABC subfamily-A transporters in the 
brain and has shown that neurons express predominantly ABCA1 and ABCA3; 
astrocytes express ABCA1, ABCA2 and ABCA3; microglia express ABCA1 and 
oligodendrocytes express ABCA2 and ABCA3 95. With its expression in liver and 
brain, ABCB1 – the prototype of the B subclass of transporters – and ABCA1 
regulate the high-density lipoprotein levels in the plasma and cholesterol contents of 
several cell types in these organs. Most interestingly, the ABCB1 transporter also 
shows strong expression in neurons of the hippocampus formation, particularly in the 
granule cells of the DG. Volk et al. 96 have demonstrated neuronal upregulation of 
ABCB1 expression in the CA3/CA4 region and hilus of the hippocampus formation 
24 h after inducing a status epilepticus in rat brains. In general, however, ABCB1 is 
predominantly localized in the apical membrane of capillary endothelial cells which 
form the Blood Brain Barrier, and in epithelial cells of the blood-cerebrospinal fluid 
barrier, while other cell types in the brain show little or no expression under normal 
conditions 96. 
The SP phenotype in mouse NSCs was probably due to the expression of ABCB1. 
Recent results show that NSCs from mouse forebrain are contained in a population 
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distinct from the SP 97. Moreover, other research data show that the ABCA2 
transporter is widely expressed in early neural progenitors developed in vitro from ES 
cells 98. ABCA2 expression in the adult mouse and rat brains seems to be region-
dependent because it is limited to the oligodendrocytic lineage – unambiguously 
excluded from astrocytes– and to a subset of cortical GABAergic inter-neurons and 
pyramidal glutamatergic neurons where it could be localized to lysosomal-related 
organelles. ABCA2 has also been suggested to be a marker of neural progenitors as it 
is expressed in the subventricular zone of the lateral ventricle and the DG of the 
hippocampal formation, sites of continual neurogenesis in the adult brain, and in 
nestin+ cells differentiated in vitro from ES cells. It was only very recently that the 
distribution and functional properties of the transporters were studied in human neural 
stem/progenitor cells (hNSPCs). It was found that more than half of the hNSPCs 
within neurospheres expressed nestin, an NSPC marker. Furthermore, all nestin+ cells 
simultaneously expressed ABCB1. Moreover, when the hNSPCs were isolated by 
fluorescence activated cell sorting (FACS) using the ABCB1 antibody, there was an 
increase in nestin+ cells compared to cells separated by control IgG. Taken together, 
these results suggest that this ABC transporter may contribute to neural 
stem/progenitor cell expansion in vitro. Further study revealed that cultured hNSPCs 
expressed functional ABCB1 as well as ABCG2 at the cell surface, and that their 
expression was downregulated during differentiation of hNSPCs, similar to the 
downregulation of ABCG2 in HSCs at the stage of lineage commitment 99, 100. It was 
observed that both ABC transporters were downregulated during hNSPC 
differentiation, together with nestin downregulation and GFAP upregulation. The 
downregulation of nestin and upregulation of GFAP are considered to be indicators of 
stem/progenitor differentiation or maturation, and therefore it was proposed that 
ABCB1 and ABCG2 may be markers of neural stem/progenitor cells, and may have a 
functional role in upholding the undifferentiated status of hNSPCs 99, 100. Consistent 
with this idea, it was found that ABCG2 had a high substrate-stimulated ATP-
hydrolysis activity in these cells, further suggesting that the ABCG2 transporter was 
functionally active in hNSPCs and may play a regulatory role in the maintenance of 
the undifferentiated state, possibly through modulating the uptake of small 
hydrophobic molecules involved in differentiation 100. The biological activities of 
ABCB1 and ABCG2 in stem cells are part of the normal tissue regeneration 
mechanism, probably conferring protection of the small stem cell population from 
cell death and enabling preservation of homeostasis under extreme stress conditions. 
Interestingly, the correlation between nestin and ABCB1 expression in hNSPCs, and 
inhibition of hNSCPs proliferation by an ABCB1 inhibitor (cyclosporine A) at a very 
low dose, suggested that the ABC transporter may contribute to neural stem/ 
progenitor cell expansion 99, 100. While ABCA2 shows higher expression in nestin+ 
mouse neural progenitors, at later developmental stages it undergoes a conspicuous 
downregulation, persisting only in limited subsets of differentiated neurons 98. Based 
on these results and the observations that the ABC transporters are expressed at high 
levels in hNSPCs but are downregulated in differentiated hNSPCs, these genes could 
potentially function as putative NSC markers in a similar way as p21CIP/WAF or 
musashi-1. For instance, while a high expression of ABCB1/ABCG2 reflects 
maintenance of proliferating NSCs in an undifferentiated state, low expression 
characterizes progenitors differentiating into neurons and astrocytes, which by 
themselves do not (or only at a very low level) express ABCB1/ABCG2 at the end of 
differentiation (Fig. 6) 99, 100. The published studies on NSCs support the hypothesis 
that ABCB1 (MDR1) might be more important than ABCG2 in controlling the 
specific phenotype of NSCs 98-100, in contrast to the HSCs where ABCG2 is involved 
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in the SP phenotype and considered as its molecular determinant. In short, ABC 
transporters have emerged as an important new field of investigation in the regulation 
of stem cell biology, and manipulation of this system may promote stem cell 
amplification via a common defence mechanism adopted by these cells through their 
high expression of ABC membrane transporters 91. 
 
 
ABC TRANSPORTERS AND HEMATOPOIETIC STEM CELLS 
 
The developmental programs that regulate gene expression profiles are tightly 
controlled and can lead to cancer if perturbed. An increasing number of genes are 
being characterized that can function as lineage-restricted transcription factors, 
directing hematopoietic cell differentiation. For example, GATA-1 is required for 
erythropoiesis, PU.1 for myelopoiesis, and Ikaros for lymphopoiesis, with crosstalk 
possible between factors modulating differentiation. The differential gene expression 
patterns that direct hematopoietic stem cell (HSC) self-renewal versus differentiation 
are less well characterized, but are of great interest 101. The cells enriched for long-
term repopulating activity have been shown to express the Sca-1 antigen, the c-kit 
receptor tyrosine kinase, but none of a cocktail of differentiation lineage markers . 
Isolation of stem cells based on the efflux of fluorescent dyes has also been an 
efficient method to further purify stem cells, and it has been demonstrated that 
Rhodamine123 (Rho123) retention is low in the most primitive hematopoietic cells. 
While the Rho-low fraction provides long-term reconstitution following injection into 
lethally irradiated mice, the Rho-high fraction provides only short-term repopulation 
102
. Hoechst 33342 is another fluorescent dye used for isolation of stem cell fractions. 
In combination with Rho123 staining, Hoechst low Rho-low cells are highly enriched 
for stem cell activity 101. 
The first identified candidate transporter for the efflux of fluorescent dyes in HSCs 
was MDR1/ ABCB1. The P-gp is highly expressed on CD34+ hematopoietic cells 103, 
suggesting that efflux pump activity could be responsible for the low retention of 
Rho123 in primitive subsets of cells. The CD34 gene codes for a transmembrane cell 
surface phosphoprotein that has been generally accepted as being a stem cell marker 
based on engraftment following bone marrow transplantation into baboons, humans, 
and mice 101. However, in recent years, this has become a point of controversy in the 
field. It was first shown that murine HSCs could be CD34 negative 104. Soon after, 
Goodell et al. demonstrated that a highly enriched stem cell fraction termed side-
population (SP) cells could be isolated following Hoechst 33342 staining 105. 
Human SP cells expressed low to undetectable levels of CD34, and the CD34– 38– 
cells could acquire CD34 during culture 101. ABC transporter activity is involved in 
the differential Hoechst staining, since the SP tail could be eliminated by treatment 
with verapamil a known inhibitor of P-gp function. Interestingly, other studies have 
also demonstrated that both mouse and human CD34+ cells can be derived from 
CD34– cells. Transplantation studies in fetal sheep 106 also showed repopulating 
activity in the CD34– population. The concept evolved that CD34 expression may be 
up-or down modulated and that HSCs may therefore be CD34+ or CD34–. Isolation 
of murine bone marrow with the cell surface marker phenotype of Sca1+/c-kit+/lin– 
(KLS) can be used to enrich for SP cells, thus showing significant overlap between 
the two populations. 
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Figure 6. Schematic illustration of the effect of ABC transporters on stem cell proliferation and 
differentiation. (1) Expression of ABC transporters (especially ABCB1 and ABCG2) in stem cells like 
the NSCs, HSCs or pancreatic stem cells is thought to be essential for their in vivo proliferation and 
probably their self-renewal activity. (2) Enforced expression of ABCB1 or ABCG2 leads to enhanced 
proliferation in HSCs. (3) Downregulation of ABCB1 or ABCG2 in HSCs is observed with the 
differentiation of HSCs. (4) Downregulation of the ABC transporters in NSCs is observed with the 
differentiation into astrocytes or neurons. (5) The hypothesis suggests that expression of the ABC 
transporters in NSCs may have an effect on NSC differentiation or proliferation, such that significant 
upregulation of ABCB1 or ABCG2 expression may lead to an increase in self-renewal of NSCs, and 
correspondingly, a decrease in ABCB1 or ABCG2 expression may lead to increased differentiation of 
NSCs. 
 
 
A common factor in all of these studies with Hoechst SP/CD34low/+ cells or KLS 
cells is that primitive hematopoietic cell populations capable of repopulating hosts 
express ABC transporter activity. It has now become clear that two specific 
transporters with unique substrate specificity are differentially expressed in this SP 
fraction during early hematopoietic differentiation. The phenotypes of knockout mice 
lacking expression of the two murine mdr1a and mdr1b homologs to the human 
MDR1 have been relatively mild, with each strain of mice showing normal health and 
viability 107, 108. mdr1a and mdr1b knockout mice did show altered pharmacokinetics 
for a number of anticancer agents and hypersensitivity to the pesticide ivermectin. No 
significant hematologic defects were observed. However, numerous other ABC 
transporters have been identified in recent years that could serve compensatory 
endogenous functions. A growing family of MDR-associated proteins, as well as the 
half-transporters have also been described. A normal percentage of SP cells was 
recently described in the bone marrow from mdr1a-1b–/– mice, suggesting the 
presence of another transporter that has been previously uncharacterized regarding 
expression in primitive hematopoietic cells 88. Further, inhibition of SP cell staining 
with either 2-deoxyglucose, a general inhibitor of ATP synthesis, or with verapamil 
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in the mdr1a-1b–/– background indicated that this activity was due to expression of 
an ABC transporter. This was not an entirely new concept, since P-gp expression 
studies in multidrug resistant myeloid leukaemia cells from patients showed 
dissociation of P-gp expression and dye efflux  60. These initial studies strongly 
suggested that alternative transporters may be active in hematopoietic cells. The 
breast cancer resistance protein (BCRP), also called ABCG2 [30], was subsequently 
identified and characterized as a novel stem cell transporter 109. ABCG2 has been 
most studied within hematopoietic cell populations. ABCG2 is the transporter 
responsible for the Hoechst 33342 dye efflux pattern in cells within the side 
population (SP) region and this population does not express MRP1-4, although 
MDR1a is expressed. Microarray analyses of cDNA from murine hematopoietic cell 
populations have identified ABCG2 expression only within the most primitive 
subpopulations (C-Kit positive/Thy1 low/Sca1 positive/lineage negative ) 110. No 
other ABC transporter expression was identified within this fraction, consistent with 
the hypothesis that although there is considerable overlap of ABC transporter 
expression in various cell populations, ABCG2 is relatively restricted to more 
primitive cells. Human stem cell products, including bone marrow, peripheral blood 
progenitor cells, and umbilical cord blood have also been evaluated for ABCG2 
expression. In human bone marrow, ABCG2 mRNA expression was highest within 
the CD34+/CD38-/lineage negative/KDR+ population and also the SP+ population 86. 
Umbilical cord blood and cytokine-mobilized peripheral blood progenitor cells also 
contain measurable ABCG2-positive populations, which are co-enriched with 
immunomagnetic selection for CD133+ and CD34+ 110. It is currently unknown 
whether the recently described human CD133+/CD34- HSC expresses ABCG2. In 
addition to expressing ABCG2, the CD34+/lineage negative/SP+ hematopoietic cell 
population expresses aldehyde dehydrogenase which has been shown to protect 
hematopoietic stem cells from the active metabolites of cyclophosphamide. This 
suggests that primitive cell populations possess several different mechanisms for 
protection against environmental toxins, a feature that would necessarily complicate 
anticancer therapy, since cancerous cells typically arise from primitive cell 
populations and could take advantage of these protective mechanisms. Additional 
evidence suggests that ABCG2 may be expressed in a lymphoid progenitor cell 
population in cord blood. The lack of P-gp expression in a Hoescht-effluxing cell 
with a primitive immunophenotype is highly suggestive of ABCG2 expression, 
although this was not directly tested. ABCG2 expression has also been reported in 
early erythroid and natural killer cell populations, in both mice and humans 86, 88. 
Little is known about the significance of ABCG2 expression or dye efflux in these 
populations. The recent finding that protoporphyrin XI is an ABCG2 substrate 
suggests a possible physiologic role in early erythroid cell populations. Measurement 
of ABCG2 mRNA expression by real-time RT-PCR has been studied as a potential 
tool for quantifying primitive HSC. One preliminary study showed a higher level of 
ABCG2 mRNA expression in cord blood mononuclear cells compared to bone 
marrow and peripheral blood, and also a correlation of ABCG2 mRNA levels with 
CD34+ and CD133+ cell frequency in mobilized PBSC 110. Therefore, one 
interpretation is that BCRP expression may define primitive quiescent HSCs whereas 
MDR1 may be expressed in more “activated” repopulating HSC. 
 
                                         
DRUG RESISTANCE IN CANCER STEM CELLS 
 
Cancer cells can acquire resistance to chemotherapy by a range of mechanisms, 
including the mutation or overexpression of the drug target, inactivation of the drug, 
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or elimination of the drug from the cell. Typically, tumours that recur after an initial 
response to chemotherapy are resistant to multiple drugs (they are multidrug 
resistant). In the conventional view of drug resistance, one or several cells in the 
tumour population acquire genetic changes that confer drug resistance (Fig. 7a). 
These cells have a selective advantage that allows them to overtake the population of 
tumour cells following cancer chemotherapy. Based on the tumour stem-cell concept, 
an alternative model posits that the cancer stem cells are naturally resistant to 
chemotherapy through their quiescence, their capacity for DNA repair, and ABC-
transporter expression (Fig. 7b).As a result, at least some of the tumour stem cells can 
survive chemotherapy and support regrowth of the tumour. In a third model of 
acquired resistance, drug-resistant variants of the tumour stem cell or its close 
descendants arise, producing a population of multidrug-resistant tumour cells that can 
be found in many patients who have recurrence of their cancer following 
chemotherapy (Fig. 7c).  
                                    
 
Figure 7. a) In the conventional model of tumour-cell drug resistance, rare cells with genetic 
alterations that confer multidrug resistance (MDR) form a drug resistant clone (yellow). Following 
chemotherapy, these cells survive and proliferate, forming a recurrent tumour that is composed of 
offspring of the drug-resistant clone. b) In the cancer-stemcell model, drug resistance can be mediated 
by stem cells. In this model, tumours contain a small population of tumour stem cells (red) and their 
differentiated offspring, which are committed to a particular lineage (blue). Following chemotherapy, 
the committed cells are killed, but the stem cells, which express drug transporters, survive. These cells 
repopulate the tumour, resulting in a heterogeneous tumour composed of stem cells and committed but 
variably differentiated offspring. c) In the ‘acquired resistance’ stem-cell model, the tumour stem cells 
(red), which express drug transporters, survive the therapy, whereas the committed but variably 
differentiated cells are killed. Mutation(s) in the surviving tumour stem cells (yellow) and their 
descendants (purple) can arise (by mechanisms such as point mutations, gene activation or gene 
amplification), conferring a drug-resistant phenotype. As in model a, the stem cell with the aquired 
mutations could be present in the population before therapy. d) In the ‘intrinsic resistance’ model, both 
the stem cells (yellow) and the variably differentiated cells (purple) are inherently drug resistant, so 
therapies have little or no effect, resulting in tumour growth.  
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The same mechanisms that allow stem cells to accumulate mutations over time, 
producing the long term consequences of exposure to irradiation or carcinogens, 
would then allow cancer stem cells to accumulate mutations that confer drug 
resistance to their abnormally developing offspring. As an example, genetic 
alterations such as those that upregulate ABCB1 expression in human leukaemia and 
lymphoma cells could have originated in the stem cell 111. In a final ‘intrinsic 
resistance’ model, both the stem cells and the variably differentiated cells are 
inherently drug resistant, so therapies have little or no effect, resulting in tumour 
growth (Fig. 7d). 
An example of the latter is an intrinsically resistant cancer such as renal-cell cancer, 
in which ABCB1 is expressed in all cells and contributes to chemotherapy tolerance. 
In this case, the resistance phenotype of the cancer stem cell persists in the 
committed, abnormally developing progenitors that comprise the proliferative pool of 
cancer cells. So in the cancer-stem-cell model of drug resistance, tumours have a 
built-in population of drug-resistant pluripotent cells that can survive chemotherapy 
and re-grow. Again, a parallel with normal stem cells can be found in stem-cell-
driven recovery of normal tissues following chemotherapy. The rapid relapse 
observed with some tumours, at times within one cycle of chemotherapy, has a 
normal-tissue parallel in the repopulation of the bone marrow by normal 
haematopoietic stem cells and the recovery of the mucosa of the gastrointestinal tract, 
both of which usually occur within one 3-week cycle. Similarly, tumour recurrences 
that occur months to years after an original response to chemotherapy can be 
modelled on the slower recovery that is observed with hair follicles. 
Although it is therapeutically attractive, the hypothesis that the intrinsic properties of 
stem cells alone provide the basis for drug resistance might be too simplistic. Recent 
studies of imatinib (Gleevec) resistance in patients with leukaemia provide an 
example of how ABC-transporter-mediated efflux in stem cells could facilitate, but 
not be solely responsible for, the acquisition of acquired mechanisms of drug 
resistance. Imatinib has been recently shown to be both a substrate and inhibitor of 
ABCG2, making it susceptible to efflux by a stem cell that expresses this ABC 
transporter 112-114. The initial studies that reported imatinib-resistant leukaemia cells 
described ‘acquired’ mutations in the kinase domain of ABL in patients with CML or 
with acute lymphoblastic leukaemia associated with t (9;22)(q34;q11). These findings 
indicate that although the expression of drug transporters by the cancer stem cell 
might provide some level of drug resistance, an acquired mutation in ABL could 
confer higher levels of drug resistance. Although these mutations might have arisen 
during therapy, their existence before the administration of imatinib has not been 
excluded. Indeed, pre-existing mutations that confer resistance to imatinib have also 
been described in a subset of patients. These findings are reminiscent of the Goldie–
Coldman hypothesis, proposed more than 20 years ago, that a small percentage of 
cells in a population harbouring intrinsic mutations confer drug resistance 115. The 
Goldie–Coldman hypothesis would theorize that the cell acquiring the mutation is the 
stem cell. Although the expression of ABC transporters could render stem cells 
resistant to drugs, it is not the sole determinant of resistance, as the DNA-repair 
capacity of the cell and the reluctance to enter apoptosis could be equally or more 
important. Generally regarded as quiescent and non-dividing, stem cells would be 
expected to be inherently refractory to drugs that target either the cell cycle or rapidly 
dividing cells. To the extent that quiescence is an important mechanism of drug 
resistance in stem cells, agents will have to be developed that are effective in non-
dividing cells. For example, studies with imatinib have shown that blocking BCR–
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ABL-positive cells at the G1/S boundary in vitro had no significant impact on the 
ability of imatinib to induce apoptosis, indicating that imatinib is effective in non-
dividing cells 21. 
 
 
 
MECHANISMS AND STRATEGIES TO OVERCOME 
MULTIPLE DRUG RESISTANCE IN CANCER 
 
By inhibiting the main transporters of chemotherapy drugs, it was thought that drug 
resistance could be avoided and tumour cells eliminated. Therefore, much effort has 
been devoted to the development of inhibitors of ABC transporters. There are many 
studies to overcome MDR by inhibiting MDR transporters, to suppress or circumvent 
MDR mechanisms. The use of anticancer drugs that could escape from the ABC 
transporters might be a solution to avoid drug resistance. Anticancer drugs which are 
not the substrates of ABC transporters are alkylating drugs (cyclophosphamide), 
antimetabolites (5-fluorouracil), and the anthracycline modified drugs (annamycin 
and doxorubicin-peptide). Another method to overcome resistance to anticancer drugs 
is to administer compounds that would not be toxic themselves, but would inhibit 
ABC transporters. The compounds that would reverse resistance against anticancer 
drugs are called MDR inhibitors, MDR modulators, MDR reversal agents or 
chemosensitizers. They may modulate more than one transporter. Clinical trials 
helped to unravel the problems associated with combination chemotherapy of 
anticancer drug(s) together with an MDR inhibitor. The first factor to be determined 
before embarking a clinical trial is to identify the ABC transporter protein involved in 
drug resistance and to utilize an anticancer drug that would benefit from inhibition of 
that transporter protein. The anticancer drug(s) utilized should match the transporter 
protein being inhibited. The second factor is to monitor the plasma concentrations and 
in vivo effectiveness of the tested MDR inhibitor in order to verify that an effective 
inhibitory concentration was in fact achieved in vivo. The pharmacokinetic 
interaction between the anticancer drug(s) and the MDR inhibitor must be searched 
and avoided to prevent a reduction in anticancer drug dosage 116. 
 
 
FIRST-GENERATION MDR MODULATORS 
 
Inhibiting P-gp and other ABC transporters has been extensively studied for more 
than two decades. Many agents of diverse structure and function that modulate MDR 
have been identified, including calcium channel blockers (e.g., verapamil), 
calmodulin antagonists, steroidal agents, protein kinase C inhibitors, 
immunosuppressive drugs (e.g., cyclosporine A), antibiotics (e.g., erythromycin), 
antimalarials (e.g., quinine), psychotropic phenothiazines and indole alkaloids (e.g., 
fluphenazine and reserpine), steroid hormones and anti-steroids (e.g., progesterone 
and tamoxifen), detergents (e.g., cremophorEL) and surfactants. First-generation 
MDR drugs had other pharmacological activities and were not specifically developed 
for inhibiting MDR. Their affinity was low for ABC transporters and necessitated the 
use of high doses, resulting in unacceptable high toxicity which limited their 
application. Clinical trials with first-generation MDR drugs failed for various reasons, 
often due to side effects. Many of the first-generation chemosensitizers were 
themselves substrates for ABC transporters and competed with the cytotoxic drugs 
for efflux by the MDR pumps. Therefore, high serum concentrations of the 
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chemosensitizers were needed to produce sufficient intracellular concentrations . 
These limitations prompted the development of new chemosensitizers that are more 
potent, less toxic and selective for the P-gp and other ABC transporters 116. 
 
 
SECOND-GENERATION MDR MODULATORS 
 
Second-generation chemosensitizers were designed to reduce the side effects of the 
first generation drugs. Second-generation MDR modulators have a better 
pharmacologic profile than the first generation compounds, still they retain some 
characteristics that limit their clinical usefulness. Co-administration of an MDR 
modulator usually elevate plasma concentrations of an anticancer drug by interfering 
its clearance or inhibiting its metabolism and excretion, thus leading to unacceptable 
toxicity that necessitates chemotherapy dose reductions in clinical trials down to 
pharmacologically ineffective levels. The affinity of second-generation MDR drugs 
towards ABC transporters was too low to produce significant inhibition of MDR in 
vivo at tolerable doses. Many of the anticancer drugs are substrates both for ABC 
transporter proteins and for the cytochrome P450 isoenzyme 3A4. Most of the 
second-generation MDR chemosensitizers are also substrates for cytochrome P450 
3A4 and metabolized by this enzyme. The competition between anticancer agents and 
MDR modulators for cytochrome P450 3A4 activity may result in unpredictable 
pharmacokinetic interactions. Co-administration of a MDR drug may significantly 
elevate plasma concentrations of an anticancer drug by interfering with its clearance 
(e.g., via biliary elimination) or metabolism (e.g., via the cytochrome P450 system). 
This would increase the concentration of an anticancer drug leading to unacceptable 
side effects, necessitating dose reductions down to pharmacologically ineffective 
levels. However since the pharmacokinetic interactions between chemosensitizers and 
cytotoxic agents are unpredictable, reducing the dose of a cytotoxic agent may result 
in under- or over-dosing in patients. The unpredictable effects of second-generation 
MDR modulators on cytochrome P450 3A4-mediated drug metabolism limits the use 
of these second-generation modulators in the treatment of multidrug resistance. ABC 
transporters have well defined physiologic roles, often involving the elimination of 
xenobiotics, in regulating the permeability of the central nervous system (blood–brain 
barrier), the testes, and the placenta, thus preventing these systems from being 
exposed to cytotoxic agents circulating in the blood. Most of the second-generation 
MDR chemosensitizers are substrates for ABC transporter family. Inhibition of these 
transporters could lessen the ability of normal cells and tissues to protect themselves 
from cytotoxic agents. Inhibition of non target transporters may enhance adverse 
effects of anticancer drugs. Side effects due to modulation of MDR protein in normal 
tissues, especially blood–brain barrier should be monitored carefully to avoid 
neurological responses. Because of these problems, MDR inhibitors have not 
improved the therapeutic efficiency of anticancer drugs unless such agents lack 
significant pharmacokinetic interactions 116. 
 
 
THIRD-GENERATION MDR MODULATORS 
 
Third-generation molecules have been developed to overcome the limitations of the 
second generation MDR modulators. They are not metabolized by cytochrome P450 
3A4 and they do not alter the plasma pharmacokinetics of anticancer drugs. Third-
generation agents specifically and potently inhibit P-gp and do not inhibit other ABC 
transporters. None of the third-generation agents tested so far have caused clinically 
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relevant alterations in the pharmacokinetics of the co-administered anticancer drugs. 
Because of their specificity for P-gp transporters and lack of interaction with 
cytochrome P450 3A4, third-generation P-gp inhibitors offer significant 
improvements in chemotherapy without a need for chemotherapy dose reductions. 
Several such compounds are currently undergoing clinical trials in several cancer 
types. Schering AG has developed a quinolone derivative MDR modulator (MS-209). 
It is used in combination with the anticancer drug (doxetaxel) in advanced solid 
(breast and lung cancer) tumors. One of the most promising third-generation P-gp 
inhibitors is an anthranilamide derivative tariquidar (XR9576) which is developed by 
NCI/Xenova/QLT Company. In phase I and II studies with paclitaxel and vinorelbine 
in ovarian cancer, tariquidar gave successful results and phase III trials have been 
initiated with tariquidar in patients with non-small cell lung cancer. It binds 
specifically and non-competitively to the P-gp pump with a high affinity and potently 
inhibits the activity of the P-gp transporter. Tariquidar inhibits the ATPase activity of 
P-gp. Tariquidar is more potent and its inhibitory action on the P-gp transporter pump 
lasts longer in comparision to the effects of first- and second- generation P-gp 
modulators. In none of the clinical trials, tariquidar caused alterations in the 
pharmacokinetics of the coadministered cytotoxic agents such as paclitaxel, 
vinorelbine, or doxorubicin in patients with solid tumors. This allows the use of 
standard doses of these chemotherapeutic agents without the need for dose reduction. 
However, clinical trials with new third-generation agents are ongoing with the aim for 
a longer survival in cancer patients. This effort continues, but none of them has found 
a general clinical use so far 116. 
 
 
NOVEL APPROACHES TO STRUGGLE WITH MDR MECHANISMS 
 
The difficulties encountered with MDR inhibitors have led several alternative 
approaches to MDR therapy. These approaches can be divided in two groups. One 
group of studies consists of trials designed to inhibit MDR mechanisms in novel ways 
and the other group focuses on trials to circumvent MDR mechanisms. There are 
several approaches to inhibit mechanisms involved in regulation of MDR 
transporters. MDR protein gene expression in tumor cells is induced upon treatment 
with cytotoxic drugs, whereas this gene expression is inhibited by several 
pharmacological inhibitors that affect the signaling pathways. It was demonstrated 
that taxol stimulated MDR1 and cytochrome P450 3A4 (CYP3A4) gene expression 
via its direct interaction with and activation of the nuclear steroid and xenobiotic 
receptor (SXR) which led to increased drug resistance and faster drug clearance . 
Hence, antagonists of the nuclear steroid and xenobiotic receptor may be utilized in 
conjunction with anticancer drugs to cope with the induction of MDR1 and CYP3A4 
117
. Recent advances in antisense oligonucleotide technologies suggest an alternative 
and more specific way to cope with MDR than the use conventional MDR inhibitors 
118
. Downregulation of ABC transporter proteins and enzymes involved in cancer cell 
resistance using antisense oligonucleotides may provide an efficient approach to 
overcome MDR. 
Recent studies clarified the role of ceramide as a second messenger in cellular 
apoptotic signaling events. A decrease in ceramide production increases cellular 
resistance to apoptosis. It was demonstrated that glucosylceramide (GC), a simple 
glycosylated form of ceramide which results from elevated GlcCer synthase activity 
accumulates in multidrug resistant cancer cells and tumors derived from patients who 
are less responsive to chemotherapy 119, 120. Overexpression of recombinant Glc-Cer 
synthase (GCS) confers resistance to adriamycin and to ceramide in GlcCer synthase-
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transfected human breast cancer cells, suggesting that drug resistance is related to 
stimulation of glucosylation of ceramide and the resultant inhibition of drug induced 
apoptotic signaling 121. Blocking the glycosylation of ceramide has been shown to 
increase cancer cell sensitivity to cytotoxics 122-124. Drug combinations that enhance 
ceramide generation and limit glycosylation have been shown to enhance 
effectiveness of chemotherapy by inducing apoptosis in cancer cell models 123, 124. 
The role of GlcCer synthase in drug resistance was demonstrated directly by 
antisense suppression of GlcCer synthase expression in MDR cells 125. 
Downregulation of ceramide glycosylation using GCS antisense in adriamycin-
resistant breast cancer cells restored cell sensitivity to adriamycin 125. In another 
study, a novel amino-ceramide analog was shown to inhibit GlcCer synthase and 
thereby elevate ceramide production in MDR cells, enhancing drug-induced apoptosis 
117
. These findings assign biological significance to ceramide metabolism and 
provides a promising approach to struggle with drug resistance. These results indicate 
that GlcCer synthase contributes to drug resistance in MDR cells by attenuating drug-
induced formation of apoptotic ceramide and suggest that GlcCer synthase may 
represent a novel drug target in cancer MDR.  
Living cells needs MDR mechanisms for their normal physiology. Therefore, 
researchers prefer to circumvent rather than directly inhibit MDR mechanisms. 
Developing anticancer drugs that are poor substrates for ABC transporters might be a 
good strategy in cancer therapy. Another approach is to prevent formation of new 
blood vessels which is called angiogenesis. For a long time, it is believed that tumors 
induce angiogenesis to provide an adequate blood supply for oxygen and nutrients. 
New vessel formation are inhibited using anti-angiogenic factors. However, most of 
the anti-angiogenic factors have other effects on the cells which limit their treatment. 
A major dose-limiting toxicity factor for anticancer drugs is to avoid complete 
eradication of bone marrow stem cells. Gottesman et al. produced multidrug resistant 
bone marrow cells by transfecting them with vectors carrying the MDR1 cDNA. This 
procedure allowed them to apply a chemotherapeutic regimen at otherwise 
unacceptable doses, and thus overcoming MDR 57, 117. 
Recent studies suggest that a mutant ABCG2 protein is an ideal candidate for human 
stem cell protection and for use as a selectable marker in gene therapy. The cDNA 
encoding this protein is relatively small (about 2 kb) and the active dimer is 
spontaneously formed in the overexpressing cells. Since the R482G variant of 
ABCG2 has different substrate specificity than the wild-type protein, this mutant has 
a special advantage in gene therapy applications 126.  
The exact mechanism of MRP1 involved multidrug resistance has not been clarified 
yet, though glutathione (GSH) is likely to have a role for the resistance to occur. N-
acetylcysteine (NAC) is a pro-glutathione drug. DL-Buthionine (S,R)-sulfoximine 
(BSO) is an inhibitor of GSH synthesis. Recently, it has been investigated the effect 
of NAC and BSO on MRP1-mediated vincristine and doxorubicine resistance in 
human embryonic kidney (HEK293) and its MRP1 transfected 293MRP cells. Human 
embryonic kidney (HEK293) cells were transfected with a plasmid encoding whole 
MRP1 gene. Both cells were incubated with vincristine and doxorubicine in the 
presence or absence of NAC and/or BSO. N-acetylcysteine increased the resistance of 
both cells against vincristine and doxorubicine. In contrast, BSO decreased NAC-
enhanced MRP1-mediated resistance, indicating that induction of MRP1-mediated 
resistance depends on GSH. The  results indicate that NAC and BSO have opposite 
effects in MRP1 mediated vincristine and doxorubicine resistance and BSO seems a 
promising chemotherapy improving agent in MRP1 overexpressing tumor cells. 
underlying the potential anticancer action of plant flavonoids await further 
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elucidation. Further in vivo studies of these bioactive constituents is necessary in 
order to develop flavonoid-based anticancer strategies. These studies demonstrate that 
antioxidants may have diverse effects in the cytotoxicity of chemotherapeutic drugs 
depending on their other pharmacological properties which may predominate their 
antioxidant effects 116. 
 
 
 
TRANSCRIPTIONAL REGULATION OF ABC DRUG 
TRANSPORTERS 
 
Herculean efforts over the past decade in the area of transcriptional regulation have 
shown that the fate of a gene is determined by the complexity and accessibility of a 
myriad of response elements within the promoter, as well as by the complement of 
transcription factors available to interact with these elements 76. The composition of 
these factors is influenced by both the intra- and extracellular milieu, which can vary 
tremendously during the life of the cell. Thus, dynamic multiprotein complexes form, 
the nature of which is grossly dictated by promoter architecture yet subtly influenced 
by different signals, leading to profound regulatory switches. Superimposed upon this 
regulation is a dynamic chromatin ultrastructure, controlled by cofactors that 
transduce signals from promoter-bound proteins to the basal transcriptional 
machinery. Thus, it appears that each subset of genes is regulated by specialized 
multiprotein complexes that include both common basic components (the basal or 
general transcription factors), as well as unique components that tailor a complex for 
the transduction of signals initiated by particular developmental, metabolic or 
environmental stimuli.  
 
 
CONSTITUTIVE (UNINDUCED) TRANSCRIPTION OF THE ABC 
TRANSPORTERS  
 
Almost half of all genes transcribed by RNA polymerase II (Pol II) contain a TATA 
box. In promoters that contain this element, a first event is the recognition and 
binding of the TATA box by a general transcription factor, TBP. Through a series of 
protein–protein interactions, Pol II is recruited to the TATA element and initiates 
transcription 25–30 nucleotides downstream. How transcription is nucleated in 
promoters that lack the TATA box (TATA less promoters) is less clear, although 
many contain an initiator (Inr) element that encompasses the transcription initiation 
site and conforms to the consensus sequence PY-PY-A(+1)-N-T/A-Py-Py 127. 
Although both the TATA box and the initiator element seem to serve similar 
functions with respect to recruitment of the transcription complex, some selectivity in 
protein requirements suggests a fundamental difference in the way these two classes 
of promoters are regulated. Interestingly, all of the human drug-related transporters 
examined to date lack an appropriately positioned TATA box (the human MRP2 
promoter was reported to contain a TATA-like element, but its location over 400 bp 
upstream of the transcription start site makes it functionally irrelevant), while several 
of their rodent homologues are TATA-dependent 76. Transcription of MDR1 is 
regulated instead by an Inr element, first identified through in vitro studies indicating 
that deletion of sequences downstream of +5 decreased elongation of correctly 
initiated transcripts to undetectable levels 128. Transient transfection studies then 
defined the sequences between -6 and +11 as sufficient for proper initiation of 
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transcription in vivo 129, 130. Although Inr’s have not yet been functionally described in 
promoters of other drug transporters, examination of the published sequences identify 
consensus or near consensus Inr’s within the promoters of the MRP2 (GTACTTT) 
and BCRP (CCACTGC) genes 76. 
 
 
GC BOXES AND CCAAT ELEMENTS 
 
‘GC’ elements and ‘CCAAT’ boxes are among the most ubiquitous Pol II promoter 
elements and are found in the majority of TATA less promoters. Each element can 
interact with different families of proteins through sequence-specific DNA 
recognition. Since mutation or removal of these elements often leads to a complete 
loss of transcription, the proteins that interact with these elements were initially 
referred to as constitutive or ‘basal’ transcription factors. However, this label can be 
misleading, since more recent studies have shown that these factors are often essential 
for mediating activation by exogenous agents, particularly those that regulate 
chromatin structure.  Like most ‘TATA less’ genes, the MDR1 promoter includes 
both an inverted CCAAT box (-79 to -75), that interacts with the trimeric 
transcription factor NF-Y 131 and a GC rich element (-56 to -43) that interacts with 
members of the Sp family of transcription factors, specifically Sp1 and Sp3 132, 133. 
Transfection analysis of promoter constructs mutated in one or both of these elements 
indicate the requirement for each element in the constitutive (i.e. operative under 
normal growth conditions) expression of MDR1 in some cell lines. Interestingly, early 
studies suggested that the YB-1 protein, a gene regulatory protein that preferentially 
interacts with RNA and single stranded DNA, specifically interacts with the MDR1 
inverted CCAAT box to mediate transcription 76. However, YB-1 does not interact 
with double stranded oligonucleotides containing the MDR1 CCAAT box; indeed, it 
interacts only with a single stranded oligonucleotide containing this element. 
Moreover, mutations within the MDR1 CCAAT box that abolish transcription and 
NF-Y binding have no effect on the interaction of YB-1 with the single-stranded 
oligonucleotide 131, strongly suggesting that NF-Y, not YB-1, is the factor regulating 
MDR1 through the CCAAT element. Nevertheless, although a direct involvement of 
YB-1 in MDR1 transcription appears unlikely, a number of studies have linked the 
expression or nuclear localization of YB-1 with an increase in MDR1 134, 135 as well as 
MRP1 expression 136. Whether YB-1 is activated in parallel with drug transporters as 
part of a global stress response or whether there is a direct non transcriptional role of 
YB-1 in their regulation remains to be determined. Upstream within the MDR1 
promoter (-110 to -103) lies an other GC element that is incapable of interacting with 
Sp1 133, but may interact with another member of the Sp family or the highly related 
Kruppel factor family of transcription factors 137. Immediately downstream and 
overlapping this GC-rich region is an inverted MED-1 element (-105 to -100) 
(multiple start site element downstream 1; iMED) that was first described in the 
hamster MDR1 orthologue, pgp1, and shown to be involved in the activation of that 
gene in drug-resistant cells 138-140. Functional disruption of iMED, either through 
mutation of the element or the use of a transcriptional decoy to sequester iMED-
binding proteins, results in a decrease in MDR1 transcription, although a role for this 
element in resistance-specific activation of the human homologue has yet to be 
established. GC elements are also important for constitutive expression of a number 
of other drug transporters. GC elements within the MRP1 promoter (-91 to +103) are 
essential for optimal activity, and Sp1 has been shown to interact with these elements 
141
. The MRP3 proximal promoter contains several GC elements (-86 to -21) that 
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have been shown to interact with Sp1; removal of this region decreases MRP3 
transcription 142. The BCRP promoter is TATA less and contains several putative Sp1 
binding sites; sequences 300 bp upstream of the transcription start site are sufficient 
to confer basal promoter activity (143. Two functional GC boxes have been identified 
in the ABCA2 gene; these elements interact with Sp1, Sp3 and the brain-specific Sp4 
family member 144. Interestingly, the proximal promoter of MRP2, although TATA 
less, appears to lack a proximal promoter GC element; a consensus Sp1 site has been 
identified at position –1709, but has not yet been functionally tested. MRP2 does 
contain a putative CCAAT box that apparently interacts with YB-1 rather than NF-Y 
in vitro but this element is not required for constitutive transcription 145. 
 
 
TUMOUR SUPPRESSORS,ONCOGENES AND MDR1 TRANSCRIPTION 
 
High levels of expression of multidrug transporters are often observed in drug-naıve 
tumours, even when the tissue of origin exhibits little or no expression of the 
corresponding gene. Hence, constitutive MDR1 or MRP gene expression is likely 
regulated in some cells by components that are involved in malignant transformation. 
It has been well established that tumours develop as a result of both uncontrolled 
proliferation and an intrinsic ability to escape cell death, mediated by the altered 
expression of various oncogenes and tumour suppressor proteins. Recently, it has 
become apparent that altered expression of several growth and death controlling 
proteins can adversely affect drug therapy in two ways: (1) by altering the cell’s 
ability to respond to death signals and (2) by influencing the transcription and thus 
the expression of drug-resistant genes. 
 
 
p53 
 
The first evidence that a tumor suppressor protein could influence the expression of a 
drug-resistant gene came from the observation that wild-type p53 repressed 
transcription of the MDR1 gene 146, 147. Although a number of mechanisms had been 
proposed for this repression, this repression is mediated by a direct interaction of p53 
with a novel binding element within the proximal MDR1 promoter (-72 to -40) (Fig. 
8) 148, making MDR1 the prototype for a new class of p53-repressed promoters. 
Binding of p53 to this element, termed the HT (head-to-tail) site, appears to induce a 
novel tetrameric conformation of p53 that converts p53 from an activator to a 
repressor, perhaps through the differential recruitment of cofactors 76. Repression by 
wild-type p53 has also been reported for the mouse and hamster MDR1 homologues, 
while other studies suggest an activating role of p53 on the murine mdr1 promoter in 
response to DNA damage and stress 76. Wild-type p53 has also been shown to repress 
transcription of the human MRP1 promoter 149, 150 and loss of p53 expression is 
correlated with increased MRP1 expression in colorectal cancer 76. Although the 
mechanism mediating the repression of MRP1 has not yet been defined, there is some 
indication that it may involve deactivation of promoter-bound Sp1 149. 
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Fugure 8. Schematic of the consensus head-to-head (HH) p53-binding site shown to mediate 
activation of target genes by p53 (top) and the non consensus head-to-tail (HT) site found within the 
MDR1 promoter and shown to bind p53 and mediate the repression of MDR1 transcription. 
 
 
Paradoxically, several common mutant p53 proteins are able to activate, rather than 
repress, the MDR1 promoter 146; at least one of these mutants activates MDR1 
through a cooperative, and apparently mutant-specific, interaction with the Ets-1 
transcription factor at a binding site within the proximal promoter region (-69 to -63) 
151
. This type of direct effect has not been observed with the MRP1 promoter, 
although it is reasonable to consider that mutations of p53 that inhibit its ability to 
repress MRP1 transcription could be viewed as indirect ‘activators’. The role of p53 
in the regulation of drug resistance genes is not without controversy. Indeed, there are 
a few cases where opposing effects were observed in different cells or under different 
conditions. Therefore, the complexity of these systems should not be underestimated, 
and it is important to keep in mind that the intricate architecture of the individual 
promoters, the complement of endogenous p53 (mutant or wild type), the presence or 
absence of other p53 family members, as well as variations in cell- and tissue-specific 
co-effectors of p53 activity are all likely to influence the ultimate transcriptional 
readout in a given cell, tissue or tumor type. 
 
 
Fos/Jun (AP-1) 
 
There is some evidence, albeit indirect, that the AP-1 complex may be involved in the 
transcription of several drug transporters. AP-1 is the general term for transcription 
factor complexes composed of members of the Fos and Jun oncogene families 152. 
AP-1 is constitutively expressed in many cell types, and DNA binding by the 
complex is induced by serum stimulation, phorbol esters and a variety of growth 
factors; it is also induced by various stress stimuli. Elevated levels of c-Fos have been 
demonstrated in a number of drug-resistant cell lines when compared to their drug-
sensitive counterparts. Inhibition of PKA, an inducer of the AP-1 complex, was found 
to decrease the expression of human MDR1 in the P388 leukemia cell line 153; 
however, PKA has also been implicated in regulation by Sp1, complicating the 
interpretation of these data. A similar line of circumstantial evidence comes from 
studies of the c-Jun NH2-terminal protein kinase (JNK), which also activates AP-1. 
In human KB-3 cells, adriamycin, vinblastine and etoposide (VP-16) activate jun 
kinase (JNK), and this was found to be associated with an increase in MDR1 
expression at the mRNA level 76. Two multidrug-resistant variants of KB-3, KB-A1 
and KBV1, showed increased basal levels of JNK activity when compared to the KB-
3 parental cell line. Putative non consensus AP-1 binding sites have been reported in 
human and rodent class I P-GP promoters. While the AP-1 site in the murine 
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homologue mediates the repression of this gene, the AP-1-binding elements in the 
promoters of the hamster (-55 to -49)  and human genes (-121 to -115) are involved in 
transcriptional activation 76. Moreover, cells transfected with c-Jun exhibit a higher 
level of expression of MDR1 RNA and P-gp protein. The MRP1 promoter also 
contains a putative AP-1 site (-498 to -492) that interacts with a complex containing 
c-Jun and JunD 154. Interestingly, levels of this complex were increased in highly 
resistant H69AR cells as compared to their parental counterparts, although the role of 
this element in the regulation of MRP1 in response to inducers has yet to be evaluated 
fully. Similarly, the MRP2 promoter contains a consensus AP-1-binding element that 
has not yet been functionally tested 155. 
 
 
Ras/WT-1 
 
The MDR1 gene is also a target of the ras/raf signalling pathway 156. Initial  studies 
indicated that signaling by ras converges on the GC-rich binding site for the zinc 
finger transcription factors Sp1 and Sp3, located within the proximal MDR1 promoter 
156
. Egr-1, a ubiquitous immediate early factor, and WT-1, the Wilms’ tumor 
suppressor protein, also interact with GC sequences through their zinc-finger 
domains. Interestingly, both Egr1 and WT-1 recognize a site within the MDR1 GC 
element that overlaps the Sp1/Sp3-binding sequence. Indeed, activation of MDR1 by 
TPA is mediated by Egr-1 76 and suppressed by WT-1  76. A similar GC element 
resides within the promoters of several MRP genes, suggesting a potential role for the 
Ras pathway and WT-1 in their regulation as well. It appears, therefore, that the 
regulation of the expression of MDR1, and perhaps other drug transporters, by 
Ras/Raf and WT1 involves a complex interplay of transcription factors within a very 
discrete promoter region. To add to this complexity, it has recently been shown that 
the activation of phospholipase C (PLC) by a variety of inducers activates MDR1 
transcription through an upstream element (-106 to –99). This activation is enhanced 
by co-expression of constitutively active v-raf and blocked by a dominant-negative 
form of raf or by inhibitors of the mitogen-activated protein kinase, suggesting that 
PLC delivers the Ras/Raf signal to the MDR1 promoter through a distinct binding site 
76
.  
 
 
APC 
 
Mutations in the tumour suppressor gene adenomatous polyposis coli (APC) have 
been documented in greater than 80% of all sporadic hereditary colon cancers. Loss 
of APC function leads to the nuclear accumulation of β-catenin, a co-activator for the 
transcription complex TCF/LEF (T-cell factor/lymphoid enhancer factor). A recent 
study showing that TCF/LEF activates the MDR1 promoter provides one possible 
explanation for the overexpression of MDR1, and subsequent ‘intrinsic’ resistance, in 
many colorectal cancers 157. In initial studies, the authors identified several TCF/LEF 
sites lying between –1813 and –261 within the MDR1 promoter. Recently, they have 
extended their observations to the murine MDR1 homologues by analysing mdr1a 
expression in Min/+ mice, which contain a mutant allele of the murine APC locus 
encoding a nonsense mutation at codon 850. Like humans with germline mutations in 
APC, Min/+ mice are predisposed to intestinal adenoma formation. Using this model, 
they have observed aberrant induction of the Mdr1a gene product, even in nascent 
microscopic adenomas of Min/+ mice. Interestingly, Min/+ mice devoid of the mouse 
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mdr1 homologues developed significantly fewer intestinal polyps, suggesting a role 
for P-gp in their genesis 158. 
 
                            
 
                   
 
 
 
Figure 9. Promoter elements and DNA-binding factors involved in the transcriptional regulation of 
MDR1. 
   
                    
CONSTITUTIVE OVEREXPRESSION IN DRUG-RESISTANT CELLS 
 
Tumor cell lines selected for resistance to MDR drugs most often exhibit constitutive 
overexpression of MDR1 or one of the other MDR-associated transporters. Although 
frequently the result of gene amplification, this overexpression can also be mediated 
at the level of transcription, particularly in the case of the MDR1 gene. Any drug-
selected mutations/ alterations in any of the factors/pathways that are involved in 
regulation of the transporters could result in constitutive up-regulation, and future 
studies are likely to identify other mechanisms in other cell types. 
 
 
MED-1/IMed 
 
A mechanism described for the constitutive increase in the transcription of a P-GP 
gene was defined for the hamster p-gp1 homologue. Drug sensitive cells utilize a 
single transcription start site, while drug resistant cells initiate transcription from 
several downstream sites 138, 140. Activation of the additional start sites is mediated by 
a novel downstream element, GCTCCC/G, designated as MED-1 (multiple start site 
element downstream) 139. The MED-1 element interacts with a multiprotein complex 
that is currently under investigation and functions within a chromatin complex. 
Interestingly, it has also identified an inverted MED-1 complex, that we had termed 
iMED, upstream of the initiation site of the human MDR1 promoter 76. Mutation of 
iMED decreases transcription in drug sensitive cells, suggesting a function of this 
element in constitutive MDR1 transcription. Although its role in drug-resistant cells 
has not been directly investigated, a recent study suggests that binding of one of the 
MED-1 (iMED) complex partners may be increased in drug resistant leukemia cells 
159
, possibly linking iMED to the activation of MDR1 in certain drug-selected cells. 
Interestingly, several other drug transporters, including MRP1 and MRP2, also utilize 
multiple start sites; whether a MED-1-like element is involved in their regulation is 
under investigation. MEF-1, a 130-kDa protein, termed MDR1 promoter-enhancing 
factor 1 (MEF1), has been shown to activate MDR1 transcription through an upstream 
promoter element (-118 to -111). Significantly, this protein was present in a drug-
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resistant HL60 subline, but not in the drug sensitive HL60 parent cells 160, thereby 
suggesting a direct role in MDR1 activation following drug selection. An interesting 
correlate has been found in MCF-7 cells, where it appears that the same promoter 
element binds an inhibitory complex containing NF-kB and c-Fos in parental cells, 
but not in resistant MCF-7/ADR cells 160. The mechanism by which MEF1 or iMED 
regulates MDR1 transcription, the interplay between MEF1 and NF-kB/c-Fos and the 
frequency with which these complexes are involved in MDR1 activation in drug 
resistant cells remain to be determined. 
 
 
STRESS INDUCTION OF DRUG RESISTANT GENES 
 
Given the role of MDR1 in protection against environmental adversity, it is not 
surprising that the MDR1 gene is highly responsive to stress signals 76. MDR1 
inducers include heat shock, partial hepatectomy, inflammation, exposure to 
carcinogens including chemotherapeutics, hypoxia and UV and X irradiation. The 
effect of these inducers on the transcription of other drug transporters has just begun 
to be investigated. Heat shock activation of MDR1 gene expression by heat shock and 
heavy metals was first reported by Gottesman and co-workers 161 and proposed to be 
mediated by a single mechanism. A heat-shock element (HSE) identified at position –
152 to –178 was shown to interact with heat-shock factor (HSF); a second HSE like 
element (–99 to –66) bound to a protein complex which was largely unchanged upon 
heat shock 162. However, the functional role of these elements in heat-shock response 
was not evaluated. More recently, it has been shown that activation by heat-shock 
requires the interaction of HSF1 with the –152/–178 HSE, while activation by other 
stress agents, including arsenite, butyrate and etoposide occur independent of 
thisHSE and HSF1 163. Indeed, activation by these and other stress inducers has been 
shown to occur through another promoter region, which we have termed the ‘MDR1 
enhancer’ 
 
 
INFLAMMATION (GR AND C/EBPb) 
  
The ‘acute-phase response’ is a general term for the complex changes that take place 
in mammals in response to inflammatory stimuli such as bacterial infection or burn 
injury. This response is often experimentally simulated in rodents by the 
administration of bacterial lipopolysaccharide (LPS). In response to LPS, 
macrophages secrete inflammatory cytokines such as interleukin (IL)-1, IL-6 and 
TNF, which in turn act on the liver to induce a change in that organ’s gene expression 
program, resulting in the synthesis of a range of acute-phase proteins 76. Most of the 
analyses of the expression of drug transporters during inflammation have relied on 
the rodent model system; thus, data have been obtained primarily for the transcription 
of the rodent homologues. Although not necessarily directly applicable to the human 
genes, the high degree of promoter conservation among family members, together 
with the similar response of the human and rodent genes to inflammatory agents, 
suggests that similar transcription pathways exist. Under acute-phase conditions, P-
GP genes are induced in the liver 164. Interestingly, at least two transcription factors 
that are known to be induced during the acute-phase response have been shown to 
regulate P-GP gene expression in some cell lines. Studies carried out in a number of 
laboratories have shown that the IL-6-induced CAAT enhancer-binding protein 
(C/EBPb) can activate the mouse and human MDR1 genes in transfection assays (-
Introduction 
 
 49 
147 to -139 in the human gene) 165, 166. The homologous region in the hamster p-gp1 
promoter also contains a C/EBPb binding site and that activation through this site can 
be modulated by the binding of the glucocorticoid receptor (GR) 76. These results 
suggest that this element may be important as a site of crosstalk between the 
inflammatory signals, mediated by cytokines through C/EBPb, and the anti-
inflammatory signals, mediated by glucocorticoids through their receptor. The 
C/EBPb inducer IL-6 was also shown to induce MRP2 expression and activity in 
human hepatoma cell lines 167; the presence of a C/EBPb-binding site within the 
upstream region of the MRP2 promoter (-356 to -343) suggests that this increase is 
mediated at the level of transcription 155. A number of studies have suggested a role 
for glucocorticoids in the transcription of MDR1 homologues, but the responses 
appear to be cell type specific. Using the mouse hepatoma cell lines Hepa 1–6 and 
hepa1c1c, it was found that the synthetic glucocorticoid, dexamethasone, elicited an 
increase in the expression of the two murine MDR1 homologues, mdr1a and mdr1b 
168
. Nuclear run-on analysis indicated that this increase occurred at least in part at the 
transcriptional level and could be abrogated by the protein synthesis inhibitor 
cycloheximide, suggesting that GR was influencing this promoter through an indirect 
mechanism. A similar increase in human MDR1 RNA levels was observed in the 
HepG2 human hepatoma cell line. In rat primary hepatocytes, however, 
dexamethasone treatment led to a decrease in mdr1b expression, and no increase was 
seen in the non-hepatoma mouse LMtk- and NIH3T3 cell lines or in the human HeLa 
cell line upon dexamethasone treatment, suggesting that the effect is cell line specific. 
A glucocorticoid response element (GRE) has been identified in the promoter of the 
hamster MDR1 homologue, p-gp1. This site, between -96 and -83, mediates the 
repression of pgp1 transcription by GR in both DC-3F Chinese hamster lung cells and 
a human osteosarcoma cell line, U2-OS. The GRE overlaps a binding site for CEBPb  
and it appears that GR represses pgp1 transcription by interfering with the actions of 
CEBPb, as both sites are required for repression to occur. Interestingly, these 
elements are conserved in the human MDR1 gene and MDR1 transcription can also be 
repressed by GR in some cell types, suggesting that a similar mechanism may be 
involved. Treatment of rats with dexamethasone increases MRP2 mRNA in vivo, 
although the mechanism underlying this increase has not yet been determined 169. The 
fact that glucocorticoids are currently used in chemotherapy for many tumors, 
including chronic lymphocytic leukemias, lymphomas, multiple myelomas and breast 
cancers makes an understanding of the role of these hormones in the regulation of 
drug transporters an important goal. 
 
 
HYPOXIA 
 
The microenvironment of many large, rapidly growing tumours lacks a sufficient 
vascular supply, resulting in oxygen deprivation or hypoxia. Prolonged hypoxia has 
been linked to metastasis, since it increases genomic instability, genomic 
heterogeneity, and may act as a selective pressure for tumour cell variants 76. This 
hypoxic environment results in the induction of many stress–response genes, 
including glycolytic enzymes, pro-angiogenic factors and pro-inflammatory genes. 
Apropos of this, it has recently been shown that P-GP expression is increased in 
hypoxic cells, and that this increase is mediated by hypoxia-inducible factor-1 (HIF-
1), a transcription factor that normally resides in the cytoplasm of normoxic cells and 
is believed to be shuttled to the nucleus upon hypoxic stress. HIF-1 activates the 
MDR1 promoter through a consensus binding sequence (5’GCGTG3’; -49 to -45) that 
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overlaps the GC element involved in constitutive and inducible expression. Indeed, 
preliminary evidence suggests that the GC-binding protein Sp1 may be involved in 
the hypoxic response. These results may in part explain the observation that hypoxic 
tumour cells are more refractory to anticancer agents 76. 
 
 
CARCINOGENS 
 
Most early studies on the effects of carcinogens on P-GP expression concentrated on 
the rat genes. These genes are induced by a number of xenobiotics including 2,3,7,8-
tetrachlorodibenzo-p-dioxin, 2-acetylaminofluorene (2-AAF) and 3-
methylcholanthrene 76. The transcriptional mechanism underlying this activation was 
elusive until it was shown that activation of rat mdr1b by 2-AAF involves an NF-kB-
binding site at position -167 to -158 within the promoter. 2-AAF was found to 
activate mdr1b through the generation of reactive oxygen species, leading to the 
activation of IkB kinase, the degradation of IkB beta and the activation of NF-Kb 170. 
A different mechanism has recently been shown to mediate hepatic induction of the 
human MDR1 gene by 2-AAF. In this case, the carcinogen activates phosphoinositide 
3-kinase and its downstream effectors Rac1, NAD(P)H oxidase and Akt, resulting in 
activation of MDR1 through an upstream binding site (-6092) that includes an NF-
kB-binding site 171. 
 
 
CHEMOTERAPEUTICS 
 
Considerable evidence has accumulated to indicate that the expression of drug 
transporter genes can be transiently induced in response to chemotherapeutics 172-174. 
This was first reported in CCRF-CEM/ ActD cells that exhibited an increased steady-
state level of MDR1 RNA following short-term exposure to actinomycin D 173; this 
increase was mediated, at least in part, at the level of transcription. Early studies 
indicated that the MDR1 promoter region from -136 to -76 was involved in activation 
by actinomycin D 175; this region was further delineated to the MDR1 enhancesome. 
Although it was initially assumed that only those drugs associated with the MDR 
phenotype would induce the expression of P-GP genes, more recent studies indicate 
that MDR1 transcription can also be induced by non-MDR drugs, such as antifolates 
and hydoxyurea 76. In this study, induction of MDR1 was associated with 
morphological indications of cell damage, suggesting that increased P-GP 
transcription may be part of a general cellular response to damaging agents. 
Interestingly, some drugs, such as mitomycin C, suppress the activity of MDR1, 
although the mechanism by which this occurs has not been determined 176, 177. It 
should also be noted that overexpression of MDR1 in response to chemotherapeutics 
was shown to be a result of changes in mRNA stabilization and translational initiation 
in several leukemia cell lines, with no apparent transcriptional component 178. Thus, it 
is likely that multiple mechanisms exist in different cell types that either 
cooperatively or exclusively regulate MDR1 gene output. While few studies have 
focused on the regulation of other drug transporters by chemotherapeutic agents, 
MRP2, MRP3 and MRP5 were shown to be induced in liver HepG2 cells by cisplatin, 
although the mechanism underlying this induction was not investigated 179.  
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‘MDR1’ ENHANCEOSOME 
 
It has been well established that MDR1 gene expression can be activated by UV 
radiation, differentiation agents such as sodium butyrate and retinoic acid, HDAC 
inhibitors, phorbol esters and certain chemotherapeutics (Fig. 10). Recent studies in 
our laboratory indicate that the signals from all these divergent stimuli converge on a 
region of the MDR1 promoter that we refer to as the ‘MDR1 enhancesome’ 131, 180. 
This region includes binding sites for the trimeric transcription factor NF-Y and the 
Sp family of GC-binding transcription factors. Together, these DNA-binding proteins 
cooperate to recruit the histone acetyltransferase P/CAF to the MDR1 promoter, 
resulting in the acetylation of promoter-proximal histones and subsequent 
transcriptional activation that is likely mediated by further chromatin remodeling. 
Recently, chromatin immunoprecipitation studies have identified a ‘switch’ in DNA-
binding Sp family members following induction. Studies are presently underway to 
determine whether this change in binding factors results in recruitment of new co-
activators/co-repressors to the MDR1 promoter, and whether other factors that have 
been shown to bind to the MDR1 GC element are also involved in stress response 
through the enhancesome complex. Although the mechanism by which each agent 
transduces the signal that results in promoter activation has yet to be determined, the 
role of the MDR1 enhancesome in the regulation of transcription by a variety of 
stimuli makes it an attractive target for therapeutic intervention 181.  
 
 
NUCLEAR RECEPTORS AND TRANSCRIPTION OF DRUG 
TRANSPORTERS 
 
While many ABC transporters are ubiquitously expressed, high levels of expression 
are usually restricted to a limited number of tissues or cell types where they 
transcriptional regulation of ABC drug transporters perform a specialized function. 
One organ that depends on the action of ABC transporters to carry out its prescribed 
function is the liver. In addition to MDR1, which is involved in lipid transport and 
drug biodistribution and is activated during inflammation and partial hepatectomy of 
the liver, several other drug transporters are involved in liver function, including 
MRP2, MRP3 and BSEP (ABCB11). The major physiological role of MRP2 is to 
transport conjugated metabolite sinto the bile canaliculus, while MRP3 is localized in 
the basolateral membrane of the hepatocytesand transports  similar metabolites back 
to the bloodstream. This may explain why mutation of MRP2 leads to Dubin–Johnson 
syndrome, characterized by elevated levels of bilirubin, increased urinary 
coporphyrin I fraction and deposition of dark pigment in the liver. Monoanionic bile 
salts are secreted into bile canaliculi by the bile salt export pump BSEP. Given the 
functional relationship among these transporters, it is not surprising that their 
transcription is regulated through similar mechanisms involving nuclear hormone 
receptors. Nuclear receptors are comprised of a family of transcription factors that 
function as heterodimers to regulate target promoters. RXR (retinoid receptor) is 
present in all heterodimers; the second partner determines the substrate ligand and the 
target promoters that will be activated. The nuclear receptor proteins that have been 
shown to be involved in transcription of drug transporters include retinoic acid 
receptor (RAR), farnesoid receptor (FXR) steroid-activated receptor (SXR; 
P(pregnane)XR in rodents) and constitutive androstane receptor (CAR). The RXR-
containing heterodimers regulate a broad range of hepatic metabolic functions, 
including bile acid synthesis, fatty acid and oxysterol metabolism, and cytochrome 
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oxidase drug metabolism. RARα in complex with RXRα has been shown to regulate 
transcription of the rat MRP2 promoter through a binding element located in the 
upstream promoter region (-422 to -398) (Denson et al., 2000); the cytokine IL-1β 
suppresses activation through this site. Although the MDR1 promoter is activated in 
neuroblastoma cell lines by all-trans retinoic acid (ATRA), activation appears to be 
independent of RAR/RXR binding and is instead mediated by the differential binding 
of Sp family members to the GC element within the MDR1 enhancesome 181. FXR, 
when combined with RXR and bile salts as its ligand, initiates feedback control of 
bile acid synthesis 181. Both BSEP and MRP2 are targets of the FXR:RXR 
heterodimer. An FXR response element identified in the human BSEP promoter (-192 
to -180) mediates the activation of BSEP transcription by bile salts; a similar element 
exists in the rat BSEP promoter (-64 to -52). Moreover, FXR-/- mice exhibit a 
dramatic decrease in the expression of BSEP, consistent with the role of this receptor 
in regulation of BSEP transcription. Notably, lithocolic acid, a potent inducer of 
choleostasis, decreases the transcription of BSEP by antagonizing the activity of 
FXR, implicating FXR and loss of BSEP in intrahepatic choleostasis 182. An atypical 
promoter element has been identified within the rat MRP2 promoter (-401 to -376) 
that interacts with FXR and mediates transcriptional activation. This binding site also 
mediates the transcriptional regulation of MRP2 by PXR (SXR) (a receptor for 
xenobiotics such as rifampin, phenobarbital, taxol, clotrimazole and hyperforin) and 
by CAR 183. Interestingly, the human MDR1 promoter has also been shown to be 
regulated by the interaction of SXR:RXR with a promoter element ~8 kb upstream of 
the transcription start site 184, 185. Taken together, these results suggest that activation 
of drug transporters through multiple nuclear receptors can alter the efflux, and 
therefore the pharmacokinetics and bioavailability of a variety of compounds, 
including chemotherapeutic agents. Notably, despite the presence of putative nuclear 
receptor binding sites within the MRP3 promoter, regulation of MRP3 by bile salts in 
enterocytes is mediated by the interaction of the alpha fetoprotein transcription factor 
(FTF) with the MRP3 promoter (-229 to -138) 186; how this promoter is regulated in 
liver cells is presently under investigation. In MDR1 promoter several of the binding 
sites for transcription factors overlap, and in most cases it is not yet known whether 
multiple factors can co-occupy their cognate promoter site at the same time, or 
whether their interaction with the promoter is mutually exclusive. Keep in mind that 
most of the studies identifying these factors were performed in tissue culture cells and 
the relevance  of these findings to the in vivo situation, particularly in the clinical 
setting, remains to be determined. 
 
 
                         
 
Figure 10.  A variety of environmental signals, including those induced by hormones (ATRA), 
radiation, HDAC inhibitors (TSA, butyrate), some chemotherapeutics, phorbol esters and others 
converge on the MDR1 enhanceosome, which includes the DNA-binding proteins Sp1, Sp3 and NF-Y, 
the histone acetylases P/CAF and P/300. depending on conditions, the transcription factors Egr1, WT-1 
and the co-repressor HDAC1 may also be found at the promoter. 
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TARGETING TRANSCRIPTIONAL REGULATION OF ABC 
TRANSPORTERS GENES. 
 
 
p53 
 
The frequent occurrence of p53 mutations in human cancer has led to numerous 
investigations evaluating its role as a potential therapeutic target. By restoring wt p53, 
investigators have sought to either: (1) revert the malignant phenotype or (2) enhance 
drug sensitivity. These goals are based on available evidence that although not 
conclusive suggests that: (1) restoration of p53 will have an impact on the malignant 
phenotype and (2) mutant p53 confers drug resistance. Numerous investigators have 
shown that levels of p53 above a certain ‘threshold’ almost invariably lead to 
apoptosis or to enhanced drug sensitivity 187, 188. Several studies have shown that wt 
p53 can be introduced using viral vectors, and the available reagents can achieve the 
‘threshold’ levels required to bring about apoptosis. Studies to date have employed 
conventional vectors and also explored innovative strategies to exploit the p53 status 
of cancer cells. The first clinical trials attempting to restore wt p53 function utilized 
retroviral vectors that constitutively expressed p53 under the control of the actin 
promoter 189. Following intratumoral injection, expression of p53 and enhanced 
apoptosis were observed in the injected tumors, and in three of nine patients limited 
evidence of tumor regression was noted. While the retroviral vector used in these 
studies proved to be inefficient, this study provided a first ‘proof of principle’, and 
became the catalyst for further studies. Subsequent studies have used adenoviral 
vectors. Advantages of the latter include the ability to infect cells in all phases of the 
cell cycle, relative ease of growth to high titers and the capacity to accommodate 
inserts of large size. Its major disadvantages include the frequent occurrence of 
antibodies in the general population, preferential but not exclusive infection of cells 
expressing the coxsackie adenovirus receptor (CAR) and au-integrin and its lack of 
selectivity, so that it infects normal cells, most notably liver, with high efficiency 190. 
Despite its limitations, Adp53 vectors appear to be well tolerated and expressed in 
most patients. Clinical trials have shown antitumor activity in patients with squamous 
cell carcinomas of the head and neck and nonsmall- cell lung cancer (NSCLC) 190. In 
evaluating these strategies, one must be mindful that p53 participates in regulating the 
expression of a wide range of genes with diverse functions and that some of these 
genes may have unanticipated roles in a vector’s efficacy. Thus, some of the genes 
expressed following infection with a p53-expressing adenovirus may modulate a 
‘bystander effect’ by which uninfected cells are damaged as a result of the expression 
of genes in infected cells. For example, p53 may indirectly regulate angiogenesis by 
modulating the expression of vascular endothelial growth factor (VEGF) and 
thrombospondin 190. p53 also participates in the expression of insulin-like growth 
factor 1-binding protein (IGF1BP), an antagonist of insulin-like growth factor 1 (IGF-
1), a growth factor implicated in tumor cell survival 190. 
 
 
 
 
Introduction 
 
 54 
YB-1 
 
The Y-box-binding protein YB-1 has multiple functions, including regulation of gene 
expression. Nuclear localization of YB-1 regulates MDR1 and MRP1 gene expression 
that is known to confer the multidrug resistant phenotype in tumor cells 191. YB-1 is 
involved in several aspects of drug resistance, and it is an important regulator of 
pleiotropic resistance 192. YB-1 overexpression with increased nuclear localization 
occurs in many malignant diseases (e.g., breast, non–small cell lung, osteosarcoma, 
ovarian, and colon carcinoma; refs. 19–23). Furthermore, YB-1 mRNA is highly 
abundant in glioblastomas and malignant melanomas and is involved in the 
progression of prostate cancer 193. Several studies indicate that YB-1 positively 
regulates cell proliferation and it was shown that YB-1 translocates from the 
cytoplasm to the nucleus at the G1-S-phase transition 194. Recent evidence suggests 
that activated Akt is involved in nuclear translocation of YB-1 and blocking of 
phosphatidylinositol 3-kinase/Akt pathway may therefore be helpful for overcoming 
chemoresistance 195. The use of replication-competent adenoviruses for cancer 
therapy receives widespread attention, especially for the treatment of tumors 
insensible to current treatments. YB-1 facilitates E1-independent adenoviral 
replication by targeting the adenoviral E2-late promoter in multidrug-resistant cancer 
cells 196. In addition, the adenoviral protein E1B55k is involved in nuclear 
translocation of YB-1. Given that complexes containing adenoviral proteins E4orf6 
and E1B55k play critical roles in productive infection as well as in nuclear 
translocation of YB-1, targeting YB-1 by a recombinant E1/E3-deleted adenoviral 
vector expressing E1B55k and E4orf6 will be capable of translocating YB-1 into the 
nucleus and in consequence to replicate and destroy tumor cells. E2-early is only 
needed in little amounts at the very early state of infection, whereas E2-late acts 
throughout the whole cycle in quite considerable quantities. The E2-early promoter is 
active at early times postinfection 193. Because YB-1 acts through the E2-late 
promoter, it represents a suitable target for oncolytic adenovirus development. E1A 
mutant adenoviruses with reduced S-phase induction show tumor-selective 
replication 193. Adenoviral expression of E1B55k and E4orf6 mediates nuclear 
translocation of YB-1 in tumor cells. Nuclear translocation of YB-1 only takes place 
when cells are infected with WT adenovirus or Xvir03 but does not occur with an 
E1B55k-deleted adenoviral vector or an E1-deleted adenoviral vector (and therefore 
lacking E4orf6 expression) expressing E1B55k under CMV control 193.  
Conditionally replicating adenoviruses have shown enhanced anti-tumour activity 
when combined with chemotherapy or radiation and it has been suggested in several 
reports that irradiation or chemotherapy creates an environment that is more 
conductive to adenoviral infection or replication, including our own data showing that 
cytostatic drugs cause an increase of nuclear YB-1 and concomitant viral replication 
193
. As mentioned earlier, YB-1 regulates, besides other factors, the expression of the 
drug-related transport proteins MDR1 and MRP1. YB-1-associated oncolytic 
adenovirus Xvir03 causes inhibition of these genes. Xvir03 inhibits the expression of 
multidrug resistance–related genes MDR1 and MRP1. Because both genes are 
regulated by YB-1, this indicates that the recruitment of YB-1 via the complex 
E1B55k/E4orf6 to the adenoviral E2-late promoter is responsible for this effect. This 
is supported by the observation that the expression level of MDR1 was unaffected by 
an E1-deleted adenoviral vector expressing E1B55k under CMV control. Nuclear 
translocation of YB-1 by Xvir03 leads to resensitization of tumor cells to cytostatic 
drugs; thus, the potential of radiation and chemotherapy is restored. Chemotherapy, 
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on the other hand, yields an increased expression and nuclear localization of YB-1 
and in consequence enhances YB-1-associated adenoviral replication. 
This reveals a link between chemotherapy and virotherapy based on the cellular 
transcription factor YB-1. Xvir03 is to our knowledge the first oncolytic vector that 
possesses as a single agent the potential of down-regulating two multidrug resistance–
related genes MDR1 and MRP1. Due to their low homology, it is unlikely that a 
potent, nontoxic inhibitor for both proteins could be developed. It is possible propose 
a model termed Mutually Synergistic Therapy (MUST), which highlights the existing 
relationship between YB-1-associated virotherapy on the one hand and chemotherapy 
on the other hand. Thus, combining YB-1-dependent virotherapy with chemotherapy 
is beneficial for both treatments. This theoretical model may be helpful in developing 
new combined strategies involving YB-1-associated virotherapy for cancer 
intervention to augment the effectiveness of cytotoxic drugs and extend patient 
survival 193.  
 
 
 
THE RISE OF DNA METHYLATION AND THE IMPORTANCE 
OF CHROMATIN ON MULTIDRUG RESISTANCE IN CANCER 
 
Thus far, we have discussed transcription as the interaction between transcription 
factors and their cognate DNA binding sites. However, superimposed upon the 
regulation mediated by those interactions is the role of chromatin in permitting this 
interplay to occur. The basal transcriptional state of chromatin is inactive – the DNA 
wrapped in a nucleosomal complex is generally inaccessible to transcription factors. 
However, chromatin is a dynamic structure that receives signals from the 
environment to trigger changes in chromosomal architecture. A number of elegant 
studies have shown that covalent modifications of the amino-termini of the core 
histones in nucleosomes are critical to the regulation of transcription. These 
modifications, which include acetylation, methylation, phosphorylation and 
ubiquitination, appear to occur in sequential patterns, leading to the hypothesis that 
their intercommunication provides a ‘histone code’ that, when deciphered by other 
components of the transcriptional machinery, signals for transcriptional 
activation/deactivation 197. Two classes of chromatin-targeted proteins have been 
identified that act as on/off switches for transcriptional competence: chromatin 
remodeling proteins and chromatin-modifying enzymes. Chromatin-modifying 
enzymes, specifically histone acetylases (HATs)/ histone deacetylases (HDACs) and 
DNA methylases, have been shown to be involved in the regulation of the MDR1 
gene (Fig. 11). 
The silencing of gene expression is associated with deacetylated histones, while 
histone acetylation neutralizes the positive charge of the lysine-rich histone tails, 
thereby weakening the interaction of histones with the negatively charged DNA and 
generating an ‘open’ chromatin conformation. Moreover, acetylation of the 
transcription factors themselves can add an additional layer of regulation to this 
process. Histone acetylation is reversed by the action of the histone deacetylase 
(HDAC) family of chromatin-modifying enzymes. How these modifying enzymes are 
recruited to specific promoters at specific times is still under intensive investigation. 
However, a general model proposes that HDACs are recruited to the promoter by 
sequence- or modification-specific proteins, thereby maintaining the gene in a 
hypoacetylated, inactive state. In response to specific stimuli, transcriptional 
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activators recruit the HATs that acetylate histones, resulting in conformational 
changes within the nucleosomal array. Treatment of cells with the HDAC inhibitors 
trichostatin A or sodium butyrate leads to the activation of MDR1 transcription and 
associated hyperacetylation of MDR1 proximal-promoter histones 180. This activation 
is mediated by the HAT protein, P/CAF, which is recruited to the promoter via its 
interaction with a transcriptional complex that we termed the MDR1 enhancesome. 
Interestingly, activation appears to be limited to cells that already express detectable 
levels of MDR1 RNA. In the few cell types in which the MDR1 gene is silenced, 
altering the equilibrium of chromatin acetylation is not sufficient to activate 
transcription. Recent studies suggest that this may be the result of hypermethylation 
of the MDR1 promoter, which acts as the ultimate ‘lock-down’ of gene expression. 
The role of DNA methylation in transcriptional silencing is due to the capacity of 
methylated DNA to assemble repressive chromatin as compared with conventional 
unmethylated chromatin. An increasing body of evidence indicates that DNA 
methylation significantly contributes to the activation and repression of many 
different genes, including MDR1 76. CpG methylation alone is not sufficient to 
instantly confer repression 198, 199. Rather, the targeting and sequences  of repressive 
complex specifies a transcriptional block. Indeed, chromatin accessibility studies 
demonstrated that DNase hypersensitivity was reduced in a cell line where the MDR1 
promoter was hypermethylated, compared to cell line where the promoters were 
hypomethylated, indicating MDR1 promoter methylation imposes a restrictive 
chromatin environment. The methyl-CpG-binding protein-2 (MeCP2) protein, a 
strong transcriptional repressor, was identified to localize to hypermethylated MDR1 
chromatin and was associated with methylation dependent silencing. MeCP2 
localization was correlated with hypermethylation and MDR1 transcriptional 
silencing, as MeCP2 was absent from the hypomethylated promoter in those cell lines 
that expressed MDR1.  
 
 
                                           
 
Figure 11. Hypothesized epigenetic models for MDR1 activation. 
 
Robust MDR1 expression was only obtained when demethylation induced by 5-
azacytidine treatment was accompanied with TSA treatment. MeCP2 silences 
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transcription by recruiting the co-repressor mSin3, Hdac1 and Hdac2 via an 
interaction with its transcriptional repressor domain (TRD). Treatment with TSA has 
been shown to partially overcome TRD-mediated repression. However, the failure of 
TSA to reactivate MDR1 demonstrated that Hdac inhibition is not the only 
mechanism of repression associated with MeCP2. more recently, MeCP2 was shown 
to interact with a protein complex containing methyltransferase activity specific to 
histone H3 lysine residue 9 (H3K9). Loss of MeCP2 was shown to reduce the level of 
H3K9 methylation at the in vivo gene target , H19, implicating H3K9 methylation as 
a second mechanism, in addition to Hdac mediated repression, by which MeCP2 
functions to repress gene expression. Interestingly, H3K9 methylation has also been 
shown to direct CpG methylation in Neurospora Crassa and Arabidopsis thaliana, 
implicating that the reverse association is also possible. However this reverse 
mechanism is yet to be identified in mammalian cells. 
The histone modification, methylation of H3K9, is heavily associated with 
heterochromatin. Targeted disruption of the mouse homologues of the H3K9 
methyltransferases, Suv39h1 and Suv39h2, resulted in disruption of pericentromeric 
heterochromatin and loss of H3K9 methylation. This was also demonstrated in yeast, 
as Clr4 (H3K9 methyltransferase) was shown to be necessary for transcriptional 
silencing at centromeric heterochromatin emphasizing the roles that H3K9 
methyltransferases and H3K9 methylation play in establishing and maintaining 
heterochromatic states. Evidence also now indicates that H3K9 methylation is 
involved in regulating euchromatic gene silencing. H3K9 methylation was localized 
to regions of silenced developmentally regulated genes in chicken, and silenced 
tumour suppressor genes in cancer. Furthermore, dynamic changes in H3K9 
methylation in response to gene activation have been demonstrated at several 
promoters. The human methyltransferase Suv39H1 and G9a, were targeted to the 
endogenous VEGF-A promoter, inducing gene silencing and thus demonstrating that 
H3K9 methylation can initiate silencing. H3K9 methylation is thought in part, to 
mediate repression by providing a docking site for the transcriptional repressor, HP1, 
and HP1 was later demonstrated to recognize and specifically bind methylated H3K9. 
loss of the H3K9 methyltransferase, Clr4 in yeasts, was shown to be necessary for 
transcriptional silencing at centromeric heterochromatin, and localization of Swi6, a 
HP1 homolgue. Whether HP1, or H3K9 methylation contributes to MDR1 silencing is 
not clear. 200 
The ABCG2 promoter in renal carcinoma was found to be methylated 201. This can be 
of therapeutic importance because renal carcinoma cell lines UOK121 and UOK143, 
having a methylated ABCG2 promoter and expressing a lower level of ABCG2, were 
found to be more sensitive to ABCG2 substrate drugs. Consistent with the role of 
DNA methylation in ABCG2 silencing, incubation of methylated cell lines UOK121 
and UOK143 with 5-aza-dC, a specific inhibitor of DNA methyltransferase, resulted 
in upregulation of ABCG2 expression in a concentration-dependent manner.  It has 
been suggested that DNA methyltransferases may act only on chromatin that is 
methylated at lysine 9 on histone H3 (H3K9) 202, 203. Indeed, H3K9 methylation is 
sufficient for initiating a gene repression pathway in vivo 204. Modifications 
(methylation and deacetylation) of histone H3 assembled at the ABCG2 promoter and 
DNA methylation of the CpG island coordinately cause silencing of the ABCG2 gene. 
The ABCG2 expression in the methylated cell lines (UOK121 and UOK143) can be 
restored by 5-aza-dC treatment, and the reactivation is associated with 
hyperacetylation of H3 at lysine 9. Thus, apart from demethylating the ABCG2 
promoter, 5-aza-dC also resets the histone code, switching it from methylation to 
acetylation at H3K9. MBD proteins mediate silencing of genes by facilitating the 
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establishment of a repressive chromatin environment 205, 206. These proteins recruit 
chromatin remodeling enzymes such as histone deacetylases and mSin3 to the DNA 
with their transcriptional repression domains, creating an inactive chromatin 
configuration 207-209. ChIP assays demonstrated binding of MeCP2, MBD2, HDAC1, 
and mSin3A to the CpG island region in UOK121 and UOK143 201. ChIP analyses 
also revealed that 5-aza-dC treatment in UOK121 and UOK143 cells facilitated an 
enrichment of acetyl-H3, a release of MBDs (i.e., MeCP2 and MBD2), and a 
decreased occupancy of HDAC1 and mSin3A on the ABCG2 promoter, consistent 
with a more open chromatin conformation that would allow transcriptional activation. 
Taken together, the data support the notion that DNA methylation dependent 
formation of a repressor complex in the CpG island contributes to inactivation of the 
ABCG2 gene 201. The binding of the MBDs to methylated DNA results in recruitment 
of HDACs to support transcriptional repression. The HDAC inhibitor depsipeptide 
could upregulate ABCG2 expression most effectively when it is unmethylated but to a 
lesser extent when is heavily methylated. This suggests that DNA demethylation is 
more critical than histone acetylation for the ABCG2 gene chromatin to switch from a 
transcriptionally non permissive to a permissive configuration. In this regard, the 
repressive histone code, MeH3K9, was found binding strongly to the proximal 
ABCG2 promoter in the methylated cell lines, which was not affected by depsipeptide 
treatment 201. In contrast, depsipeptide did reduce the association of MeH3K9 with 
the ABCG2 promoter in the unmethylated cell line. This may explain why 
depsipeptide has less effect on upregulation of ABCG2 in the methylated cell lines 
than in the unmethylated cell line 201. A similar finding has been reported for FMR1 
transcriptional silencing in fragile X cells 210.  
DNA methylation can confer a selective growth advantage to cells when it occurs in 
the promoter regions of genes repressing the expression of tumor suppressor genes, 
resulting in the development of cancer 211, 212. Since ABCG2 normally functions as an 
efflux transporter, the physiological significance of this methylation-dependent 
repression in cancer is not clear. 
Whether the repression of ABCG2 would provide an advantage to the cell, or merely 
be an epiphenomenon, is open to speculation. Regardless of whether ABCG2 
repression could be of benefit to cancer cells, the identification of patients whose 
tumours have repressed ABCG2 could be important. Drugs that are substrates for 
ABCG2 would be expected to be more effective in such a patient population. A more 
important role of ABCG2 methylation could be that in normal physiology. Gene 
methylation is believed to be the basic mechanism for the establishment and 
maintenance of genomic imprinting 213. Imprinted genes are marked in the male and 
female germ lines and retain the molecular memory of their parental origin, resulting 
in allelic expression differences. However, gene regulation at the promoter level 
during normal growth and development is not well understood. Furthermore, ABCG2 
is normally expressed in the placenta and in stem cells 88, 101. The possible role of 
promoter methylation in regulating ABCG2 expression in stem cells and their progeny 
has not been evaluated. Since it would require isolation of different populations of 
cells, including stem cells, progenitor cells, and terminally differentiated cells, this 
pursuit must await progress in the identification of specific markers for cells at 
different stages of development. 
The role of chromatin in the regulation of other drug transporters has not fully been 
investigated. Activation of the MRP7 promoter by TSA has also been observed, 
although the mechanistic basis of this activation has not been elucidated 76. 
Interestingly, in HepG2 cells, TSA repressed transcription of the MRP2 gene through 
an upstream region (-517 to -197), suggesting that chromatin modification may 
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permit binding of a repressor complex to this promoter 76; TSA had no effect on the 
expression of MRP3 in these studies.  
 
 
CHEMOTHERAPY CAN INDUCE LOSS OF METHYLATION 
 
A dominant role for CpG methylation in MDR1 silencing indicates that the 
methylation mark may need to be removed in order to acquire Pgp mediated MDR. 
Long term selection for drug resistant cell lines was associated with hypomethylation 
of the MDR1 promoter, however the extended kinetics of the exercise suggested that 
selection of hypomethylated drug resistant clones was the primary mechanism for the 
loss of methylation. Several studies have shown that demethylation of the MDR1 
promoter does occur during the course of clinical chemotherapy, resulting in the 
activation of MDR1 expression. This raised the intriguing question of whether the 
cytotoxic action of chemotherapeutic drugs could induce active demethylation of the 
MDR1 promoter. Alternatively, methylation may be a permanent mark of the MDR1 
promoter, and instead, the observed loss of methylation may have been due to the 
selection of cells with a reduced methylation pattern, and hence, resulted in increased 
MDR1 expression following drug treatment. A protein with demethylase activity has 
not been conclusively identified that can reverse DNA methylation, even though 
evidence exists that demethylation does occur at some genes over time. 
MBD2, a methyl-binding domain protein associated with methylation dependent 
silencing, was demonstrated to have demethylase capabilities that were promoter and 
time dependent. However similar activity for MBD2 were not demonstrated in other 
studies, therefore, there is only weak evidence to support a scenario whreby 
chemotherapeutic drugs coul direct a putative demethylase activity to the MDR1 
promoter to reverse the methylation 200.  
 
 
 
THE Myc/Max/Mad NETWORK AND THE TRANSCRIPTIONAL 
CONTROL OF CELL BEHAVIOR 
 
The Max network comprises a group of nuclear transcription factors whose functions 
profoundly affect cell behavior 214.These factors possess two common attributes. 
First, members of the network are a subset of the larger class of proteins containing 
basic helix-loop-helix zipper (bHLHZ) motifs. This domain is known to mediate 
protein-protein interactions and DNA binding 214. Second, each of the members of the 
network utilizes its bHLHZ domains to form individual dimers with Max, itself a 
small bHLHZ protein (Fig 12). Association with Max results in the formation of a 
heterodimer possessing sequence-specific DNA binding and transcriptional activities. 
Max itself can homodimerize and bind DNA, but such Max homodimers appear to be 
transcriptionally inert 215, 216. The ability to modulate transcription is derived from 
specific domains within the Max interacting factors which, in turn, appear to mediate 
associations with specific 
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Figure 12. Max-interacting proteins. Max forms heterodimers with members of the Myc and Mad 
protein families as well as with the Mnt (or Rox) and Mga proteins. Each of these proteins interacts 
with Max through its bHLHZ domain. 
 
 
coactivators or corepressors, resulting in the formation of higher-order complexes. 
Because Max-interacting proteins homodimerize poorly on their own and therefore 
bind DNA weakly, it can be argued that it is through the highly specific association 
with Max that the activities of these proteins are manifested. In general, Max 
interacting proteins have short half-lives and their biosynthesis is highly regulated. 
Max, on the other hand, is stable and constitutively expressed, suggesting that the 
regulation of the network is largely dependent on the abundance of the Max 
associated transcription factors 217, 218. Our understanding of the Max network grew 
out of research on the MYC oncogene family. MYC was originally defined as an 
oncogene (v-MYC) transduced by a number of avian retroviruses capable of potently 
inducing neoplastic disease 219. Subsequently c-MYC, the cellular homolog of v-MYC, 
was identified and eventually shown to be a member of a family of proto-oncogenes 
comprising c-MYC, N-MYC, and L-MYC (Fig. 13). These genes are considered proto-
oncogenes in the sense that alterations in their structure and expression have been 
linked to a wide variety of human and other animal cancers 220-224. The proteins (Myc) 
encoded by MYC family genes are predominantly localized in the cell nucleus, and 
their expression generally correlates with cell proliferation. When it was shown that 
the N-terminal region of Myc could function as a transcriptional activation domain 225 
and that the C-terminal region possessed homology to bHLHZ proteins 226, it was 
widely assumed that Myc proteins would form homo- or heterodimers, bind DNA, 
and function as transcriptional activators. Because neither dimerization nor specific 
DNA binding could be readily demonstrated for Myc, except at high protein 
concentrations, a search for novel Myc interactors was initiated, leading to the 
identification of Max. Max was shown to interact specifically with all Myc family 
proteins, and the resulting heterocomplexes recognize the hexameric DNA sequence 
CACGTG (belonging to the larger class of sequences known as E-boxes, CANNTG) 
at concentrations at which binding by either partner alone is undetectable 227-229. 
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Importantly, Myc requires Max to activate transcription of genes containing E-box 
binding sites 215. Furthermore, Myc has been shown to repress transcription at certain 
target promoters 230. The transcription activation function of Myc is mediated at least 
in part by recruitment of a histone acetyltransferase (HAT) 231. 
 
 
 
 
 
 
 
Figure 13. Structural domains of Myc oncoproteins. MB1 and MB2 domains are higly conserved 
within this family and are required for transactivation functions. MB2 is also required for the 
interaction with co- transcriptional activator TRAPP. TAD is a transactivation domain. 
 
 
 
The fact that Max is expressed in the absence of Myc led to the question of whether 
Max might have additional dimerization partners. This prompted a search for new 
Max-interacting proteins by the use of expression cloning and two-hybrid screens. In 
this manner, two novel, but related, Max-interacting bHLHZ proteins were 
discovered, Mad1 and Mxi1, followed later by Mad3 and Mad4 214. These four 
proteins, considered to compose the Mad protein family, behave much like Myc in 
that they have only weak homodimerization and DNA-binding capacities but readily 
heterodimerize with Max and bind the E-box consensus sequence. However, in 
contrast to Myc, which activates transcription at promoters proximal to E-box sites, 
the Mad-Max heterodimers act as transcriptional repressors at the same binding sites. 
Each of the Mad proteins acts as a repressor by associating with the mSin3 
corepressor complex 232. Also, in contrast to Myc, expression of Mad family proteins 
appears closely linked to terminal differentiation 214. Max interacts with at least two 
other bHLHZ proteins in addition to the Myc and Mad family members, Mnt (also 
called Rox) and Mga. Both of these proteins possess transcriptional activities which 
appear to be context dependent. Thus Mnt, similar to the Mad family proteins, 
recruits the mSin3 corepressor complex and represses transcription in some, but not 
all, cell types 233, 234. Mga contains two functional DNA-binding domains, a bHLHZ 
region, which interacts with Max, and a Brachyury or T-box domain. Activation of 
transcription by Mga at T-box binding sites depends on binding of Max to the distal 
bHLHZ domain, suggesting that dimerization with Max displaces a repressor or 
induces a conformational change in Mga 214. Although yet other Max-interacting 
proteins are likely to be identified, the basic outlines of the Max network are 
emerging. Max is a stable, ubiquitously expressed protein with little transcriptional 
activity of its own. The ability of Max to heterodimerize with several distinct groups 
of highly regulated proteins (outlined in Fig. 12) results in transcriptional activation 
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or repression directed at specific sets of target genes. Furthermore, the different 
complexes may have antagonistic properties whose functions play out at the level of 
chromatin structure. The involvement of these proteins in key biological events 
suggests that network function may be critical for growth and development. Indeed, 
the recent report that targeted deletion of Max results in very early embryonic 
lethality in mice underscores the importance of Max-dependent functions 235. 
 
 
 
                    
   
 
 
Figure 14. a) Structure of heterodimer Myc-Max bound to DNA; b) Structure of heterodimer Mad-
Max bound to DNA. 
 
 
BIOLOGICAL FUNCTIONS OF MYC 
 
The intense scrutiny with which MYC has been studied over the last 15 years derives 
mainly from its apparent involvement in a wide range of cellular processes including 
proliferation, differentiation, and tumorigenesis. In the following sections we 
summarize the evidence for MYC’s role in both normal and abnormal cellular 
behavior, with special attention to the effects of deregulated expression of MYC. 
 
 
INDUCTION BY MITOGENIC SIGNALS 
 
One of the most compelling ideas about MYC is that it functions to drive proliferation 
in response to diverse signals. This notion arises from several broad lines of evidence 
which will be briefly reviewed here. First, MYC family genes are broadly expressed 
during embryogenesis, and targeted deletions of c-MYC or N-MYC genes in mice lead 
to lethality in midgestation embryos 236-242. Second, there is a strong correlation 
between MYC  expression and proliferation. This probably applies to all MYC family 
genes but has been most extensively documented for c-MYC. MYC expression is 
known to be induced in many cell types by a wide range of growth factors, cytokines, 
and mitogens 243-245. The increase in MYC levels has been shown to occur through 
Introduction 
 
 63 
both transcriptional and post-transcriptional mechanisms 246 and appears to occur as 
an immediate early response to most mitogenic factors, suggesting that the MYC  
regulatory region is a nexus for multiple growth signal response pathways. 
Regulation of translation initiation also occurs upon mitogenic stimulation 247. For a 
number of receptors (including those for interleukin-2, macrophage colony-
stimulating factor, Epo, epidermal growth factor, platelet-derived growth factor, and 
antigens), it can be argued that induction of MYC  is a necessary, but probably not 
sufficient, component of the mitogenic response. Moreover, a failure to induce MYC  
in response to mitogenic signalling inhibits quiescent cells from entering the cycle. In 
contrast, ligands such as transforming growth factor beta and gamma-interferon, 
which in some settings act to inhibit proliferation, also cause rapid down-regulation 
of c-MYC expression 214. Thus MYC expression strongly correlates with growth and 
proliferation. 
 
 
MYC  OVEREXPRESSION 
 
The idea that Myc plays a critical role in the proliferative process is also consistent 
with results from experiments involving its ectopic expression in a variety of different 
cell types under a range of conditions. In these experiments, MYC expression is 
uncoupled from its normal physiological regulation; it is overexpressed and cannot be 
down-regulated. MYC overexpression in cycling cells has been reported to reduce 
requirements for growth factors, block exit from the cell cycle, accelerate cell 
division, and increase cell size 248-251. In the absence of survival factors, c-Myc 
overexpression elicits a proliferative response but leads to apoptosis through a 
mechanism at least partly dependent on the Arf-Mdm2-p53 pathway 252-254. 
Experiments with primary murine embryo fibroblasts (MEFs) demonstrate that loss 
of p53 or Arf greatly attenuates c-Myc-induced apoptosis and permits cells to survive 
crises and proliferate continuously in the absence of serum 253. In some cell types, 
MYC requires coexpression of other genes (such as RAS, JUN, and FOS) in order to 
drive entry into S phase 214. Myc levels rapidly diminish during the terminal 
differentiation of many cell types, and enforced expression of Myc inhibits or 
modulates terminal differentiation of myoblasts, erythroleukemia cells, adipocytes, B 
lymphoid cells, and myeloid cells among others. There is some evidence that Myc 
may not directly interfere with the programmed expression of differentiation genes 
but rather is incompatible with the cell cycle exit required for terminal differentiation 
214
. However, not all differentiation events involve cell cycle arrest, and there are 
indications that Myc may play a role in advancing cells along pathways of epidermal 
and hematopoietic differentiation. Perhaps Myc is important for changes in cell 
growth and metabolism that are required for lineage commitment. 
 
 
MYC DEREGULATION IN TUMOURS 
 
The ability of overexpressed Myc to facilitate roliferation and inhibit terminal 
differentiation fits well with the fact that tumours of iverse origins contain genetic 
rearrangements involving MYC family genes. These rearrangements include retroviral 
transductions, amplifications, and chromosomal translocations, as well as viral 
insertions, and in general are thought to increase MYC expression levels and prevent 
MYC turnoff rather than alter the function of the Myc protein through mutation 220-224, 
255
. Indeed, many of the genomic alterations in MYC result in increased MYC mRNA 
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levels through increased transcription initiation, decreased transcription attenuation, 
and augmented stability of the MYC messenger RNA 246. However, although 
mutations in the Myc protein are relatively rare, they nonetheless do occur, 
particularly in retrovirus-transduced MYC genes and in translocated MYC genes 214. It 
has been suggested that these mutations influence Myc’s transactivation ability by 
altering binding to inhibitors such as the retinoblastoma protein (Rb) or p107 or by 
modulating the effects of serine and threonine phosphorylation required for full 
transcriptional activity 214. Another possibility is that the transcriptional effects of 
mutations are secondary to alterations in Myc protein degradation. Myc family 
proteins have short half-lives, on the order of 20–30 min 256, and, although some 
instances of stabilization have been detected, it was reported earlier that in most 
tumour-associated Myc proteins, stability was not consistently affected 257, 258. More 
recently, it has been discovered that Myc degradation is carried out through the 
ubiquitin-mediated proteosome pathway 259, 260 and that many tumour-related 
mutations in Myc result in significant stabilization of the protein 260. Furthermore, 
activated Ras, an oncoprotein that collaborates with Myc in the transformation of 
primary cells, has also been reported to induce stabilization of Myc protein 261. The 
molecular consequences of Myc stabilization are unknown, but the heightened 
stability must contribute to an overall increase in Myc protein levels and is likely to 
exacerbate the transcriptional effects of Myc. In this regard it is intriguing that the 
highly conserved region called Myc box II (see below), which is essential for 
transformation and at least some of Myc’s transcriptional activities, has also been 
shown to regulate Myc protein turnover 260. There is also evidence that c-Myc 
translation can be regulated by the switch from an apparently inefficient cap-
dependent mechanism to a capindependent internal ribosome entry site within the 50 
untranslated region 262. This has been shown to occur during apoptosis as well as 
serum stimulation and has been suggested to also increase the rate of Myc translation 
during transformation 262. The idea that the tumor-associated Myc mutations serve to 
activate Myc is attractive. However, a study systematically examining the effects of 
these mutations on Myc function in tissue culture cells has revealed that they have 
little if any effect on transformation, proliferation, apoptosis, or target gene 
expression 263. Indeed the most common Myc mutation found in Burkitt’s 
lymphomas, T58I, confers decreased transforming activity, with no evident change in 
apoptosis compared with wild-type Myc. These results may reflect important 
differences between in vitro transformation assays and in vivo tumorigenesis. 
Furthermore, the maintenance of apoptotic function in these Myc mutants may simply 
come from the ability of tumoUr cells to circumvent Myc-induced cell death by other 
mechanisms such as loss of p53 or Arf activities. Studies of Myc’s role in 
oncogenesis indicate that augmented Myc levels can arise through transcriptional, 
post-transcriptional, and post-translational mechanisms. Several recent studies using 
murine models of epithelial and hematopoietic transformation have demonstrated that 
high MYC levels are continuously required to maintain the tumorigenic phenotype 264, 
265
. Because, as described above, Myc overexpression in tissue culture cells can result 
in extended proliferation, it seems likely that similar effects occur in tumour cells and 
that secondary mutations in other genes cooperate with MYC  to generate overt 
tumours. Another, not mutually exclusive role for Myc may be to induce genomic 
instability 264, 266, 267. Although the mechanism for this has not been established, 
instability might generate cooperating mutations in other genes. A large number of 
genes that cooperate with MYC in mouse models of lymphomagenesis have been 
identified. 
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While in many cases the functions of these cooperating genes are unknown, recent 
work suggests that an important subset is likely to act by abrogating the apoptotic 
function of Myc. This notion had surfaced earlier when it was found that the 
antiapoptotic protein Bcl-2 inhibited Myc-induced apoptosis in tissue culture cells 
and also promoted lymphomagenesis in mice in collaboration with Myc 268, 269. More 
recent experiments have demonstrated that in mice carrying a c-MYC transgene 
whose expression is directed to lymphoid cells (Eµ-MYC mice) 270 the MYC-
overexpressing progenitor cells exhibit high rates of spontaneous apoptosis and 
contain an intact Arf-Mdm2-p53 checkpoint pathway 271. However, lymphomas 
derived from these same mice display spontaneous inactivation of the p53 pathway 
through mutation or loss of p53 or Arf or via elevation of Mdm2 levels 271, nicely 
echoing the findings in MEFs 253 and in K562 cells, where Myc has also been shown 
to antagonize the effects of p53. As expected from these results, MYC-transgenic 
mice with hemizygous or null ARF alleles showgreatly accelerated lymphomagenesis 
271
, as do Eµ-MYC mice lacking p53 272. The importance of Arf and apoptosis in myc-
induced lymphomagenesis was strikingly underscored by experiments demonstrating 
that the protein encoded by the cooperating oncogene BMI1 is a member of the 
Polycomb class of repressors that acts to suppress expression from the Ink4a locus, 
which encodes Arf and p16INK4a 273. Moreover, loss of one or both bmi1 alleles 
inhibits lymphomagenesis in Eµ-MYC mice by increasing Arf-dependent apoptosis 
274
. This work represents perhaps the clearest example of a mechanism through which 
Myc collaborates with other genes during tumour evolution. It is likely that other 
cooperating oncogenes will similarly act to evade the apoptosis inducing activity of 
deregulated MYC. 
 
 
TRANSCRIPTION ACTIVATION AND THE Myc BOX II RIDDLE  
 
When introduced into cells, Myc can activate transcription of synthetic reporter genes 
containing promoter proximal E-boxes in both yeast and mammalian cells 215, 216. In 
addition, Myc stimulates natural E-box-containing promoters or sequences derived 
from putative Myc target genes 229, 275-277. This transcriptional activity appears to 
require two regions of Myc: the C-terminal bHLHZdomain and the N-terminal 
transactivation domain comprising the first 143 amino acids  215, 216, 225. The 
implication from these results is that Myc heterodimerizes with the ubiquitously 
expressed endogenous Max to permit sequence-specific DNA binding followed by 
Myc-dependent activation of transcription. This is consistent with many studies in 
which Myc bHLHZ mutations, leading to the loss of association with Max and/or 
decreased DNA binding, serve to abrogate Myc’s transcriptional activation and 
biological activities. Further evidence supporting the necessity of Myc-Max 
interaction for transcriptional activation comes from experiments exchanging HLHZ 
domains of Myc and Max as well as altering the dimerization specificity of the zipper 
regions so that the mutant proteins dimerize with each other but not with their wild-
type counterparts. These altered-specificity Myc and Max proteins fail to function on 
their own but are dependent on each other for stimulating transcription, proliferation, 
transformation, and apoptosis 278, 279. Interestingly, artificial Myc homodimers 
generated through altered dimerization specificity-inducing mutations are deficient in 
biological function and transcriptional activation, suggesting that an interaction with 
Max is required for Myc-Max DNA binding or transcriptional activity. The 
dependence on Max for Myc function is consistent with other studies demonstrating 
that Myc-Max complexes can be detected in cells and that Max alone has little 
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transcriptional activity 217, 225. Taken together, these experiments suggest a strong link 
between Myc-Max heterodimerization and transcriptional activation. While it seems 
likely that Myc’s transactivation is crucial to its function, these studies offer no 
formal proof. 
The region of Myc responsible for gene activation (the transactivation domain, or 
TAD) was initially defined by using fragments of c-Myc protein fused to the DNA 
binding domain of the yeast Gal4 protein 225. These experiments mapped 
transcriptional activation to a segment lying between amino acids 1 and 143, which 
encompasses two regions, Myc box I (MBI; from approximately amino acids 45–63) 
and Myc box II (MBII; approximately amino acids 128–143), containing sequences 
highly conserved among the different Myc family proteins throughout evolution. An 
N-terminal region containing both MBI and MBII (amino acids 41–143) exhibits the 
highest transcriptional activity of any of the N-terminal Myc fusion proteins (Kato et 
al 1990). In this context, deletion of either MBI or MBII, as well as at least part of the 
sequence lying between them, diminishes transcriptional activation potential 10- or 
50-fold, respectively. In biological assays, MBI deletion was found to attenuate only 
Myc transforming activity while an MBII deletion completely abolished it 280. 
Although MBII is clearly required for Myc’s transforming function, its role in 
transcription has been controversial. This is because deletion of MBII from the full-
length c-Myc protein has little effect on activation in transient assays using either 
synthetic reporter genes or promoters derived from putative Myc target genes 230. On 
the other hand, a careful study of the E-boxes in the promoter of α-prothymosin, a 
putative Myc target gene, shows that deletion of MBII eliminates Myc-induced 
activation at sites distal to the promoter while activation of more-proximal sites does 
not require MBII 281. 
 
 
                            
 
 
Figure 15.  Factors which interact with Myc. CTD domain inlude “bHLHZ”, and interacts with Max 
and other factors. NTD domain includes MB1 and MB2 regions involved in interactions with other 
proteins involved in transcriptional regulation, chromatin remodelling and apoptosis. 
 
 
 
However, this detailed analysis has not been performed on the promoters of other 
target genes. Other work bearing on MBII and transactivation involves a naturally 
occurring variant of Myc, Myc-S (residues 101–439 of wild-type Myc), which lacks 
the majority of the transactivation domain but retains MBII. Myc-S has repression 
Introduction 
 
 67 
activity but does not appear to function as a transactivator in transient assays 214. 
Nonetheless, Myc-S can induce the expression of a number of endogenous Myc target 
genes. The correlation between the biological functions and the transcriptional 
activities of MBII is controversial because MBII has been shown to be important for 
Mycinduced repression. If MBII is not required for activation, then we might well 
conclude that cell transformation by Myc is more dependent on gene repression than 
on activation. Perhaps one problem is that assays using synthetic reporter genes, 
while capable of demonstrating the intrinsic activation or repression functions of 
transcription factors, may not faithfully reproduce the chromatin context 
characteristic of endogenous target genes. Indeed, the finding that MBII interacts with 
a coactivator complex with HAT activity argues for MBII’s involvement in 
chromatin-dependent activation 231. 
 
 
MECHANISMS OF Myc TRANSACTIVATION 
 
The initial excitement generated by the iscoveries that Myc heterodimerizes with 
Max, binds DNA, and activates transcription oon gave way to the disappointing 
realization that Myc’s ability to ransactivate both engineered reporters and putative 
endogenous target genes was relatively weak generally ranging from 3- to 10-fold 
transactivation when assayed in mammalian cells. In general, transactivation domains 
function by facilitating recruitment of the basal transcription machinery either directly 
or indirectly. In nearly all cases, TAD function involves interactions with other 
proteins. Although the N-terminal Myc TAD has been shown to associate with a 
number of proteins, few provide obvious clues to the mechanism of Myc-induced 
activation. A striking exception has been the recent identification of a novel nuclear 
cofactor called TRRAP as a Myc-binding protein. TRRAP was identified by using 
Myc-TAD as an affinity reagent to isolate interacting proteins and was shown to 
require MBII for binding 282. The TRRAP sequence is homologous to the ATM/PI-3 
kinase family, although amino acid changes in the active-site region suggest that 
TRRAP is unlikely to possess kinase activity 282. Concomitantly, studies of the yeast 
Saccharomyces cerevisiae identified a protein highly related to TRRAP as a 
component of the SAGA complex, a molecular assembly containing the HAT GCN5 
and other components which facilitate TBP positioning 283, 284. 
 
 
                                                   
 
Figure 16.  Myc regulates chromatin structure in close proximity to E-Box sequenze. MBII domain 
determines the recruitment of TRRAP and GCN5.   
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A mammalian counterpart of SAGA has been identified 285. While it is still unclear 
whether this entire complex is associated with the Myc TAD, a recent report indicates 
that HAT activity coimmunoprecipitates with Myc protein both in vitro and in vivo 
231
. The recruitment of the TRRAP-GCN5 complex places Myc, and specifical ly the 
MBII region of Myc, among the group of transcriptional activators. When considered 
with earlier work indicating that Mad-Max and Mnt-Max dimers repress transcription 
through recruitment of a corepressor complex containing histone deacetylase 
(HDAC) activity 286, these findings produce a satisfyingly symmetrical view of Myc 
and Mad functions and immediately suggest that Myc and Mad antagonism stems 
from the opposing enzymatic activities directed toward histone modification. 
Although many of the Mad proteins are induced during terminal differentiation, when 
Myc is downregulated, there is also evidence of Mad family and Mnt expression in 
proliferating and quiescent cells. One possible explanation for this is that the Myc-
Max complex exhibits weak transactivation activity because its major role is not to 
fully activate targets but rather to augment the accessibility of regions of chromatin 
that have closed through the action of Mad- or Mnt-associated deacetylases. The 
region of chromatin opened through Myc would permit subsequent binding and 
activation by constitutive transcription factors (such as USF). This view of Myc-Max 
as a derepressor has received some support from recent work on the cyclin D2 
promoter. Induction of a conditional Myc can activate expression of the endogenous 
D2 gene, although Myc is inactive in transient assays with the D2 promoter. When 
Mad-Max is used to repress the promoter, then Myc can induce its expression 287. 
Interestingly, induction of cyclin D2 mRNA can also be achieved by treatment of 
cells with a HDAC inhibitor. This suggests that Myc may function most efficiently in 
a context of repression. Myc has also been linked to an SWI/SNF-like ATP-
dependent chromatin remodelling complex. A recent report showed that Myc can 
interact in vivo with the SNF5 homolog INI1 through Myc’s bHLHZ domain and that 
putative dominant interfering forms of INI1 and BRG1/hSNF2 can block Myc 
transactivation 288. 
Because INI1 is a strong candidate tumor suppressor 289, its potential role as a 
positive mediator of Myc function is somewhat puzzling. A major unanswered 
question is whether INI1 acts to displace Max from the HLHZ region or forms a 
ternary complex with Myc and Max. Perhaps binding of the INI1 complex to Myc 
alters Myc’s target specificity or transcriptional activity. In any event, it is intriguing 
to imagine that Myc recruits both histone-modifying and chromatin-remodeling 
activities. A number of other interesting proteins have been identified as being 
capable of associating with Myc and possibly influencing activation (or repression). 
For most of these proteins, functional information is limited, and it still remains to be 
determined whether interactions occur when the partners are expressed at 
physiological levels.  
 
 
TRANSCRIPTIONAL REPRESSION BY Myc 
 
For a number of years it has been observed that high levels of Myc expression in 
transformed cell lines correlate with down-regulation of specific mRNAs. These 
mRNAs include those encoding cell surface proteins such as the class I HLA 
molecules in melanoma cells, the α3 β1 integrin in neuroblastomas, and the LFA-1 
(αL β2 integrin) cell adhesion protein in transformed B cells as well as H-ferritin 214, 
289
 . More recently a DNA element required for Myc-mediated repression has been 
demonstrated to lie within the promoters of repressed target genes, indicating that 
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Myc repression is likely mediated at the transcriptional level 230. These studies have 
raised two major questions: first, what is the mechanism of Myc repression and, 
second, what roles do repression and activation play in Myc’s biological functions? 
Do repression and activation cooperate to facilitate Myc function, and are they 
antagonistic or separable independent activities? The question of mechanism again 
leads to the highly conserved MBII region. MBII is required for repression of the 
growth arrest gene GAS1 and for the down-regulation of the C/EBPα  and the 
albumin promoter in transient assays 230, 290. However, the region of Myc spanning 
residues 96–106 appears to be required for down-regulation of the cyclin D1 mRNA. 
Taken at face value, these studies indicate that there are at least two regions involved 
in repression and that these regions are contained within the transcriptional activation 
domain. Evidence suggesting that Myc repression may require both recognition of a 
specific DNA sequence and interaction with specific proteins has accumulated. A 
number of Myc-repressed targets contain a subclass of initiator elements (INRs; 
consensus, YYCAYYYYY, where Y is a pyrimidine base) which are usually, but not 
invariably, present at TATA-less promoters. Other Myc-repressed genes, such as 
GADD45, do not contain INR sequences; rather, repression appears to be mediated by 
a GC-rich region that is potentially recognized by WT1 and p53 291. INR elements are 
recognized by TFIID as well as a number of regulatory proteins, such as the 
transcription initiation factor TFII-I, YY-1, and the POZ domain protein Miz-1. 
Interestingly, the last three proteins have been reported to associate with the bHLHZ 
region of Myc 214. While there has been little follow-up on the initial reports 
involving Myc interaction with TFII-I, the association of Miz-1 with Myc has been 
recently confirmed and shown to promote stabilization of Myc by inhibiting its 
ubiquitin-dependent degradation 260. Perhaps a stable Myc-Miz1 interaction blocks 
the ability of Miz-1 to initiate transcription at INR-containing and other promoters 292. 
Similarly, high Myc levels in the cell are thought to sequester YY-1 and prevent 
transcription of one of its target genes, although another report suggests that the 
effects of YY-1 on Myc are indirect 214. There is also evidence that a naturally 
occurring Max protein variant (dMax) lacking a basic region and helix 1 can interact 
with c-Myc to block its transcriptional activation function but promote its repression 
activity 293. Perhaps the common theme underlying Myc repression is a loss of Myc 
E-box binding function, for example by displacement of Max by other bHLHZ 
binding proteins, permitting Myc to associate with and sequester positively acting 
transcription factors (e.g. Miz-1). Here the role of MBII in recruiting TRRAP-HAT 
might involve not acetylation of chromatin at E-box sites but rather an inhibitory 
acetylation of the sequestered transcription factors. Indeed, there are several reports 
of acetylation altering protein specificity and activity 294.  
Myc represses also the p21 promoter, which encodes for the cyclin-dependent kinase 
inhibitor, through the short GC-rich region just upstream of the transcription start site, 
although Myc does not appear bind directly its promoter. c-Myc does not need to 
heterodimerize with Max for repression of p21 promoter. this proximal region of the 
p21 promoter lacks Myc-canonical binding sites, but contains multiplr Sp1-binding 
sites and a potential Inr element. c-Myc mediated p21 repression is independent of 
histone deacetylase activity 295 (Fig. 17).  
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Figure 17. Multiple factors employ distinct mechanisms to repress the p21 promoter. Myc exerts their 
action through the proximal promoter region. Myc oncoproteins tend to interfere with positive 
regulators of p21 transcription, such as p21 and Miz1.  
 
 
 
What is the relative importance of Myc’s activation and repression functions? 
Unfortunately, an unequivocal answer to this question is not available. Recent data 
from DNA microarray experiments attempting to determine the effects of Myc 
overexpression on global gene expression profiles have demonstrated that multiple 
genes are both activated and repressed by Myc, with the majority being activated 214. 
However, the relative importance of activated and repressed genes cannot be 
accurately assessed at this point. Nonetheless, it seems likely that both activation and 
repression are required for Myc biological function. Only when we learn more about 
the molecular details of Myc’s transcriptional functions will we be able to generate 
mutations permitting us to distinguish the consequences of activation vs repression. 
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CELL CULTURES 
 
Human neuroblastoma Tet21/N, SHEP cells were grown in DMEM containing 10% 
FBS and 50 µg/ml gentamycin. Human neuroblastoma SH-SY-5Y, LAN-1 and LAN-
5 were grown in RPMI medium 1640 containing 20% FBS and 50 µg/ml gentamycin. 
HL60, P493, Kazumi-4,K562, KG1A cells were grown in RPMI medium 1640 
containing 10% heat-inactivated FBS and 50 µg/ml gentamycin. 
 
RNA EXTRACTION 
 
The step by step protocol is described for cultured cells grown in two 100-mm dishes, 
containing 1-1,5  x  107 cells per dish. Remove the medium and add slowly 1ml of 
PBS1X. wash and remove. Harvest the cells using trypsin treatment and when the 
cells detach from the culture dish, add 1 volume of fresh medium and  transfer the 
sunspension to a tube. Centrifuge for 5 minutes at 1000 rpm, then remove the 
supernatant. Add 1-1,5 ml of TriReagent (Sigma). Pipet gently up and down and 
incubate for 5 minutes at room temperature. Add 300 µl of chloroform and vortex for 
10 seconds. Incubate 5-10 minutes at room temperature. Centrifuge fo 5 minutes at 
12000rpm at 4°C. transfer acqueous phase in a new tube an add 750 µl of isopropyl 
alcohol. Mix gently and incubate for 5-10 minutes at room temperature. Centrifuge at 
12000rpm for 10 minutes at 4°C. remove the supernatant and wash the pellet with 1,5 
ml EtOH 75% treated with DEPC and centrifuge at 12000 rpm for 5 minutes at 4°C. 
remove the supernatant and dry the pellet. Then, resuspend the pellet in 30-50 µl of 
DEPC-treated water and heat the sample at 55°C for 10 minutes. 
 
THERMOSCRIPT RT-PCR SYSTEM 
 
The ThermoScript RT-PCR was designed for the sensitive and reproducible detection 
and analysis of a RNA molecules in a two-step process. ThermoScript RT, an avian 
reverse transcriptase with reduced RNase H activity, was engineered to have higher 
thermal stability, produces higher yields of cDNA, and produce full-length cDNA. 
cDNA synthesis was performed using total RNA with oligo(dT).  
In a 0,2-ml tube, combine primer (oligo(dT)), 2µg total RNA and dNTP 10mM mix, 
adjusting volume to 12 µl with DEPC-treated water. Denature RNA and primers by 
incubating at 65°C for 5 min and then place on ice. Vortex the 5X cDNA Synthesis 
buffer for 5 sec just prior to use. Prepare a master reaction mix on ice, with 5X 
synthesis buffer, 0,1M DTT, RNaseOUT (40U/ µl), DEPC-treated water and 
ThermoScript RT (15units/ µl). vortex this mix gently. Pipet 8 µl of master reaction 
mix into each reaction tube on ice. Transfer the sample to a thermal cycler preheated 
to the appropriate cDNA synthesis temperature and incubate for 100 min at 50°C. 
terminate the reaction by incubating at 85°C for 5 min. Add 1 µl of RNase H and 
incubate at 37°C for 20min. Add 80 µl of MQ-water for each reaction and store at -
20°C or use for qPCR immediately. Use only 2-5 µl of the cDNA synthesis reaction 
for qPCR. 
 
SYBR GREENER qPCR   
 
SYBR GreenER qPCR SuperMix (Invitrogen) for ICycler is a ready to use cocktail 
containing all components, except primers and template, for real-time quantitative 
PCR (qPCR) on ICycler BioRad real time instruments that support normalization 
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with Fluoresceina Reference Dye at final concentration of 500nM. It combines a 
chemically modified “hot-start” version of TaqDNA polymerase with integrated 
uracil DNA glycosilase (UDG) carryover prevention technology and a novel 
fluorescent dye to deliver excellent sensitivity in the quantification of target 
sequences, with a linear dose response over a wide range of target concentrations. 
SYBR GreenER qPCR SuperMix for ICycler was supplied at a 2X concentration and 
contains hot-start TaqDNA polymerase, SYBR GrenER fluorescent dye, 1 µM 
Fluorescein Reference Dye, MgCl2, dNTPs (with dUTP instead of dTTp), UDG, and 
stabilizers. The SuperMix formulation can quantify fewer than 10 copies of a target 
gene, has a broad dynamic range, and is compatible with melting curve analysis. The 
TaqDNA polymerase provided in the SuperMix has been chemically modified to 
block polymerase activity at ambient temperatures, allowing room-temperature set up 
and long term storage at 4°C. Activity is restored after a 10-minutes incubation in 
PCR cycling, providing an automatic hot start for increased sensitivity, specificity 
and yield. UDG and dUTP in the SuperMix prevent the reamplification of carryover 
PCR products between reactions. dUTP ensures that any amplified DNA will contain 
uracil, while UDG removes uracil residues from single or double-stranded DNA. A 
UDG incubation step before PCR cycling destroys any contaminating dU-containing 
product from previous reactions. UDG is then inactivated by the high temperatures 
during normal PCR cycling, thereby allowing the amplification of genuine target 
sequences. Fluorescein is included at a final concentration of 500nM to normalize the 
fluorescent signal on instruments that are compatible with this option. Fluorescein 
can ajust for non-PCR-related fluctuations in fluorescence between reactions and 
provides a stable baseline in multiplex reactions. Program real time instrument for 
PCR reaction as shown following: 50°C for 2 minutes hold (UDG incubation), 95°C 
for 10 minutes hold (UDG inactivation and DNA polymerase activation), 40 cycles 
of: 95°C for 15 seconds and 60°C for 60 seconds. For multiple reactions, prepare a 
master mix of common components, add the appropriate volume to each tube or plate 
well, and then the unique reaction components (e.g. template, forward and reverse 
primers at 200nM final concentration). Cap or seal the reaction tube/PCR plate, and 
gently mix. Make sure that all components are at the bottom of the tube/plate, 
centrifuge briefly and place reactions in a pre-heated real-time instrument 
programmed as described above.  
 
MTT ASSAY 
MTT assay is a laboratory test and a standard colorimetric assay (an assay which 
measures changes in colour) for measuring cellular proliferation (cell growth). It is 
used to determine cytotoxicity of potential medicinal agents and other toxic materials. 
Yellow MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a 
tetrazole) is reduced to purple formazan in the mitochondria of living cells. A 
solubilization solution (usually either dimethyl sulfoxide or a solution of the detergent 
sodium dodecyl sulfate in dilute hydrochloric acid) is added to dissolve the insoluble 
purple formazan product into a colored solution. The absorbance of this colored 
solution can be quantified by measuring at a certain wavelength (usually between 500 
and 600 nm) by a spectrophotometer. This reduction takes place only when 
mitochondrial reductase enzymes are active, and therefore conversion is directly 
related to the number of viable (living) cells. When the amount of purple formazan 
produced by cells treated with an agent is compared with the amount of formazan 
produced by untreated control cells, the effectiveness of the agent in causing death of 
cells can be deduced, through the production of a dose-response curve.  
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MTT stock solution: 5mg/ml (Promega) in RPMI-1640 without phenol red. This 
solution is filtered through a 0,2 µm filter and stored at 2-8°C. 
MTT working solution: 1:10 diluition of the 5mg/ml stock 
Wash cultured cells with warm RPMI-1640 withot phenol red. Prepare MTT working 
solution. Add MTT working solution into wells being assayed, for example 1 ml for 
each well of 12-well plate. Incubate at 37°C for 30min to 3hrs (this time depends on 
cell density and cell type). At the end of the incubation period, the medium can be 
moved if working with attached cells. the converted dye is solubilized with 1ml 
acidic isopropanol (0,04M HCl in absolute isopropanol). Pipette up and down several 
times to make sure the converted dye dissolves completely. Transfer the dye solution 
with the cells into a 1,5ml eppendorf tube and centrifuge at 13000 rpm for 2 min. 
transfer the supernatant into a new eppendorf tube. Absorbance of the converted dye 
is measured at a wavelenght of 570nm with background subtraction at 650nm. For the 
measurement, use Beckman DU-600 Spectophotometer and disposable plastic. 
MULTI-DRUG EFFLUX ASSAY  
 
The Multidrug Resistance Direct Dye Efflux Assay Kit (Chemicon) includes two of 
the best characterized and most commonly used multidrug resistance ABC transporter 
substrates, DiOC2(3) and rhodamine 123. The kit enables researchers to directly 
assess the functional activity of the MDR1, MRP1 and BCRP membrane pumps in 
living cells under physiologic conditions by directly measuring the relative 
fluorescence of cell populations that actively extrude fluorescent multidrug resistance 
transport substrates. 
 
Cold Efflux Buffer – In a sterile field, mix the contents of the 200 ml sterile 5x 
RPMI-1640 bottle (200 ml) and 800 ml sterile water (tissue culture grade) in a sterile 
1 liter bottle. With a sterile pipet, add 34.5 ml of the sterile 30% BSA to obtain sterile 
efflux buffer. If desired, to maintain sterility, add 1 ml of Gentamicin Solution, 
1000x, and mix. Chill on ice for at least 2 h before using in the assay. Open the 
container only in a sterile environment. Store unused portion at 4ºC for up to 12 
months. Discard if contamination is evident. Approximately 10 ml Efflux Buffer total 
is required for each test.  
Warmed Efflux Buffer – Remove an aliquot of Cold Efflux Buffer and warm to 37ºC 
at least one hour before use in the assay; keep in water bath at 37°C until use.  
DiOC2(3) Loading Buffer – On the day of the assay, dilute DiOC2(3) Solution 
1:1000 in the desired amount of Cold Efflux Buffer. A volume of 250 µl per test is 
required. Invert 5-10 times to mix. Keep on ice until adding to cells. Protect solutions 
containing DiOC2(3) from prolonged exposure to light.  
Rhodamine 123 Loading Buffer – On the day of the assay, dilute Rhodamine 123 
Solution 1:100 in the desired amount Cold Efflux Buffer. A volume of 250 µl per test 
is required. Invert 5-10 times to mix. Keep on ice until adding to cells. Protect 
solutions containing Rhodamine 123 from prolonged exposure to light.  
Note: The user has the choice of using either DiOC2(3) or Rhodamine 123, or both 
as two separate experimental points, as an efflux probe in a given experiment, 
depending on the application of the user.  
Warmed Efflux Buffer containing 22 µM Vinblastine – On the day of the assay, 
dilute Vinblastine Solution 1:1000 in Warmed Efflux Buffer. For tests to assess 
vinblastine inhibition of dye efflux, a volume of 1 ml per test is required. Keep at 
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37ºC until use. Warmed Efflux Buffer containing DMSO – On the day of the assay, 
dilute DMSO 1:1000 in Warmed Efflux Buffer. For tests to assess dye efflux in the 
absence of vinblastine, a volume of 1 ml per test is required. Keep at 37ºC until use 
Propidium Iodide Buffer – Dilute Propidium Iodide Stock Solution 1:50 in Cold 
Efflux Buffer before use in flow cytometry. A volume of 0.5 ml per test is required. 
Protect solutions of Propidium Iodide from prolonged exposure to light. (Optional) 
Cold efflux buffer or other antibody staining buffer containing 0.01% sodium azide. 
Needed if staining with an antibody will be performed after the efflux assay. 
 
             
Assay Protocol 
 
Note: Because membrane transport mediated by MDR1, MRP1 and BCRP is a 
complex process that is highly dependent on multiple factors, such as physiological 
conditions of the target cell population, intracellular ATP status, the degree of 
expression of MDR1, MRP1 and BCRP, and fluorescent dye concentration, some 
parameters may need to be adjusted for each experimental series. At the same time, it 
is essential that all temperature conditions and media formulations strictly 
correspond to the underlying protocol. 
 
Grow cell line of choice in its appropriate medium. The cells should be kept in media 
lacking multidrug resistance substrates for at least one week (selective drugs may 
interfere with dye efflux). Antimicrobial agents appear not to interfere with multidrug 
resistance ABC transporter function and may be included in the media. Media should 
be replaced one day before the assay. Approximately 2.5 x 100000 cells are required 
for each test. Adherent cells should be dislodged from plates by standard methods, 
and used in the assay in suspension. Count cells. Calculate the total number of cells 
required for the number of tests to be performed, and take volume necessary to get 
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the desired number of cells. Centrifuge cells at 200 x g for 5 min. Discard the 
supernatant and retain the cell pellet. Resuspend the cell pellet at 1 x 106 cells/ml in 
cold DiOC2(3) or Rhodamine 123 Loading Buffer. 
 
Note: At this step, cells intended to be used in separate tests can be loaded with the 
fluorescent dye of choice in one tube. Minimize light exposure of dye-containing 
samples by handling quickly when in ambient light, and performing incubations in 
containers that offer protection from light. 
 
 
 
For loading with DiOC2(3), incubate for 15 min on ice. For loading with Rhodamine 
123, incubate for 30 min to 2 h on ice. Centrifuge cells at 200 x g for 5 min. Remove 
supernatant. Resuspend pellet in 2.5 ml Cold Efflux Buffer per 106 cells. Repeat 
previous step. At this point, distribute resuspended cells into different tubes for each 
different treatment. For an initial confirmation of specificity of efflux, use 3 tubes, 
each containing 625 µl (2.5 x 105 cells).  
 
Note: An initial characterization of the time course of dye efflux by each individual 
cell type is strongly recommended. For time course experiments, the quantity of cells 
undergoing the same treatment can initially be put in the same tube. For example, for 
n time points, put n x 2.5 x 100000 cells(n x 625 µl at the cell density given in step 8) 
into one tube for each treatment. 
 
Centrifuge cells at 200 x g for 5 min. Remove supernatant. Resuspend cells in the 
following media, at 1 ml per test containing 2.5 x 100000 cells: 
 
A. 37ºC-Warmed Efflux Buffer containing DMSO 
B. 37ºC-Warmed Efflux Buffer containing vinblastine 
C. Ice-Cold Efflux Buffer 
 
Immediately transfer tubes A and B to a 37ºC water bath. Do not perform incubations 
in an incubator, which does not have adequate temperature control. Keep tube C on 
ice. Incubate for the desired time period. 
 
Note: For time course experiments, remove 1 ml aliquots from the incubation tube, 
add to Cold Efflux Buffer, and immediately return the incubation tube to its proper 
incubation temperature to continue the time course. Cell types with high levels of 
MDR1 expression (e.g. KB-8-5-11 or KBV-1 cell lines) tend to efflux dyes within 15 
min. Cell types expressing lower amounts or endogenous MDR1 (e.g. normal 
lymphocytes or hematopoietic stem cells) will require 30 min to 3 h to efflux dyes. 
 
Add 5 ml Cold Efflux Buffer per test, and immediately put the tube on ice. 
 
Note: Low temperatures stop the efflux reaction. For time course experiments, the 
earlier time points may be kept on ice at this point until all of the samples are 
collected. 
 
Centrifuge at 200 x g for 5 min in a refrigerated centrifuge at 4ºC. Remove 
supernatant. Resuspend cells in 1 ml per test (2.5 x 105 cells) Cold Efflux Buffer. 
Centrifuge at 200 x g for 5 min in a refrigerated centrifuge at 4ºC. Remove 
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supernatant.(Optional) If antibody staining of cells subjected to the efflux assay is 
desired, use a PE-conjugated antibody and perform the staining using ice-cold buffers 
after the efflux phase is completed For analysis by flow cytometry, resuspend cells in 
0.5 ml per test Cold Propidium Iodide Buffer. For analysis in a fluorescence plate 
reader, resuspend cells in 0.25 ml per test Cold Efflux Buffer. Maintain on ice until 
analysis by flow cytometry or fluorometry. Cells may be kept on ice for several 
hours. Longer times are not recommended, as prolonged exposure to the dyes and 
vinblastine can be toxic to the cells. Analyze by flow cytometry, with DiOC2(3) and 
rhodamine 123 on FL1, PE (if employed in step 18) on FL2, and PI on FL3. Collect 
2500-10,000 events. Alternatively, cell suspensions can be dispensed into the wells of 
a blackwalled 96-well plate and measured in a fluorescence plate reader at an 
excitation wavelength of 485 nm and an emission wavelength of 530 nm. 
 
 
ChIP- CHROMATIN IMMUNOPRECIPITATION 
 
The step by step protocol is described for cultured cells grown in two 100-mm dishes, 
containing 1-1,5  x  107 cells per dish. Two 100-mm dishes are used for each 
immunoprecipitation. In the specific case the protocol is intended for human 
neuroblastoma cells growing adhesively. Minor adjustments have to be introduced for 
other cell types especially for those growing in suspension. Based on our experience, 
one of the most critical steps in performing ChIP regards the conditions of chromatin 
fragmentation, which need to be empirically set up for each cell types employed. 
 
In each plate add 270 µl formaldehyde from a 37% stock solution and mix 
immediately. Incubate samples on a platform shaker for 10 minutes at room 
temperature. In each plate add 500 ml glycine from a 2,5 M stock solution and mix 
immediately. Incubate on a platform shaker for 10 minutes at room temperature. 
Transfer the plates in ice and remove the medium. Harvest the cells with a scraper 
and then centrifuge at 1500 rpm for 4 minutes in cold centrifuge, then keep  samples 
on ice. Remove the supernatant and wash pellet 3 times with 10 ml ice-cold PBS1X/ 
1 mM PMSF. After each washing centrifuge at 1500 rpm for 5 minutes at 4°C. 
Remove supernatant and resuspend pellet in 500 µl ice-cold Cell Lysis Buffer. Pipet 
up and down 10-20 times, then incubate on ice for 10 minutes. Centrifuge at 3000 
rpm for 5 minutes at 4°C. Remove supernatant and resuspend pellet in 600 µl ice-cold 
RIPA buffer. Pipet up and down 10-20 times, then incubate on ice for 10 minutes. 
Sonication of crosslinked cells is performed in two distinct steps. First, cells are 
sonicated with a Branson Sonifier 2 times for 15 seconds at 40% setting. Next, cell 
samples are further sonicated with the Diogene Bioruptor for 20 minutes at high 
potency in a tank filled with ice/water in order to keep cell samples at low 
temperature during sonication. Centrifuge samples at 14000 rpm for 15 minutes at 
4°C. Transfer supernatant to a new tube and pre-clear lysate by incubating it with 50 
µl of Immobilized Protein A (Pierce) for 15 minutes in the cold room at constant 
rotation. Centrifuge samples at 3000 rpm for 5 minutes at 4°C.  Take the supernatant, 
after having saved 50 µl aliquot for preparation of INPUT DNA, and add 5 µg of 
specific antibody. Rotate the sample O/N in the cold room. Add 50 µl of Immobilized 
Protein A (Pierce) and incubate by constant rotation for 30 minutes at room 
temperature. Centrifuge the sample at 4000 rpm for 5 minutes at room temperature. 
Remove the supernatant and proceed to wash the beads. For each wash, incubate the 
sample by constant rotation fro 3 minutes at room temperature and the centrifuge at 
4000 rpm for 2 minutes at room temperature. Wash 4 times with 1 ml Ripa Buffer. 
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Wash 4 times with 1 ml Washing Buffer. Wash 2 times with 1 ml TE buffer. Remove 
the supernatant and add 200 µl TE buffer to the beads. Add 10 µg RNAse A and 
incubate at 37°C for 30 minutes. Add 50 µl Proteinase K Buffer 5X and 6 µl 
Proteinase K (19 mg/ml). Then, incubate at 65°C in a shaker at 950 rpm for 6 hrs. 
Centrifuge at 14000 rpm for 10 minutes at 4°C, then transfer the supernatant (250 µl) 
to a new tube.  
Extract once with phenol/chlorophorm/isoamylalcohol. Recover the aqueous phase 
(200 µl) and transfer to a new tube. Add 100 µl TE buffer to the remaining 
phenol/chlorophorm fraction and re-extract DNA. Recover the aqueous phase and add 
it to the previous one. Extract once with chlorophorm/iso-amyl-alcohol. Recover the 
aqueous phase (200 µl) and transfer to a new tube. Add 1 µl glycogen (Glycogen is 
20 mg/ ml stock solution), 10 µg Salmon Sperm, 1/10 volumes Na-acetate 3M pH 
5.2, and 2.5 volumes of cold ethanol100% Vortex and precipitate at -80°C for 40 
minutes. Centrifuge at 14000 rpm for 30 minutes at 4°C. Remove the supernatant and 
wash pellet with 200 µl EtOH 70%. Resuspend IP-DNA and INPUT samples in 50-
100 µl 10 mM TrisHCl pH 8.  Use 2-4 µl of IP-DNA for Real Time PCR analysis. 
 
Cell Lysis Buffer:                                RIPA Buffer                  Washing buffer 
5 mM PIPES pH 8                                150mM NaCl                   100mMTrisHCl pH 8 
         85 mM KCl                                           1% NP40                         500mM LiCl  
         0,5% NP40                                            0,5% NaDoc                    1% NP40 
         1 mM PMSF                                          0,1% SDS                        1% NaDoc 
Protease inhibitor cocktail  (Roche)      50 mM TrisHCl pH 8 
                                                               1 mM PMSF 
                                                               Protease inhibitor cocktail (Roche) 
 
 
DUAL-STEP CHROMATIN IMMUNOPRECIPITATION 
 
The step by step protocol is described for cultured cells grown in two 100-mm dishes, 
containing 1-1,5  x  107 cells per dish. Two 100-mm dishes are used for each 
immunoprecipitation. In the specific case the protocol is intended for human 
neuroblastoma cells growing adhesively. Minor adjustments have to be introduced for 
other cell types especially for those growing in suspension. Based on our experience, 
one of the most critical steps in performing ChIP regards the conditions of chromatin 
fragmentation, which need to be empirically set up for each cell types employed. 
 
Remove medium and add 2 ml PBS 1X/ 1 mM PMSF to each plate  and scrape cells 
at room temperature. Pool together the cells from two plates and centrifuge at 1500 
rpm for 5 minutes at room temperature. Wash cell pellet with 20 ml PBS1X/ 1 mM 
PMSF at  room temperature and centrifuge at 1500 rpm for 5 minutes. Repeat this 
step 3 times. Resuspend pellet in 20 ml PBS1X/ 1 mM PMSF.  Add disuccinimidyl 
glutarate (DSG) to a final concentration of 2mM and mix immediately. DSG is 
prepared as a 0.5 M stock solution in DMSO. (Note1) Incubate for 45 minutes at 
room temperature on a rotating wheel at medium speed (8-10 rpm). At the end of 
fixation, centrifuge the sample at 1500 rpm for 10 minutes at room temperature. 
Wash cell pellet with 20 ml PBS1X/ 1 mM PMSF at room temperature and centrifuge 
at 1500 rpm for 5 minutes. Repeat this step 3 times. Resuspend pellet in 20 ml 
PBS1X/ 1 mM PMSF. Add 540 µl formaldehyde from a 37% stock solution and mix 
immediately. Incubate samples on a rotating wheel for 15 minutes at room 
temperature. Add 1 ml glycine from a 2,5 M stock solution and mix immediately. 
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Incubate on a rotating wheel for 10 minutes at room temperature. Centrifuge samples 
at 1500 rpm for 4 minutes in cold centrifuge, then keep  samples on ice. Remove the 
supernatant and wash pellet 3 times with 10 ml ice-cold PBS1X/ 1 mM PMSF. After 
each washing centrifuge at 1500 rpm for 5 minutes at 4°C. Remove supernatant and 
resuspend pellet in 500 µl ice-cold Cell Lysis Buffer. Pipet up and down 10-20 times, 
then incubate on ice for 10 minutes. Centrifuge at 3000 rpm for 5 minutes at 4°C. 
Remove supernatant and resuspend pellet in 600 µl ice-cold RIPA buffer. Pipet up 
and down 10-20 times, then incubate on ice for 10 minutes. Sonication of crosslinked 
cells is performed in two distinct steps. First, cells are sonicated with a Branson 
Sonifier 2 times for 30 seconds at 40% setting. Next, cell samples are further 
sonicated with the Diogene Bioruptor for 20 minutes at high potency in a tank filled 
with ice/water in order to keep cell samples at low temperature during sonication. 
(Note 3)  Centrifuge samples at 14000 rpm for 15 minutes at 4°C. Transfer 
supernatant to a new tube and preclear lysate by incubating it with 50 µl of 
Immobilized Protein A (Pierce) for 15 minutes in the cold room at constant rotation. 
Centrifuge samples at 3000 rpm for 5 minutes at 4°C.  Take the supernatant, after 
having saved 50 µl aliquot for preparation of INPUT DNA, and add 5 µg of specific 
antibody. Rotate the sample O/N in the cold room. Add 50 µl of Immobilized Protein 
A (Pierce) and incubate by constant rotation for 30 minutes at room temperature. 
Centrifuge the sample at 4000 rpm for 5 minutes at room temperature. Remove the 
supernatant and proceed to wash the beads. For each wash, incubate the sample by 
constant rotation fro 3 minutes at room temperature and the centrifuge at 4000 rpm 
for 2 minutes at room temperature. Wash 4 times with 1 ml Ripa Buffer. Wash 4 
times with 1 ml Washing Buffer. Wash 2 times with 1 ml TE buffer. Remove the 
supernatant and add 200 µl TE buffer to the beads. Add 10 µg RNAse A and incubate 
at 37°C for 30 minutes. Add 50 µl Proteinase K Buffer 5X and 6 µl Proteinase K (19 
mg/ml). Then, incubate at 65°C in a shaker at 950 rpm for 6 hrs. Centrifuge at 14000 
rpm for 10 minutes at 4°C, then transfer the supernatant (250 µl) to a new tube.  
Extract once with phenol/chlorophorm/isoamylalcohol. Recover the aqueous phase 
(200 µl) and transfer to a new tube. Add 100 µl TE buffer to the remaining 
phenol/chlorophorm fraction and re-extract DNA. Recover the aqueous phase and add 
it to the previous one. Extract once with chlorophorm/iso-amyl-alcohol. Recover the 
aqueous phase (200 µl) and transfer to a new tube. Add 1 µl glycogen (Glycogen is 
20 mg/ ml stock solution), 10 µg Salmon Sperm, 1/10 volumes Na-acetate 3M pH 
5.2, and 2.5 volumes of cold ethanol100% Vortex and precipitate at -80°C for 40 
minutes. Centrifuge at 14000 rpm for 30 minutes at 4°C. Remove the supernatant and 
wash pellet with 200 µl EtOH 70%. Resuspend IP-DNA and INPUT samples in 50-
100 µl 10 mM TrisHCl pH 8 Use 2-4 µl of IP-DNA for Real Time PCR analysis. 
 
 
 
Notes 
1).We have tested several crosslinking agents including DSG (disuccinimdyl 
glutarate), EGS [ethylene glycol bis(succinimidylsuccinate], DMA (dimethyl 
adipimidate) and DSS (disuccinidimyl suberate). In our conditions, DSG was the one 
that worked best, although we also obtained good results with EGS. 
2) Sometimes, insoluble aggregates form when DSG is added to cells resuspended in 
PBS 1X . However, this seems not to preclude the efficiency of the crosslinking 
reaction.  
3) Through this procedure we could efficiently fragment chromatin in a range 
between 500 and 200 bp. As stated above, this is a critical step that must be 
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empirically set up for each cell line tested. For example, HL-60 cells that grow in 
suspension, are sonicated with a Branson Sonifier 4 times for 30 seconds at 40% 
setting and subsequently with the Biogene Bioruptor at a full power for 30 minutes. 
This procedure allows fragmentation of HL-60 chromatin to a size range of 1000-500 
bp. 
 
 
LUCIFERASE ASSAY 
 
The Dual-Luciferase® Reporter (DLR.) Assay System (Promega) provides an 
efficient means of performing dual-reporter assays. In the DLR. Assay, the activities 
of firefly (Photinus pyralis) and Renilla (Renilla reniformis, also known as sea pansy) 
luciferases are measured sequentially from a single sample. The firefly luciferase 
reporter is measured first by adding Luciferase Assay Reagent II (LAR II) to generate 
a stabilized luminescent signal. After quantifying the firefly luminescence, this 
reaction is quenched, and the Renilla luciferase reaction is simultaneously initiated by 
adding Stop & Glo® Reagent to the same tube. The Stop & Glo® Reagent also 
produces a stabilized signal from the Renilla luciferase, which decays slowly over the 
course of the measurement. In the DLR. Assay System, both reporters yield linear 
assays with subattomole sensitivities and no endogenous activity of either reporter in 
the experimental host cells. Furthermore, the integrated format of the DLR. Assay 
provides rapid quantitation of both reporters either in transfected cells or in cell-free 
transcription/translation reactions. 
 
Note: The LAR II, Stop & Glo® Reagent and samples should be at ambient 
temperature prior to performing the Dual-Luciferase® Assay. Prior to beginning this 
protocol, verify that the LAR II and the Stop & Glo® Reagent have been warmed to 
room temperature. 
 
The assays for firefly luciferase activity and Renilla luciferase activity are performed 
sequentially using one reaction tube. The following protocol is designed for use with 
a manual luminometer or a luminometer fitted with one reagent injector.  
Predispense 100µl of LAR II into the appropriate number of luminometer tubes to 
complete the desired number of DLR. Assays. Program the luminometer to perform a 
2-second premeasurement delay, followed by a 10-second measurement period for 
each reporter assay. Carefully transfer up to 20µl of cell lysate into the luminometer 
tube containing LAR II; mix by pipetting 2 or 3 times. Do not vortex. Place the tube 
in the luminometer and initiate reading. 
 
Note: We do not recommend vortexing the solution at Step 3. Vortexing may coat the 
sides of the tube with a microfilm of luminescent solution, which can escape mixing 
with the subsequently added volume of Stop & Glo® Reagent. This is of particular 
concern if Stop & Glo® Reagent is delivered into the tube by automatic injection. 
 
If using a manual luminometer, remove the sample tube from the luminometer, add 
100µl of Stop & Glo® Reagent and vortex briefly to mix. Replace the sample in the 
luminometer, and initiate reading.Discard the reaction tube, and proceed to the next 
DLR. Assay. 
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CO-IMMUNOPRECIPITATION AND GST-PULL DOWN ASSAYS 
 
The interaction between different proteins is assessed by immunoprecipitation and 
Western blotting. Cells are washed two times in PBS 1X+ PMSF (0,1%) and lysed in 
the following buffer for isolation of nuclei: Hepes 10mM, NaCl 50 mM, EDTA 
1mM, DTT 1mM, NaPirophosphate 1 mM, NaOrtovanadate 1 mM, 
Nafluorophosphate 1 mM, PMSF 1 mM, protease inhibitor (Complete, ROCHE). 
Nuclei are lysed in  Tris-Cl pH 7,5 50 mM, NaCl 150 Mm, EDTA 10 mM, DTT 1 
mM, protease inhibitors. Nuclear lysate (1 mg) is immunoprecipitated with  antibody 
to HDAC (Upstate), N-Myc, SP1 (Upstate) overnight at 4°C. The day after, specific 
immunoprecipitated material is incubated with 40µl of slurry-beads protein A, 
allowing the link between our specific antibody and protein A. The beads with 
immunocomplexes are washed five times with  nuclear lysis buffer + NP40 0,25% 
and boiled in Laemmli sample buffer for  5 min at 100°C.  Eluted proteins are 
separated by SDS-PAGE and analyzed by Western blot. 
For GST pull-down assay HEK293 cells are transfected with pRK7-SP1-HA 
construct and harvest 48 hrs after transfection. Cell lysates are pre-cleared by 
incubation with GST-saturated glutathione beads for 1 hr. lysates are incubated with 
GST-N-Myc 1-88, GST-N-Myc 82-254, GST-N-Myc 249-361 and GST-N-Myc 336-
644 for 1 hr at 4°C followed by incubation with glutathione  beads for 1hr. bound 
protein are eluted with sample buffer and subjected to SDS/PAGE and analyzed by 
Western blot. 
 
SOUTHERN BLOT 
Southern blotting is the transfer of DNA fragments from an electrophoresis gel to a 
membrane support. The transfer or a subsequent treatment results in immobilization 
of the DNA fragments, so the membrane carries a semipermanent reproduction of the 
banding pattern of the gel. After immobilization, the DNA can be subjected to 
hybridization analysis, enabling bands with sequence to a labeled probe to be 
identified. The blotting is performed onto a positive charged nylon membrane with an 
alkaline buffer. The advantage of this combination is that no post-transfer 
immobilization step is required, as the positively charged membrane binds DNA 
irreversibly under alkaline transfer conditions. The method can also be used with 
neutral nylon membranes but less DNA will be retained. 
Digest the DNA samples with appropriate restriction enzymes, run in a agarose gel 
with appropriate DNA size markers, stain with ethidium bromide, and photograph 
with a ruler laid alongside the gel so that bend positions can later be identified on the 
membrane. The gel should contain the minimum agarose concentration needed to 
resolve bands in the area of interest and should be < 7mm thick. The amount of DNA 
that must be loaded depends on the relative abundance of the target sequence that will 
subsequently be sought by hybridization probing. Rinse the gel in distilled water and 
place in a clean glass dish containing ~10 gel volumes of 0,25 M HCl. Shake slowly 
on a platform shaker for 30 min at room temperature. This step results in a partial 
depurination of the DNA fragments, which in turn leads to strand cleavage. The 
length reduction improves the transfer of longer molecules.pour off the HCl and rinse 
the gel with distilled water. Add ~10 vol of 0,4M NaOH into the dish and shake 
slowly on a platform shaker for 20 min. This is the denaturation step. Set up the 
transfer via downward capillary transfer in a glass dish filled with enough 0,4M 
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NaOH solution. The transfer pyramid is composed of 2-3 cm of paper towels, 
Whatman 3MM nylon membrane and gel. An O/N transfer is sufficient for most 
purposes. Make sure that the reservoir of 0,4M NaOH does not run dry during the 
transfer. At the end of the transfer remove the paper towels and filter paper and 
recover the membrane. Rinse the membrane in 2XSSC, place on a sheet of Whatman 
3MM filter paper, and allowto air dry. Baking or UV crosslinking is not neede with a 
positevely charge membrane; in fact UV crosslinking is detrimental. Store the 
membranes dry between sheets of Whatman 3MM paper for several months at room 
temperature. 
HYBRIDIZATION ANALYSIS OF DNA BLOTTED 
Heat pre-hybridization buffer at 65°C and equilibrate the membrane in 50ml of this 
buffer. Incubate on a rotor for 1hr. Then eliminate this solution and incubate with 
10ml of pre-hybridization buffer for 3hrs, adding 1mg of placental DNA previously 
denatured at 100°C for 5 min. Labell the probe. The Megaprime (Biosciences) 
systems allow DNA from a variety of sources to be labelled in vitro to high specific 
activity with 32P and other radionuclides. Dissolve the probe to be labelled to a 
concentration of 2,5-25ng/µl in TE buffer. Place the rquired tubes from the 
Megaprime system, with the exception of the enzyme, at room temperature to thaw. 
Leave the enzyme at -15°C to -30°C until required, and return immediately after use. 
Place 25ng of template DNA into a microcentrifuge tube and to it add 5 µl of primers 
and the appropriate volume of water to give a total volume of 50µl in the final 
reaction. Denature by heating to 95-100°C for 5 minutes in a boiling water bath. Spin 
briefly in a microcentrifuge to bring the contents to the bottom of the tube. Keeping 
the tube at room temperature and add the nucleotides and reaction buffer followed by 
radiolabelled dNTPs and enzyme. Mix gently by pipetting up and down and cap the 
tube. Spin for a few seconds in a microcentrifuge to bring the contents to the bottom 
of the tube. Incubate at 37°C for 10 minutes and then stop the reaction by the addition 
of 5µl of 0,2M EDTA. Denature the labelled DNA by heating to 100°C for 5 min, 
then chill on ice. At the end of pre-hybridization remove the buffer and add 10 ml of 
hybridization buffer with the denatured probe. Incubate O/N at 65°C and then wash 
2-3 times the membrane with 50ml of washing buffer at 65°C for 45 minutes for each 
washing. Place the membrane in a x-ray film cassette with a sheet of autoradiography 
film on top of themembrane. Close the cassette and expose at -80°C for 1 week.
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TRANSCRIPTIONAL REGULATION OF ABC TRANSPORTERS GENES IN 
NEUROBLASTOMA CELL LINES. 
 
Some ABC genes, such as MRP1/ABCC1 and MRP4/ABCC4 represent predictive 
prognostic markers of a poor outcome for children neuroblastoma 44, 72. A strong 
association between N-MYC amplification or overexpression and enhanced levels of  
MRP1 and MRP4 has been demonstrated in neuroblastoma tumours 44, 72.  It has been 
previously shown that N-Myc regulates the MRP1 gene, interacting with a putative E-
box element in addition to other cis-acting factors 75. It is therefore of interest to 
investigate whether other members of ABC genes family can be directly regulated by 
N-Myc oncoprotein. To address this issue we compared transcriptional profile of the 
48 human ABC genes with that of N-MYC. We used a NB cell line stably transfected 
with N-MYC construct, the transcription of which is under the control of the rTET-
inducible expression system (Tet21/N) 296. The transcriptional level of each ABC 
gene was evaluated by qRT-PCR during a time course with tetracycline and cluster 
analysis was performed using CIMminer microarray tool (Fig.1). ABC genes can be 
grouped in four different clusters, differently correlated with N-MYC expression. A 
first group represents ABC genes, the expression of which don’t change during time 
course with tetracycline; a second group identifies ABC genes, which are positively 
correlated with N-MYC down-regulation; whereas a  third group of ABC genes 
presents a transcriptional profile contro-correlated with N-MYC expression. Finally, 
transcriptional profile of several ABC transporters genes are not here represented 
because they are not expressed in Tet21/N cell line. Particularly interesting is that 
three ABC transporters, and precisely MRP1/ABCC1, MRP4/ABCC4 and 
MRP3/ABCC3, have great clinical relevance. High levels of  MRP1/ABCC1 and 
MRP4/ABCC4, associated with low levels of MRP3/ABCC3 represent the most 
predictive marker of poor clinical outcome in neuroblastoma (Haber et al, data 
unpublished).  
                                          
 
 
Figure 1.  Relative mRNA expression of ABC transporter genes was determined in TET/21-N 
neuroblastoma cells as a function of N-Myc downregulation.  (A) Cluster analysis performed using the 
CIMMiner microarray tool. (B) Relative expression of ABC transporter genes positively (top) or 
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negatively (bottom) regulated by N-MYC in TET/21-N cells at different time points of tetracycline 
treatment. 
Although MRP3 shows structure homology with MRP1 and MRP4 transporters, 
normally involved in chemoresistance,  there is no evidence of  a clear association 
between MRP3 and drug resistance phenomenon. To verify that ABC transcription 
profile was also correlated with that of N-MYC in other cell lines, their mRNA levels 
were evaluated in five human neuroblastoma cell lines, which express different levels 
of N-Myc. Figure 2b shows a cluster analysis diagram of ABC expression across 
these five neuroblastoma cell lines. ABC genes upregulated by N-Myc were highly 
expressed in Lan-1 and SK-N-BE where the oncogene is amplified or overexpressed, 
whereas their expression was lower in SH-SY-5Y, SK-N-SH and SHEP (with low 
level of N-MYC). Otherwise, MRP3/ABCC3 was expressed in those cells, where N-
MYC expression is low, while its transcription resulted decreased when N-MYC was 
amplified or overexpressed. 
Based on the results of the qRT-PCR analysis, we therefore propose that N-Myc is a 
transcriptional activator for several ABC genes and a transcriptional repressor for 
MRP3/ABCC3. 
       
 
 
 
 
Figure 2.  mRNA expression of ABC transporters was determined in five distinct human 
neuroblastoma cell lines and correlated with that of N-MYC.  Results show that in most cases 
transporter gene expression was significantly higher in cells overexpressing N-MYC. 
 
 
N-Myc AFFECTS DYE AND DRUG EFFLUX IN NEUROBLASTOMA CELL 
LINES 
 
To determine how N-Myc can influence drug response we have compared the 
sensitivity of several neuroblastoma cell lines to chemoterapeutics commonly used in 
therapy. Cells were incubated with increasing concentration of some 
chemotherapeutic agents, such as vincristine and doxorubicin, which are transported 
by MDR1, MRP1 and BCRP transporters. Furthermore, doxorubicin and vincristine 
forms an integral part of the therapy of many childhood solid tumours, including the 
therapy of neuroblastoma. High-risk neuroblastoma tumours, highly correlated with 
N-MYC amplification, demonstrated drug resistance against these compounds. 
Therefore, it was important to understand whether N-Myc might induce cellular drug 
resistance against these agents.  
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Cell survival to these compounds was measured by MTT assay. Following 72h of 
continuous exposure to each compound, the cell lines with amplification or 
overexpression of N-MYC displayed an ID50 of more than five times higher than the 
neuroblastoma cell lines with low expression of N-MYC itself (Fig. 3). 
 
 
 
 
Figure 3. N-MYC expression levels correlate with cell resistance to drugs. 
 
 
 
In order to  understand whether the increased resistance in NB cell lines with N-MYC 
overexpression could be  associated with increased efflux activity, we evaluated the 
accumulation of two dyes, Rhodamine and DiOC2, in Tet21/N in absence of 
tetracycline (Tet21/N -) or following its addition (Tet21/N+).  
DiOC2 is highly specific for Mdr1, and is not transported by the related multidrug 
resistance protein, MRP1 297. Rhodamine 123 is effluxed by MDR1 and to a lesser 
extent by MRP1, and thus serves as a more broad indicator of total cellular efflux 
activity. Another member of the ABC family, breast cancer resistance protein 
(BCRP), weakly transports DiOC2, but does not transport Rhodamine 123 298. We 
evaluated the functional activity of the MDR1, MRP1 and BCRP membrane pumps 
by directly measuring the relative fluorescence of cell populations that actively 
extrude fluorescent multidrug resistance transport substrates. The efflux activity of 
MDR1 and its relatives is highly temperature sensitive. They optimally function near 
37ºC, but are effectively inactive at 4ºC. ABC transporters-expressing cells preloaded 
with MDR1 fluorescent substrates retain the dye and consequently have high 
fluorescence when incubated at 4ºC. Conversely, cells incubated at 37ºC more readily 
efflux the dye and show reduced fluorescence (37ºC + DMSO,). A specific inhibitor, 
vinblastine, was also used as a substrate for MDR1 and it competitively blocks efflux 
of DiOC2(3) and Rhodamine 123. Inclusion of excess vinblastine in the efflux 
reaction at 37ºC therefore results in high fluorescence (37ºC + vinblastine). 
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Consistent with the results of cytotoxicity assay, N-Myc can influence the efflux of 
specific ABC transporters substrates, directly influencing their transcriptional 
activity. Indeed, a highly significant reduction in the amount of each specific dye 
retained in the cell was observed in cells with high N-MYC expression but not in cells 
where N-MYC is silenced (Fig. 4). In presence of vinblastine, the fluorescence of cell 
populations resulted unchanged, demonstrating that the efflux of these dyes is 
specifically controlled by MDR1, MRP1 and BCRP. 
 
 
                     
 
 
 
Figure 4.  The efflux activity of ABCB1/MDR1, ABCC1/MRP1 and ABCG2/BCRP was  compared 
between TET/21-N –TET (high N-Myc) and TET/21N +TET (low N-Myc). 
 
 
 
 
N-Myc REGULATES TRANSCRIPTION OF ABC GENS BY BINDING 
DIRECTLY TO THEIR PROMOTERS 
 
To confirm the direct association of N-MYC with the promoters of ABC genes up-
regulated by N-Myc itself, ChIP studies were performed in Tet21/N- cell line. Each 
ABC promoter was evaluated for the presence of canonical and non-canonical Myc 
binding sites (E-Box) by bioinformatic tools. We therefore searched for E-Box motifs 
located within a distance of 2 Kb on either side of the transcriptional start site. 
Immunoprecipitated DNA was analyzed by qPCR using pairs of primer flanking the 
specific binding sites. ChIP results indicated that heterodimer N-Myc/Max binds the 
promoters of tested ABC genes in close proximity to the transcriptional start site. 
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abcb1 represents an exception, because its promoters was not bound by N-Myc, thus 
it could be proposed as a secondary target of N-Myc oncoprotein (Fig. 5). 
ChIP analysis confirmed that N-Myc is directly associated with nine ABC genes 
(ABCA2, ABCB9, ABCB10, ABCC1, ABCC4, ABCE1, ABCF1, ABCF2 and ABCG2). 
However, the binding of Myc at its consensus sequence appears to be required, but 
not always sufficient for transcriptional activation (Frank et al.; Fernandez et al.). 
 
 
 
 
 
Figure 5.  N-Myc is a direct regulator of several ABC transporter genes and binds ABC transporter 
promoters in close proximity to the transcription start site.   
 
 
 
To demonstrate that N-Myc binding to ABC promoters directly affected their 
transcriptional activity, we performed a luciferase assay. For each ABC gene, we 
have cloned the promoter into luciferase expression vector. Luciferase assay was 
performed in Tet21/N, and we have evaluated promoter activity in dependence of N-
Myc expression. For ABC genes directly bound by N-Myc, luciferase assay displayed 
a decreased promoter activity when N-MYC was downregulated, by suggesting that 
the binding of the oncoprotein is necessary for their transcriptional activation (Fig. 6). 
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Figure 6.  c-Myc role on ABC gene transcription is recapitulated by transient transfection assay. ABC 
transporter promoters were cloned into a luciferase reporter vector. Constructs were testet in Tet21/N 
cells as function of c-MYC expression (+/- Tetracycline). The ABCA10 gene was used as a negative 
control in that it does not respond to N-Myc. 
 
 
N-Myc REPRESSES THE ABCC3 PROMOTER BY INTERACTION WITH 
TRANSCRIPTION FACTOR SP1 
 
Myc exerts its biological functions at least in part through the transcriptional 
regulation of target genes. The best understood function of the protein is its ability to 
activate genes through recruitment of several activating cofactors to DNA 299. 
Interestingly, MYC can acts also as transcriptional repressor. Indeed, detailed 
evidence has accumulated to suggest that cell-cycle inhibitory genes and other genes 
such as MAD4 and NDRG2 are repressed by c-Myc 299. Three alternate mechanisms 
have been proposed that might explain repression by c-Myc.  The Myc mediated 
repression does not require DNA binding, but interaction with some transcriptional 
activators such as Miz-1, Sp-1 and SMAD. These factors, interacting with Myc, lose 
their transactivator function by determining an inhibition of gene transcription 300.  
Based on ABCC3 transcriptional profile in Tet21/N and in some neuroblastoma cell 
lines (Fig.1 and 2) we proposed that N-Myc might regulate negatively its expression 
acting as a repressor. Since there is a significant functional overlapping between c- 
and N-Myc, we hypothesized that also N-Myc may repress transcription through a 
mechanism similar to that of c-Myc.  
 
                                 
 
Figure 7.  Schematic representation of ABCC3 gene promoter. The localization of the CpG island is 
indicated by sky-blue line, while Sp1 binding sites are represented by the vertical red lines. 
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Thus, we have analyzed ABCC3 promoters for the presence of Sp-1 binding sites. 
ABCC3 promoter doesn’t contain E-Boxes in close proximity to its transcriptional 
start site, whereas GC boxes and Inr element are located around its start site (Fig. 7).            
Thus, we have evaluated the binding of Sp1 to its cognate sites and we have checked 
if also N-Myc could bind ABCC3 promoter on GC boxes through its specific 
interaction with Sp1. We have tested this hypothesis in a Dual-Step ChIP assay. 
Conventional ChIP technique, using a single formaldehyde cross-linking step, is 
insufficient to detect the binding of transcription factors that participate to the 
regulation of gene transcription by interacting with other proteins, associated with 
promoters, but not with DNA. To overcome this problem, we thought of using the 
cross-linking agent DSG (Di(N-succinimidyl)glutarate) in addition to formaldehyde 
that may improve the formation of covalent links between proteins and stabilize the 
association of proteins to DNA, though not directly bound to it. Based on other 
studies we set up a dual cross-linking ChIP protocol that we have successfully 
employed to improve immuno-precipitation of complexes in which tested factors are 
not in direct contact with DNA. Specific ABCC3 promoter region supposed to be 
engaged with Sp1 and N-MYC were analyzed by qPCR. We found that either Sp1 or 
N-Myc bind ABCC3 promoter on a specific region located between +200 and +500bp 
and containing three GC boxes (Fig. 8). This finding, together with the evidence that 
we was not able to detect N-Myc binding on ABCC3 promoter using conventional 
ChIP (data not shown), supported the hypothesis that N-Myc can repress ABCC3 
transcription through a direct interaction with Sp1 but not with its DNA promoter. 
 
          
 
Figure 8.  N-Myc represses ABCC3 gene transcription. Dual cross-linking ChIP and quantitative PCR 
were applied to Tet21/N- cells. Fold enrichment of a given DNA region immunoprecipitated with anti 
N-Myc, Max or Sp1 antibodies was calculated as the ratio between the enrichment obtained with a 
specific antibody and that obtained with the pre-immune serum. p21 represents positive control for N-
Myc mediated repression. 
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To investigate the role that these GC box elements play in the regulation of ABCC3, 
reporter constructs were generated and transiently transfected into Tet21/N cells. The 
highest level of ABCC3 promoter activity was observed with the full length promoter 
reporter construct, which contains all three GC boxes, in Tet21/N+ cells, where N-
MYC is downregulated. On contrary, ABCC3 promoter activity resulted decreased 
when N-MYC was switched on (Tet21/N-), indicating that N-Myc represses ABCC3 
promoter. When transfection assay was performed with promoter reporter construct 
that doesn’t contain these three GC boxes, the promoter activity was lower and didn’t 
change in dependence of N-MYC expression. The effects of increased N-MYC 
expression on ABCC3 promoter activity were examined also in a co-transfection 
assay with a plasmid which contained SP1 coding sequence under the control of a 
CMV promoter (pRK7-SP1). Also in this case N-Myc was able to repress the wild 
type promoter activity, but not influenced the activity of deleted construct, indicating 
that the region of ABCC3 promoter which contains the three GC boxes, located 
between +250 and +500bp, is required for N-Myc mediated repression (Fig. 9).   
 
  
   
 
 
Figure 9.  ABCC3 promoter requires the Sp1 core region for N-myc repression. Luciferase activity of 
the two reporters ABCC3 and ∆ABCC3 was determined in presence  (- TET) or absence ( +TET)  of 
N-Myc expression and normalized to that of  renilla    
 
 
 
To determine whether N-Myc repression of the ABCC3 promoter is based on 
interactions between N-Myc and the transcription factor Sp-1, we co-transfected N-
Myc-FLAG vector and HA-Sp1 vector in HEK-293 cell line and performed 
immunoprecipitations using antibody against HA-Sp1 followed by immunoblotting 
with antibodies against N-Myc-FLAG. We also performed co-immunoprecipitation 
assay in SK-N-BE in order to detect endogenous interaction. Nuclear extracts were 
prepared and subjected to immunoprecipitation with Sp1 antibody, followed by 
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immunoblotting with N-Myc antibody. Using these assays we have observed 
association between N-Myc and Sp1 (Fig. 10a).  
To identify the region of N-Myc that is responsible for interaction with Sp1, we used 
GST-fusion protein containing four different domains of N-Myc (∆1-88, ∆82-254, 
∆249-361 and ∆336-644). These GST-fusion proteins were used in pull-down 
experiments with extract from HEK-293 cells transfected with the plasmid expressing 
SP1 (pRK7-SP1). We identified that two N-Myc domains (∆82-254 and ∆336-644) 
are involved in interaction with SP1 (Fig. 10b)  
 
 
             A.                                                                 B. 
        
 
 
 
              C.    
 
Figure 10.  N-Myc is associated with Sp1. a) Immunoprecipitation (IP) with HA antibody was 
performed with nuclear extracts from HEK-293 cells transiently tranfected with mammalian 
expression constructs encoding N-Myc-FLAG and Sp1-HA, followed by immunoblotting with 
monoclonal anti-M2 Flag antibody b). Immunoprecipitation (IP) with Sp1 antibody was performed 
with nuclear extracts from SK-N-BE neuroblastoma cell line, followed by immunoblotting with 
monoclonal anti-N-Myc antibody. c).  HEK293 cells were transfected with pRK7-Sp1-HA or pRK7-
HA and harvested 48h after transfection. Pull-down assays were performed by incubating lysates with 
GST or GST-N-Myc∆1-88, GST-N-Myc∆82-254, GST-N-Myc∆249-361, GST-N-Myc∆336-644 for 
1h at 4°C followed by incubation with glutathione beads for 1h. bound proteins were subjected to 
SDS/PAGE followed by immuniblotting with anti-HA antibody. 
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c-Myc IS ALSO A POSITIVE AND DIRECT REGULATOR OF SEVERAL 
ABC TRANSPORTER GENES. 
 
Many haematological malignancies are often associated also with alterations in the 
level of c-MYC expression. Understanding how c-Myc can promote the leukemic 
phenotype will provide novel tools for designing more efficient drugs to promote 
regression of leukemic tumours. We have tested the hypothesis that, like N-Myc, c-
Myc could play a critical role in the insurgence of drug resistance phenomenon in 
CML and AML, may be controlling the expression of ABC drug transporter genes.  
To achieve this aim, ABC genes expression was monitored in HL60, a human 
promyelocytic cell line in which c-MYC is overexpressed and can be turned off by 
treating cells with DMSO, and in P493, a lymphoblastoid cell line modified to 
overexpress c-MYC under a tet-off promoter. In these cell lines, we have examined 
the expression level of all forty-eight human ABC drug transporters as a function of 
c-MYC silencing. Their transcription profiles was determined by qRT-PCR and 
described by cluster analysis (Fig. 11). Our results demonstrated that c-Myc affected 
the transcription of several ABC genes, such as ABCA2, ABCB10, ABCC1, ABCC4, 
ABCE1, ABCF1, ABCF2 and ABCF3, a majority of which, has been found implicated 
in chemoresistance. 
 
 
Figure 11. Transcriptional profiles of ABC drug transporters genea as function of c-MYC expression. 
The analysis was performed in P493 and HL-60 cell lines. Relative mRNA expression of all 48 human 
ABC transporter genes was determined by qRT-PCR as a function of c-MYC silencing. The analysis 
describes those genes that are positively or negatively regulated by c-Myc or for which c-MYC 
silencing has no effect on their expression. Genes, the expression of which is totally absent in the two 
cell lines, are noy listed in the cluster study. 
A B 
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Furthermore, performing ChIP assay, we have demonstrated a direct binding of c-
Myc to the promoters of the ABC genes positively regulated by c-Myc itself (Fig. 
12). 
 
               
 
 
Figure 12.  c-Myc is a direct transcriptional regulator of ABC transporter genes.  
 
 
 
DNA METHYLATION AND CHROMATIN STRUCURE MAY PLAY A KEY 
ROLE IN MULTIDRUG RESISTANCE IN CANCER. 
 
 
These data were compared to those obtained in Tet21/N cell line and the results show 
that both c-Myc and N-Myc appear to control a large number of ABC transporter 
genes. Venn diagram (Fig. 11b) shows that nine common genes are positively 
regulated by c-Myc and N-Myc. Although ABCB1 and ABCG2 seemed not to be 
regulated by c-Myc, however, these genes were not expressed either in P493 or in 
HL60 and for this reason we couldn’t exclude that c-Myc was involved in their 
transcriptional control. Epigenetic events may influence ABCB1 and ABCG2 
transcriptional regulation. These two genes are expressed at high levels in 
haematopoietic stem cells, but they are turned off in most committed progenitor and 
mature blood cells 91. Several studies have demonstrated that methylation of the 
ABCB1 promoter was linked with a lack of ABCB1 expression in cell lines and 
samples from patients that were diagnosed with AML, acute lymphocytic leukaemia, 
chronic lymphocytic leukaemia, colorectal cancer and bladder cancer 200. Thus, 
ABCB1 promoter methylation imposes a restrictive chromatin environment. However, 
when treated with a DNA demethylating agent (5’-Aza-2’-deoxycytine), P493 cells 
showed reactivation of several ABC genes, including ABCB1 and ABCG2, otherwise 
silent (Fig. 13).  
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Figure 13.  Transcriptionale reactivation of some ABC genes following the treatment with 3µM of 5’-
Aza-2’-deoxycytine for 72 h in P493 cell line. 
 
 
 
 
 
Based on the evidence that Abcg2 plays a key role in regulating drug resistance in 
leukaemia malignancies, we focused our attention on the chromatin structure of its 
promoter. The reactivation of ABCG2, following treatment with 5’-Aza-2’-
deoxycytine, allows us to hypothesize that its promoter and more specifically the Myc 
binding sites present in it, are methylated in  P493 cells, thus inhibiting Myc binding 
as previously proposed. In order to evaluate the methylation of ABCG2 promoter in 
P493 and HL60 cell lines we have performed a Southern Blot analysis. We have 
digested genomic DNA with MspI, which recognizes and cleaves CCGG elements 
independently of their methylation status; HpaII, which cleaves the same sequence 
only when demethylated; and PmlI which recognizes Myc binding site (CACGTG) 
but is sensitive to methylation status of this sequence. The results showed that, in 
these cell lines, ABCG2 promoter was hypermethylated, even if Myc binding site 
remained unmethylated (Fig. 14). 
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Figure 14. Southern Blot analysis of ABCG2 promoter. Genomic DNA (15 µg) digested with the 
indicated enzymes was electrophoresed on an agarose gel and analyzed by Southern blot hybridization. 
The ABCG2 probe extends from the promoter region to within the coding sequence. Position of the 
HpaII/MspI sites are shown schematically over the ABCG2 gene diagram.  The digestion profile of 
genomic DNA with MspI was quite different from that of HpaII, indicating that several CpG sites were 
methylated. We digested P493 and HL60 genomic DNA also with PmlI, which cleaves E-Box site 
(CACGTG) only when demethylated. The digestion profile for PmlI, if compared with EcoRI 
digestion profile, showed that the only one N-Myc binding site was unmethylated.  
 
 
c-Myc CONTROLS EXPRESSION OF ABC DRUG TRANSPORTERS IN 
CD34+ HEMATOPOIETIC PROGENITORS 
 
The treatment of haematological malignancies appears to be unsatisfactory in child 
and adult patients with acute myeloid leukaemia. An important problem in the 
treatment of acute myeloid leukaemia is caused by a pre-existent or acquired drug 
resistance. P-gp/MDR1 is strictly associated with unfavourable outcome in paediatric 
ALL patients, whereas MRP1 and BCRP do not seem to play a major role in this type 
of leukaemia. Also in the treatment of  chronic myeloid leukaemia several patients 
does not respond and others lose response during treatment. CML is linked to a 
acquired genetic abnormality. Identification of the BCR-ABL kinase fusion protein as 
a central player in the pathogenesis of CML leaded to develop of a selective inhibitor 
of this fusion protein, named imatinib. The resistance to this chemotherapeutic agent 
can be due to overexpression/amplification of BCR-ABL kinase or to emergence of 
its mutant isoforms 301. In addition, BCR-ABL itself may regulate ABCG2 expression 
via AKT activity, suggesting that ABCG2 may be a mediator of imatinib resistance 
302
. Moreover also the overexpression of ABCB1 and its protein seems to be 
responsible for resistance to imatinib and inhibitors of this transporter are able to 
restore the drug sensitivity 303. Thus, like AML, also CML presents a drug resistance 
strictly related to ABC transporters expression. Furthermore, we have investigated the 
expression of c-MYC and ABC genes in chronic myeloid leukaemia (CML) in order 
to verify whether high expression levels of c-MYC may affect transcription of ABC 
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drug transporters also in CML cells. CML is characterized by the Philadelphia (Ph) 
chromosome translocation, which generates BCR-ABL fusion gene. This 
rearrangements is detected in about 95% of patients with CML and, because of its 
constitutively activated tyrosine kinase activity, it is considered to be the causative 
molecular abnormality in CML. BCR-ABL may positively regulate c-Myc expression 
304
. CML is characterized by high levels of c-MYC expression and a large expansion 
of the CD34+ stem cell population in the peripheral blood 305, 306. We have performed 
a transcriptional analysis of c-MYC and ABC genes (qRT-PCR) in CD34+ cells from 
newly diagnosed chronic phase (CP)-CML patients, and we have found that several 
ABC genes, particularly ABCC1 and ABCC4, were overexpressed in CD34+ 
population if compared to entire population of mononuclear cells from which stem 
cells have been purified (Fig. 15). 
 
          A. 
        
 
   B. 
               
 
Figure 15. c-Myc controls expression of ABC drug transporters in CD34+ hematopoietic progenitors. 
a) Relative expression of c-MYC and ABC genes of  CD34+ cell population was compared to that of 
the entire population of mononucleated cells (MNC). Each colored bar (up) or dots (below) 
corresponds to a single patient. ABCA7 which has been used as a negative control  results to be 
repressed in CD34+ cells as compared to MNC cells. b) Mann-Whitney statistical test applied to 
results of panel A confirms that the expression level of analysed genes is significantly different in the 
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two cell populations . Results are reported as ∆Ct values which were calculated as the difference 
between Ct of the ABC mRNA and Ct of the GUSB mRNA used for normalization of qRT-PCR. 
Particularly interesting is that ABCG2 is expressed in CD34+ population and its 
expression is correlated to that of c-MYC. This result indicated that ABCG2 promoter 
is probably demethylated in CD34+ cell population of CML patients, and that in this 
condition c-Myc is able to act directly on its transcription. Finally, through ChIP 
assay, we have confirmed that c-Myc was physically associated with promoters of 
ABC drug transporter genes in CML or AML derived cells (Fig. 16).  
 
 
 
 
Figure 16. c-Myc is physically associated with promoters of ABC drug transporter genes in CML 
derived cell lines. To demonstrate that c-Myc can directly control transcription of ABC tranporter 
genes in CML we have performed ChIP in three distinct cell lines: KG1a derived from AML and 
expressing the CD34 antigen (control); K562 Ph+, but not expressing the CD34 antigen; Kasumi-4 
Ph+ and expressing the CD34 antigen.  
 
 
It is remarkable that ABCG2 is expressed in KG1a cell line, derived from AML and 
expressing the CD34+ antigen. These cells are blocked at an early stage of 
development and remain in the proliferative pool, saving parameters of staminality. 
For this reason, ABCG2 promoter remained unmethylated, allowing the c-Myc 
binding to its cognate site. 
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Resistance to chemotherapeutic agents is a major obstacle for successful treatment of 
cancer. The failure of the curative treatment of cancer patients often occurs as a result 
of intrinsic or acquired drug resistance of the tumours to chemotherapeutic agents. 
The resistance of tumours occurs not only to a single cytotoxic drug used, but also 
occurs as a cross-resistance to a whole range of drugs with different structures and 
cellular targets. This phenomenon is called multiple drug resistance (MDR). 
Multidrug resistance (MDR) severely limits the effectiveness of chemotherapy in a 
variety of common malignancies and is responsible for the overall poor efficacy of 
cancer chemotherapy 116. 
Therefore, understanding how chemoresistance develops and eventually how it can be 
contrasted becomes crucial to fight cancer effectively. Chemoresistance of cancer 
cells is in part caused by misregulation of the activity of membrane proteins, named 
ATP-binding cassette transporters, responsible for the efflux of chemotherapeutic 
agents in cancer cells 9, 34. Such misregulation may be achieved by mutations 
affecting the biophysical and biochemical properties of the transporters or by an 
increase in their expression level. The human genome codes for forty-eight functional 
ABC transporter genes, which can be grouped into seven subsets (from A to G) based 
on their degree of sequence homology 307. A common strategy adopted to overcome 
drug resistance in tumours is based on the administration of compounds that inhibit 
ABC transporters in association with chemotherapeutic agents, normally used in 
therapy 117. Although these ABC inhibitors are not toxic themselves, they might 
inhibit ABC transporters also in normal tissues, enhancing adverse effects of 
anticancer drugs. Side effects due to modulation of ABC transporters in normal 
tissues, especially blood-brain barrier should be monitored carefully to avoid 
neurological response. Thus, considering the limited success of available treatment 
modalities for the therapy of multidrug-resistant tumour cells, alternative and 
complementary strategies need to be developed. Antisense oligonucleotide 
technologies and oncolytic adenovirus strategy represent two novel approaches to 
struggle with MDR mechanisms and are based on the capability to restore normal 
transcriptional levels of ABC transporters 193. For this reason, establishing how the 
forty-eight human ABC genes are regulated at transcription level and which 
transcription factors concur to such a control, is crucial to understanding the role of 
ABC transporters in physiological as well as in pathological contexts, such as cancer. 
Although many studies have focused on the transcriptional regulation of the 
ABCB1/MDR1 gene, which encodes the P-glycoprotein 76, yet very little is known 
about the molecular mechanisms underlying transcription of the large family of ABC 
transporter genes. A recent study by Gottesman and colleagues has proposed that the 
definition of the transcription profile of all forty-eight genes may be important in 
predicting the possible arising of a multidrug resistance phenotype in a given type of 
cancer 308, 309. Considering recent data showing that 2.9 million new cases of cancer 
were diagnosed in year 2004 and over 1.7 million cancer deaths occurred in Europe 
alone 310, it is clear that any improvement in predicting chemoresistance or in 
preventing its arising will have a strong impact on the quality of patient’s life and 
healthcare costs.  
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CANCER CHEMORESISTANCE: THE RELATIONSHIP BETWEEN N-Myc 
AND MULTIDRUG TRANSPORTERS IN NEUROBLASTOMA TUMOURS 
 
Although many high-risk neuroblastoma tumours initially respond to the first cycles 
of intensive chemotherapy, they frequently become refractory to treatment as the 
disease progresses. Multidrug resistance in neuroblastoma is particularly apparent in 
patients whose tumours exhibit amplification or over-expression of the N-MYC 
oncogene. N-MYC clearly contributes to the drug resistance phenotype of 
neuroblastoma and it represents one of the most powerful indicators of poor outcome 
in this disease 69, 70. However, high levels of N-MYC gene expression is strongly 
predictive of poor prognosis in older children with neuroblastoma, but not in infants 
311
. The N-Myc oncoprotein is associated with increased growth potential and 
tumorigenicity 311 and appears to act as a transcriptional regulator, perhaps 
influencing the transcription of critical genes involved in multidrug resistance 
phenomenon, such as ABC transporter genes. Only a single study, performed by 
Manohar et al., demonstrated that N-Myc acts as transcriptional activator on 
regulation of the MRP1/ABCC1 promoter in human neuroblastoma 75. The expression 
of the MRP1 gene at high levels in primary neuroblastoma tumours predicts reduced 
event-free survival and shorter overall survival in children with this neoplasm 72. 
Furthermore, since N-Myc regulates expression of ABCC1, it has been observed that  
N-MYC amplification or overexpression has no prognostic value when MRP1 
expression is included as a prognostic factor 72. 
In this study, we show that several ABC transporters genes, including ABCC1, can be 
regulated by N-Myc, defining the role of the oncoprotein in the development of a 
multidrug resistance phenotype in neuroblastoma. Indeed, we analyzed the 
transcriptional profile of all forty-eight human ABC transporter genes in a N-MYC 
inducible neuroblastoma cell line (Tet21/N) and we found that the expression of 
several ABC genes, such as ABCA2, ABCB1, ABCB9, ABCB10, ABCC1, ABCC4, 
ABCE1, ABCF1, ABCF2, ABCF3 and ABCG2 , paralleled N-MYC expression, 
indicating that a subset of ABC transporter genes can be positively regulated by N-
Myc itself. Furthermore, we found an inverse regulation between N-MYC and another 
subset of ABC transporter genes, which seem to be repressed by the oncoprotein. 
Specifically, for this latter group,  we focused on the regulation of the ABCC3/MRP3 
transcription by N-Myc. Indeed, a coordinate expression of  ABCC3/MRP3, 
ABCC1/MRP1 and ABCC4/MRP4 influences the aggressiveness of neuroblastoma. 
Multivariate analysis reveals that overexpression of  ABCC1/MRP1 and 
ABCC4/MRP4, when associated with low transcription of ABCC3/MRP3, represents 
the stronger prognostic marker of poor outcome in neuroblastoma tumour (Haber, M. 
et al. unpublished). 
A strong correlation between N-MYC expression and transcriptional levels of  these 
ABC drug transporter genes has been demonstrated also in other five neuroblastoma 
cell lines, which differ from each other to express different levels of N-Myc protein. 
In particular, ABC genes positively regulated by N-Myc display higher 
transcriptional activity in neuroblastoma cell lines with N-MYC amplification or 
overexpression than cell lines expressing low levels of the oncoprotein. On the 
contrary, ABCC3/MRP3 presents a lower transcriptional activity in those 
neuroblastoma cell lines with high levels of N-Myc rather than in cell lines where the 
oncogene is not expressed. This transcription analysis, performed in several 
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neuroblastoma cell lines as well as in the N-MYC inducible system (Tet21/N), 
allowed us to hypothesize that N-Myc may play a crucial role in the development of 
multiple drug resistance in neuroblastoma, mediating the transcriptional regulation of 
several ABC transporter genes.  
Furthermore N-Myc, acting as transcriptional regulator of ABC transporter genes, can 
affect drug resistance in human neuroblastoma. We performed MTT assay to evaluate 
the survival of different neuroblastoma cell lines after treatment with some 
chemotherapeutic agents commonly used in therapy, such as vincristine and 
doxorubicin. We found that neuroblastoma cell lines with amplification or 
overexpression of N-MYC are extremely resistant to chemotherapeutic agents, 
indicating that N-Myc expression may predict drug resistance due to ABC 
transporters. Indeed, N-Myc is able to affect drug efflux in human neuroblastoma 
cancer cells. In the N-MYC inducible cellular system, we show that cellular efflux of 
two dyes, such as Rhodamine123 and DiOC2, is decreased when N-MYC is down-
regulated. Since these fluorescent molecules are specific substrates of ABCB1/MDR1 
and related transporters like ABCC1/MRP1 and ABCG2/BCRP, their decreased 
efflux, detected in absence of  N-Myc, indicate that regulation of ABC transporters by 
N-Myc itself may affect drug transport outside the cell. 
Evaluating the association of the N-Myc/Max heterocomplex with ABC transporter 
promoters at its specific cognate sites, we can assert that N-Myc can directly regulate 
transcription of ABC transporters. Formaldehyde ChIP assay performed in Tet21/N 
cell line reveals that N-Myc is a direct transactivator of many of the ABC genes 
identified by transcriptional analysis. In agreement with previous reports 229, 312, we 
observed that most Myc binding sites localize to predicted CpG islands and are 
proximal to the gene transcription start site, suggesting that the N-Myc/Max 
heterocomplex may preferentially function close to the transcription start site. We 
show that, with the exception of ABCB1/MDR1, N-Myc/Max is physically associated 
with the promoter of all transporters upregulated by N-Myc itself, suggesting that N-
Myc directly control the transcription of several ABC transporters acting as 
transactivator factor. Regarding ABCB1/MDR1 we propose that N-Myc regulates its 
transcription through a secondary mechanism, even if conflicting reports exist 
regarding the correlation between MDR1 and N-MYC. Indeed, an experimental in 
vitro metastatic neuroblastoma model reported that N-Myc directly regulated 
MDR1gene expression. In this model, the degree of drug resistance directly correlated 
with the expression levels of N-MYC and MDR1 expression 313. However, although P-
glycoprotein expression was reported to be a predictor marker of outcome in  
neuroblastoma patients in some studies 71, 314, other series have failed to show any 
correlation 72, 315. Furthermore in contrast to MRP1, the level of expression of MDR1 
is lower in tumours with N-MYC amplification compared to those without 
amplification 72, 315. Finally, to confirm that N-Myc binding affects the transcriptional 
activity of ABC promoters upregulated by N-Myc itself, luciferase assays were 
performed with a series of ABCs promoter/reporter constructs. Thus, we could 
recapitulate, in a transient transfection assay, ABC promoters activity as a function of 
N-MYC expression. Furthermore, we can state that the N-Myc binding on tested ABC 
promoters is required and sufficient to activate their transcription. However, we show 
that N-Myc may control some ABC transporters transcription also by acting as 
repressor. In particular, we provide the first evidence to indicate that human 
ABCC3/MRP3 is a real N-Myc down-stream regulated gene. c-Myc represses some 
target genes through three different mechanisms, where c-Myc acts by interacting 
with other transcription factor, such as Miz1, Sp1 and Smad, and blocking their 
transacting activity 295, 300. The mechanisms of repression of c-Myc is different from 
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that of activation, which is dependent on the direct binding of the Myc/Max 
heterodimer to the E-Boxes in the target genes. In agreement to this proposition, the 
N-terminal MBII of c-Myc is required for the repression, but not for activation 230. 
Thus, when c-Myc acts as repressor, it binds a DNA promoter region through an 
interaction with another transcription factor and not directly. Furthermore, in 
literature there are few studies about c-Myc mediated repression, but there is no 
evidence regarding N-Myc mediated repression. However, since c- and N-Myc 
present a significant functional overlapping, we hypothesized that also N-Myc may 
repress transcription of its target genes by interacting with other factors, such as 
Miz1or Sp1. ABCC3/MRP3 promoter contains three Sp1 binding sites (GC box), 
whereas no E-Box is found in close proximity to the transcriptional start site. We 
evaluated the binding of N-Myc in the region where GC boxes are located. However, 
to achieve this aim we set up a new technique, named Dual-Step ChIP. Through this 
novel approach, we overcame some limits of normal ChIP. In Dual-Step ChIP, to 
improve the formation of covalent links between proteins and stabilize the association 
of proteins to DNA, though not directly bound to it, we used cross-linking agents in 
addition to formaldehyde. Through this technique, we show that either Sp1 or N-Myc 
binds ABCC3/MRP3 promoter the +200bp to +500bp region containing multiple Sp1 
binding sites. Furthermore, we show, by transient luciferase assay, that this region is 
strictly required for N-Myc mediated repression of ABCC3/MRP3 in neuroblastoma. 
To test that N-Myc really interact with Sp1, we performed a co-immunoprecipitation 
assay and a GST pull down assay and we established that the central and DNA 
binding domain of N-Myc are involved in  interaction with Sp1. It is clear that the 
association of N-Myc to ABCC3/MRP3 core promoter is mediated by Sp1 and in 
agreement with this speculation, the deletion of the Sp1 binding sites abolished the 
repression of N-Myc completely. Clinical drug resistance in human neuroblastoma, as 
in other cancers, is believed to be a multifactorial process involving the action of 
multiple gene pathways. High-risk neuroblastoma tumours develop resistance 
phenotype where cancer cells become resistant simultaneously to different drugs with 
no obvious structural resemblance and with different cellular targets. It is reasonable 
that several ABC drug transporters with different substrate specificity are involved in 
the development of this phenotype. In our study, we show that in neuroblastoma cell 
lines with amplification or overexpression of N-MYC, the transcription levels of some 
ABC genes result increased, influencing the drug sensitivity to some 
chemotherapeutic agents. Therefore we propose that N-Myc play a key role in the 
insurgence of drug resistance, because it acts simultaneously regulating the 
transcriptional levels of several ABC genes. Many ABC transporters upregulated by 
N-Myc, such as ABCA2, ABCC1, ABCC4, ABCG2 pumps drug molecules from the 
cytosol to the extracellular medium. However, intracellular drug concentrations often 
remain high in drug resistance cells and therefore do not explain how drug pumping 
at the plasma membrane confers multidrug resistance. Recent work indicates how 
drug sequestration in cytoplasmic organelles can account for these paradoxical 
results. The intracellular drug distribution is modified in many MDR cell lines, 
leading to increased drug sequestration in acidic vesicles, such as the trans-Golgi 
apparatus, recycling endosomes, and lysosomes, followed by transport to the plasma 
membrane and extrusion into the external medium. Since most anticancer agents 
target DNA or nuclear enzymes, sequestration of drug in cytoplasmic organelles will 
lead to decreased drug-target interaction and thereby, decreased cytotoxicity 316, 317. 
Some ABC transporters up-regulated by N-Myc, such as ABCB9 and ABCB10, are 
expressed in mitochondria and lysosomes respectively and may contribute to alter 
intracellular drug concentration.  N-Myc controls the development of 
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chemoresistance phenomenon mainly acting as transactivator factor. However, we 
provide the evidence that ABCC3/MRP3 is repressed by N-Myc. Although, MRP3 is 
thought to increase elimination of bile salts from the hepatocyte, it is expressed also 
in normal human adrenal gland, in the cells of the zona fasciculata and in the zona 
reticularis 38. Most neuroblastomas arise from the adrenal glands and may develop 
anywhere along the sympathetic chain 318. Thus, we hypothesize that MRP3 may be 
silenced during the development of neuroblastoma tumour at the same time with N-
MYC amplification or overexpression. Furthermore, non steroidal anti-inflammatory 
drugs induce MRP3 expression in colorectal cancer and seems to be involved in the 
suppression of tumorigenesis 319. Initial studies on MRP3 in a panel of drug-resistant 
cancer cell lines did not turn up any association between MRP3 levels and resistance 
37
 and clinical studies have revealed that low expression of ABCC3, when associated 
with high transcriptional levels of ABCC1 and ABCC4, is indicative of poor outcome 
in primary human neuroblastoma (Haber, M. data unpublished). These evidences 
support the hypothesis that ABCC3 may act as tumor suppressor gene and for this 
reason it might be necessary to silence its expression during tumour development.  
 
                     
 
 
Figure 1. Coordinate regulation of ABC drug transporter genes by N-Myc in human neuroblastoma 
cell lines. 
Taken together, this study indicates that N-Myc plays a key role in controlling the 
development of drug resistance phenotype in human neuroblastoma, operating a 
direct and concerted regulation of multidrug resistance genes, acting either as 
transactivator or as transcriptional repressor (Fig.1). For these reasons, strategies 
aimed at inhibiting N-MYC may have therapeutic potential in children with aggressive 
neuroblastoma, above all N-Myc may represent a downstream target to control the 
insurgence of drug resistance. 
 
 
CANCER CHEMORESISTANCE: THE RELATIONSHIP BETWEEN c-Myc, 
MULTIDRUG TRANSPORTERS AND EPIGENETIC EVENTS. 
 
Our study propose that, like N-Myc, also c-Myc plays a crucial role in the 
development of drug resistance phenomenon in leukaemia cell lines, such as 
lymphoblastoid and promyelocytic cell lines. c-MYC overexpression has been 
demonstrated in many human malignancies and it is involved in the neoplastic 
transformation process. So far, no lines of evidence have been provided about its 
ability to control the drug resistance in cancer. According to our findings c-Myc can 
control transcriptional activity of several ABC drug transporters, by directly binding 
their promoters at its cognate sites. Like N-Myc, c-Myc may induce an 
Discussion 
 
 102 
overexpression of ABC transporters, such as ABCA2, ABCC1, ABCC4, involved in 
the pumping of drug molecules from the cytosol to the extracellular medium. 
However, like N-Myc, also c-Myc is involved in the intracellular drug distribution, 
controlling transcriptional levels of ABC transporters, such as ABCB9, ABCB10, 
localized in cytoplasmic organelles. Therefore, c-Myc may regulate drug 
concentration in tumor cells increasing drug efflux of tumour cell and increasing drug 
sequestration in acidic vesicles, such as trans-Golgi apparatus, leading to decreased 
drug-target interaction and thereby decreased cytotoxicity. Altered intracellular drug 
distribution and the overexpression of drug efflux pumps are usually associated in 
cancer cells which develop drug resistance. 
Finally, either N-Myc or c-Myc are direct transactivator of ABCE1 transporter gene. 
Although this gene is a member of the ATP-binding cassette (ABC) multigene 
family, it is mainly involved in the inhibition of ribonuclease L, a nuclease induced 
by interferon in mammalian cells. Human ABCE1 interacts also with the eukaryotic 
initiation factors eIF5 and eIF2 components of the pre-initiation complex46, thereby 
Myc proteins, inducing ABCE1 overexpression, control translational process, 
determining a dramatic increase of cellular growth. 
It is interestingly to note that in leukaemia cell lines, c-Myc is not able to control 
transcriptional levels of ABCB1 and ABCG2. Both these genes seem to be silenced in 
some leukaemia cell lines. Regarding ABCB1 some studies implicated epigenetics in 
the control of its transcription 320. The ABCB1/MDR1  promoter region, including 
exon 1 and intron 1, is GC rich and constitutes a CpG island according to specified 
criteria. Several studies demonstrate that methylation of the ABCB1/MDR1  promoter 
is linked with a lack of MDR1 expression in cell lines and samples from patients that 
were diagnosed with AML, acute lymphocytic leukaemia, chronic lymphocytic 
leukaemia, colorectal cancer and bladder cancer. Our findings demonstrate that also 
ABCG2 promoter is methylated in leukemia cell lines, even if Myc binding site 
continue to be unmethylated, indicating that other heterochromatic markers may 
avoid the binding of c-Myc on the ABCG2 promoter. Furthermore, we demonstrate 
that treatment with 5’-Aza-2’-deoxycytine results in a activation of ABCG2 
expression, as well as other ABC transporter genes. Therefore, epigenetic events play 
a crucial role in controlling ABC transporter gene expression. Recently, the 5’-Aza-
2’-deoxycytine (decitabine) has been approved for the treatment of myelodisplastic 
syndromes and other kind of leukaemias. Decitabine is a hypomethylating agent and 
at low concentrations is considered to exert its anticancer effects by inducing 
hypomethylation of tumour suppressor genes 321. However we propose that its effects 
may be broader and may lead to reactivation of other genes, such as some ABC drug 
transporters, promoting the development of drug resistance phenomenon and 
increasing the aggressiveness of the tumour. Finally, the treatment with 
demethylating agents may play a critical role in misregulating Myc transcription 
functions during tumour development, allowing the binding of the oncoprotein at the 
promoters, such as ABCG2 promoter, and causing altered expression of its target 
gene, otherwise silenced. Interestingly, hypomethylation correlates also with 
overexpression of c-MYC and an increased frequency of hematological tumours in 
mice 322. For these reasons, the therapy with demethylating agents could result 
ineffective and dangerous in treatment of cancer.  
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CANCER CHEMORESISTANCE: THE ROLE OF c-Myc IN CONTROLLING 
EXPRESSION OF MDR IN HEMATOPOIETIC CANCER STEM CELLS. 
 
Recent findings have demonstrated that cells with stem-cell qualities are present in 
malignancies of haematopoietic origin and in some solid tumours. The existence of 
such population would imply that the stem cell represents the cell of origin for the 
tumour. Cancer stem cells are likely to share many of the properties of normal stem 
cells that provide for a long lifespan, including relative quiescence, resistance to 
drugs and toxins through the expression of several ABC transporters, an active DNA-
repair capacity and a resistance to apoptosis 79. This observation supports a novel 
point of view on how drug resistance may be achieved by cancer cells. In the 
conventional model of tumour cell drug resistance, rare cells with genetic alterations 
that confer multidrug resistance (MDR) form a drug resistant clone. Following 
chemotherapy, these cells survive and proliferate, to form a recurrent tumour that is 
composed of offspring of the drug resistant clone. In the alternative model, drug 
resistance can be mediated by stem cells. According to this model, tumours contain a 
small population of tumour stem cells and their differentiated offspring, which are 
committed to a particular lineage. Following chemotherapy, the committed cells are 
killed, but the stem cells, which express drug transporters, survive. These cells 
repopulate the tumour, resulting in a heterogeneous tumour composed of stem cells 
and committed but variably differentiated offspring 79. The drug transporting property 
of normal and cancer stem cells conferred by ABC drug transporters represents an 
important marker in the isolation and analysis of haematopoietic stem cells. Most 
cells accumulate the fluorescent dyes Hoechst 33342 and Rhodamine 123, but stem 
cells do not, as these compounds are effluxed by ABCG2/BCRP and ABCB1/MDR1, 
respectively. Because they don’t accumulate these fluorescent dyes, stem cells can be 
sorted by collecting cells that contain only a low level of Hoechst 33342 
fluorescence. These cells are referred to as “side population” (SP) cells 79. A large 
fraction of haematopoietic stem cells are found in the SP fraction 105. The exact origin 
of pluripotent stem cells in tumours might vary. They could arise from the malignant 
transformation of a normal stem cell that has accumulated oncogenic insults over 
time 79. Alternatively, the original tumour cell could be a more differentiated cell that 
develops the capacity for continual self-renewal, thus acquiring the properties of a 
stem cell 323. Distinguishing between these two might be difficult. Evidence that cells 
other than stem cells can acquire the ability to undergo self-renewal has been recently 
proposed in studies examining the progression of chronic myelogenous leukaemia 
(CML) 83. The chronic phase of this disease occurs when a stem cell acquires the 
expression of BCR-ABL fusion protein, leading to increased proliferation of cells 
within the granulocyte-macrophage progenitor pool and their downstream progeny. 
Furthermore, the progression to blast crisis follows additional genetic or epigenetic 
events that confer progenitor stem cells with the capacity to self renew, making them 
indistinguishable from a leukaemic stem cell. For these reasons, the stem cell 
compartment is not rigidly defined, suggesting a degree of plasticity in CML, and 
generally in cancer 79, 83. It was therefore important to identify the population that 
contains leukemic stem cells in CML and to identify events leading to the progression 
of leukaemia, the outcome of these events, and the order of their appearance in 
leukemic stem cells and their precursors.  
In our study, we isolated a stem cell population from newly diagnosed chronic phase 
(CP)-CML patients. Indeed, CD34 is a glycophosphoprotein expressed on early 
hematopoietic precursor cells, which can be easily identified and purified by 
immunological tecniques. Immunophenotype of bone marrow (FACS analysis) in 
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CML patients revealed a broader CD34+ cell population than that revealed in healthy 
donors. The number of CD34+ progenitor cells provides useful diagnostic and 
prognostic information regarding the evolution of CML. Furthermore, in chronic 
myelogenous leukaemia,  cancer stem cells CD34+ are characterized by the t(9;22) 
(q34;q11) reciprocal chromosomal translocation (chromosome Ph), which forms the 
BCR-ABL fusion gene 324. We find that these cancer stem cell population expresses 
high transcriptional levels of several ABC drug transporter genes if compared to 
those observed in the entire population of mononuclear tumour cells from which 
CD34+ stem cells have been purified. We show that also c-MYC is highly expressed 
in CD34+ stem cells fraction and that it is almost silenced in mononuclear tumor 
cells. Therefore, we can hypothesize that, in CML, CD34+ cancer stem cells are 
mainly responsible to develop aggressive forms of this kind of leukaemia, and that, 
expressing high levels of several drug transporters, they may repopulate the tumour 
after chemotherapy, spawning a tumour mass completely refractory to treatment with 
chemotherapeutic agents. It is interesting to point out that in patients with a response 
to imatinib there is a significant decrease in the number of CD34+ cells, whereas 
samples from patients with imatinib-resistant CML increase number of granulocyte-
macrophage progenitors 83. Resistance to imatinib is generally seen in patients who 
display a genomic amplification of BCR-ABL or point mutations in the BCR-ABL 
kinase domain. However, resistance to imatinib may be due to overexpression of 
some ABC transporters 325. Indeed, imatinib is a good substrate for the ABCG2 drug 
pump 325, whose expression is regulated by c-Myc.  Furthermore, ABCG2 promoter is 
often silenced in leukaemia. However, we show that CD34+ cancer stem cell 
population derived from CML patients expresses ABCG2/BCRP. This evidence 
support the model for which high-expression/hypomethylated ABCG2 cells has an 
advantage during chemotherapy. 
In Kazumi- 4,  a cell line derived from a Ph+ CML patient and that expresses the 
CD34 antigen, we show that c-Myc is directly associated with the promoter of ABC 
genes highly expressed in CD34+ cancer stem cells. Taken together, our findings 
support the hypothesis that c-Myc, acting as a direct transactivator of several drug 
transporters, play a key role in controlling the development of drug resistance in 
cancer stem cells. In CML, it is also known that c-MYC expression is required for the 
oncogenic effects of BCR-ABL and that the overexpression of c-MYC is mediated by 
BCR-ABL itself, through the Jak2 kinase 304, 326. How c-Myc might do in CD34+ Ph+ 
cells was still unknown. In our study we propose that one possible effect of c-Myc in 
CD34+ Ph+ cells is linked to its capacity to develop drug resistance, by inducing 
transcriptional activity of some ABC drug transporters. Therefore, through this 
mechanism, c-Myc may mediate the outward-directed transport of imatinib, 
determining the failure of chemotherapeutic treatment in CML. 
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